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1.1 Chronic airway diseases - asthma and COPD 
 
Chronic airway diseases, including asthma and chronic obstructive pulmonary 
disease (COPD) are a major global health problem. The global incidence of asthma 
and COPD is rising, and predicted to reach epidemic proportions in 2020 for COPD 
(1). Asthma is one of the most common chronic diseases, which affects 
approximately 300 million individuals worldwide, especially children. According to 
the Global Initiative for Asthma (2), asthma is defined as “a chronic inflammatory 
disorder of the airways in which many cells and cellular elements play a role. The 
chronic inflammation causes an associated increase in airway hyperresponsiveness 
that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and 
coughing, particularly at night or in the early morning. These episodes are usually 
associated with widespread but variable airflow obstruction that is often 
reversible either spontaneously or with treatment” (2). From the definition, it is 
clear that airway inflammation and obstruction play a substantial role in the 
pathophysiology and pathogenesis of asthma. An early onset and genetic 
inheritance, affecting individuals in early childhood or adolescence are key 
features of asthma (3). Although current drug therapy can adequately control the 
disorder in most patients, a subgroup of patients with difficult-to-treat severe 
asthma exists, characterized by chronic symptoms, underscoring the need for the 
development of novel drug therapy (4, 5). 
COPD is commonly caused by long-term exposure to toxic gases and particles, in 
particular by cigarette smoking (6). According to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines (7), COPD is defined as “a common 
preventable and treatable disease, characterised by persistent airflow limitation 
that is usually progressive and associated with an enhanced chronic inflammatory 
response in the airways and the lung to noxious particles or gases. Exacerbations 
and comorbidities contribute to the overall severity in individual patients” (7). In 
contrast to most patients with asthma, the airflow limitation in COPD is 
progressive and not fully reversible (8). 
 
1.1.1 Pathogenesis and pathophysiology of asthma and COPD 
1.1.1.1 Asthma 
Asthma is characterised by a chronic Th2-type inflammation of the airways, 
associated with widespread and variable airway obstruction. Most patients are 



















characterised by early and late asthmatic reactions. The early asthmatic reaction 
is induced by IgE-mediated mast cell activation, causing the release of various 
bronchoconstricting and pro-inflammatory mediators, including histamine, 
leukotrienes and cytokines. This results in airway smooth muscle contraction, 
increased vascular permeability and mucus secretion, all contributing to the acute 
airway obstruction (8). The late asthmatic reaction is caused by chemokine and 
cytokine-induced recruitment and activation of inflammatory cells, particularly 
eosinophils. In addition to the release of contractile and pro-inflammatory 
mediators by these cells, eosinophil-derived cationic proteins like major basic 
protein are involved in the development of acute and reversible airway 
hyperresponsiveness to non-allergic stimuli (9). In addition, chronic airway 
hyperresponsiveness as well as irreversible decline in lung function can be 
induced by airway remodelling due to recurrent inflammatory reactions in the 
airways, which may involve mediators, cytokines and growth factors released 
from both inflammatory and structural airway cells (8-10). 
 Structural changes observed in asthmatics airways are epithelial damage, 
thickening of the basement membrane, subepithelial fibrosis, goblet cell 
hyperplasia, submucosal gland enlargement, increased airway smooth muscle 
mass, decreased cartilage integrity and increased airway vascularity (11, 12). A 
particularly important feature of airway remodelling is the increased airway 
smooth muscle mass, as in addition to contraction, airway smooth muscle cells 
can participate in inflammatory and remodelling processes by the release of 
specific cytokines, extracellular matrix proteins and growth factors, thereby 
communicating with structural and inflammatory cells in the airways in an 
autocrine and paracrine fashion (13-16). This will be further discussed below. 
 
1.1.1.2 COPD 
COPD is characterised by pulmonary inflammation associated with progressive 
loss of lung function. COPD includes both emphysema and chronic bronchitis and 
these conditions often coexist (17). Chronic inflammation in COPD patients can 
trigger structural alterations and narrowing of particularly the small airways, as 
well as emphysema, characterised by parenchymal and alveolar destruction. The 
loss of lung function may result from both airway remodelling, characterised by 
peribronchiolar fibrosis, increased airway smooth muscle mass and mucus cell 
hyperplasia, as well as loss of elastic recoil by parenchymal damage (18, 19). In 




factors like chemicals and dusts, genetic predisposition seems to be an important 
risk factor for the development of COPD as only 15 to 20% of the smokers develop 
COPD (20). Accordingly, genome-wide association studies found several loci which 
have been associated with COPD susceptibility (21-26). COPD has a slow and late 
onset, is progressive in nature, and primarily affects the middle-aged and the 
elderly with a smoking history. The highest prevalence is in patients over 65 years 
of age (27).  
Neutrophils, macrophages and CD8+ T lymphocytes are predominantly recruited 
to the airways of COPD patients, which is largely driven by cytokines and 
mediators such as interleukin (IL)-1β, IL-8, tumour necrosis factor-α (TNF-α), 
leukotriene B4 (LTB4), interferon-γ and matrix metalloproteinases (28). The 
inflammatory response in COPD occurs predominantly in the small airways and 
the lung parenchyma (28), and is involved in the structural changes mentioned 
above. 
 
1.1.2 Current drug therapy 
Inhaled β2-adrenoceptor agonists and glucocorticosteroids are the mainstay 
therapy for asthma (2). Short-acting β2-agonists, like salbutamol and terbutaline, 
are used as reliever therapy for episodes of dyspnoea, whereas inhaled 
glucocorticosteroids, with or without long-acting β2-agonists such as formoterol 
and salmeterol, are used as controller therapy for persistent asthma. According to 
the current guidelines, short-acting anticholinergics, like ipratropium and 
oxitropium, may be used as alternative bronchodilators to relieve exacerbations in 
uncontrolled severe asthma.  
Since cholinergic tone appears to be the major reversible component of airways 
obstruction in COPD, short-acting ipratropium and oxitropium as well as long-
acting tiotropium are mainstay bronchodilator therapies in this disease, together 
with short- and long-acting β2-agonists (7). In contrast to patients with asthma, 
most patients with COPD are relatively resistant to anti-inflammatory therapy 
with inhaled glucocorticosteroids. Therefore, effective treatment of patients with 
COPD is a major unmet need. 
The guidelines for the treatment of asthma and COPD (2, 7) advocate 
anticholinergics for their bronchodilator properties. Interestingly, recent findings 
also suggest non-bronchodilator actions of these drugs, which could involve anti-
inflammatory and anti-remodelling properties (29). Moreover, experimental 



















remodelling (30-38). In this thesis, potential novel mechanisms underlying 
muscarinic receptor-mediated airway inflammation and remodelling will be 




1.2 Airway smooth muscle and its role in disease 
 
The primary role of airway smooth muscle is constriction of the airways, 
regulating bronchial tone. In asthma and to a lesser extent in COPD, increased 
airway smooth muscle mass is a major contributor to chronic airway narrowing 
(39). In addition, recent studies demonstrate that airway smooth muscle cells can 
communicate with their environment to modulate local airway inflammation and 
remodelling. 
 
1.2.1 Airway smooth muscle remodelling 
Airway smooth muscle remodelling occurs in both asthma and COPD. In asthma, 
airway smooth muscle mass may be increased in both large and small airways, 
whereas smooth muscle thickening of the small airways is predominantly 
observed in COPD patients (40-42). A correlation between smooth muscle mass 
and the severity of the disease has been found both in asthma and in COPD (43, 
44). Both hyperplasia and hypertrophy of smooth muscle cells occur in the airway 
smooth muscle bundle in asthma, and possibly in COPD (43, 45-48). The relative 
contribution of these processes to airway smooth muscle thickening in asthma is 
still under debate (43, 46, 47) and could be dependent on the disease phenotype 
(48, 49). Furthermore in asthma an increase in extracellular matrix deposition is 
observed within and surrounding the smooth muscle bundles (45, 50, 51), which 
results in airway wall thickening, but also in increased stiffness of the tissue, 
limiting the ability of airway smooth muscle to induce airway narrowing as 
detailed below (52). The mechanisms underlying the increase in airway smooth 
muscle mass in asthma and COPD have not completely been identified. Secreted 
growth factors and cytokines from both the airway epithelium and infiltrated 
inflammatory cells may contribute to the increased airway smooth muscle mass, 
as well as the thickening of the airway smooth muscle towards the epithelium (53, 
54). Furthermore, airway smooth muscle cells produce pro-remodelling, but also 




endothelial growth factor (VEGF), connective tissue growth factor (CTGF) and 
extracellular matrix proteins (55-57), which may be enhanced in smooth muscle of 
asthma an COPD patients (28, 45). Mechanical stimuli can also stimulate the 
expression of cytokines as well as of contractile proteins in airway smooth muscle 
cells (58). Furthermore, exposure to cigarette smoke drives airway smooth muscle 
cells to proliferate (59). The mechanisms involved and their pathophysiological 
implications will be discussed in detail below. 
 
1.2.2 Communication with inflammatory cells 
Although airway inflammation is associated with cellular and structural changes in 
the airways (40, 60), there is as yet no consensus about the causal role of 
inflammation in airway remodelling. It has been proposed that chronic 
inflammation drives the airway remodelling in asthmatic patients, as mediators 
including TGF-β, IL-1β and IL-6, produced by both inflammatory and structural 
cells, can induce airway remodelling (14, 61). In addition, the airway smooth 
muscle may directly facilitate the inflammatory processes in asthma and COPD. 
For example in asthma, the expression of the chemokine eotaxin by airway 
smooth muscle cells allows eosinophils to be attracted to the airways, leading to 
local release of cytotoxic mediators, pro-inflammatory cytokines, and TGF-β (62). 
Airway smooth muscle cells also express several receptors and mediators, 
including cellular adhesion molecules (CAMs), cytokine receptors, Toll-like 
receptors, chemokines, proteases, and growth factors, facilitating inflammatory 
and remodelling processes within the airways (63-65). For instance, both 
autocrine and paracrine secretion of IL-1β, LTB4, IL-6, IL-8, eotaxin and RANTES by 
airway smooth muscle cells has been reported, enhancing inflammation (Figure 
1.1, (66)). Inflammatory cells can also release numerous mediators, including IL-6, 
IL-8, and TGF-β, allowing activation of the airway smooth muscle cells (45, 53, 67), 
and contributing to airway smooth muscle remodelling (Figure 1.1). Overall, this 
underlines that anti-inflammatory treatment could be a potential strategy to treat 




















Figure 1.1. Bidirectional cellular communication in the airway wall. Growth factors can 
be released by epithelial cells or inflammatory cells in response to environmental factors, 
inducing airway smooth muscle cells to proliferate and release specific cytokines to 
communicate with other structural or inflammatory cells. Epithelial cells can be triggered 
by proteolytic allergens, environmental pollutants or Th2 cytokines. See text for further 
details. EGF: epidermal growth factor; PDGF: platelet-derived growth factor; TGF-β: 
transforming growth factor-β; LTB4: leukotriene B4; IL: interleukin.  
 
1.2.3 Communication with structural cells  
Bidirectional communication between the airway smooth muscle and other 
components of the airway wall, including different structural and inflammatory 
cell types and the extracellular matrix, is involved in various physiological and 
pathophysiological effects of the airways (16). The airway epithelium is the 
interface between the external environment and the airways (68). Injured or 
stressed airway epithelium by environmental factors, such as allergens and 
tobacco smoke, increases the release of fibroproliferative and fibrogenic growth 
factors. Indeed, in asthmatic airway epithelial cells, the release of numerous pro-
inflammatory cytokines (e.g. IL-6 and IL-8) and mediators (e.g. LTB4) as well as pro-
remodelling factors, including growth factors like platelet-derived growth factor 
(PDGF), epidermal growth factor (EGF), TGF-β and VEGF is enhanced compared to 
normal epithelium (68-70) (Figure 1.1). Similar responses of the airway epithelium 
are observed in COPD patients. The airway epithelium is also altered in COPD 
patients, particularly due to the exposure to cigarette smoke, which stimulates 




TGF-β (45, 71, 72). Overall, the release of these cytokines and growth factors will 
affect the airway smooth muscle cells by promoting inflammatory responses, but 
also remodelling responses, including deposition of extracellular matrix proteins 
and airway smooth muscle growth. For example, the secretion of IL-8, IL-6 and 
MCP-1 by damaged airway epithelium promotes smooth muscle cell proliferation 
(73). The secretion of several cytokines including IL-1β, IL-6 and IL-8 by airway 
smooth muscle cells can in turn affect the epithelial layer, but also attract 
inflammatory cells (45, 63). Further, mechanical stimulation of bronchial epithelial 
cells by constricted airways can induce the release of TGF-β, endothelin-1, early 
growth response-1 and the extracellular matrix protein fibronectin (74-76).  
 
1.2.4 Extracellular matrix and integrins 
Extracellular matrix, the non-cellular component within tissues, provides airway 
structure and function. The amount and composition of extracellular matrix are 
altered in patients with asthma and COPD compared with healthy subjects (16, 
77). In asthma, the basement membrane is thickened and there is deposition of 
extracellular matrix beneath the basement membrane as well as within and 
surrounding the airway smooth muscle bundles in both large and small airways. In 
COPD, the thickness of the subepithelial basement membrane is usually 
unchanged; however peribronchial fibrosis occurs in particularly the small airways 
(78). Increased deposition of collagen I, III, and V, fibronectin, tenascin, 
hyaluronan, versican, biglycan, lumican and laminin α2/β2-chains, and decreased 
deposition of collagen IV, decorin and elastin were observed in the airway wall of 
asthmatics compared to healthy subjects (79-81). Also in COPD patients, increased 
expression of collagen I, III and IV, fibronectin and laminin, and decreased 
expression of decorin compared to healthy subjects has been reported (82). In 
asthma, deposition of extracellular matrix is correlated with the severity of the 
disease, but not with age or duration of the disease (83). The expression of the 
extracellular matrix protein elastin within the bronchial wall is inversely related to 
airway hyperresponsiveness in asthmatic patients (51). 
In addition to their structural role, extracellular matrix proteins have been 
reported to be involved in the regulation of various cellular processes, including 
migration, proliferation, attachment, cytokine release and contraction (79, 80, 84-
89). Additionally, extracellular matrix proteins play a role in the maturation of 
airway smooth muscle cells (90). Airway smooth muscle cells grown on fibronectin 



















calponin and sm-MHC, which is associated with modulation of the airway smooth 
muscle cell phenotype towards a proliferative state (80, 87). Indeed, collagen I 
and fibronectin enhanced growth factor-induced airway smooth muscle 
proliferation (90), which requires interaction with α2β1, α4β1 and α5β1 integrins 
through the arginine-glycine-aspartic acid (RGD) sequence within these 
extracellular matrix proteins (85, 91). Integrins are major cell-surface receptors for 
extracellular matrix proteins, including collagens, fibronectin and laminins (92). 
These heterodimeric transmembrane glycoproteins interact with specific amino 
acid sequences within the extracellular matrix proteins, including the RGD 
sequence. The human repertoire of the integrin superfamily is constituted of 24 
α/β heterodimers (92), of which the α5β1 integrin is a major regulator of airway 
smooth muscle cell function (79, 85, 91, 93-95). Accumulation of extracellular 
matrix within the airway smooth muscle bundles could have both protective and 
detrimental effects. Thus, it may protect against excessive bronchoconstriction 
due to the increased stiffness leading to greater internal resistance against 
shortening (96, 97). On the other hand, in vivo studies also support detrimental 
effects of extracellular matrix proteins in airway smooth muscle remodelling. In a 
guinea pig model of chronic asthma, treatment with an integrin blocking peptide 
containing the RGD binding motif inhibited allergen-induced airway smooth 
muscle remodelling, including airway smooth muscle hyperplasia and contractility 
(91), suggesting a potentially beneficial role for RGD-specific inhibitors in the 
treatment of airway remodelling. 
 
1.2.5 Airway smooth muscle phenotype switching 
Phenotype switching of airway smooth muscle cells contributes to the increased 
airway smooth muscle mass observed in asthmatics and COPD patients. 
Phenotype switching is defined as a dynamic process whereby differentiated 
airway smooth muscle cells can reversibly change their phenotype to a 
proliferative/synthetic state (modulation) or a contractile state (maturation), 
depending on their environment (98, 99). In presence of specific extracellular 
matrix proteins, including fibronectin and collagen I, or growth factors, including 
PDGF, airway smooth muscle cells can undergo modulation from a contractile 
state into a proliferative/synthetic state, among others characterised by the 
synthesis of organelles for protein and lipid synthesis and mitochondria (100). This 
process is reversible, as airway smooth muscle cells can undergo re-maturation by 




absence of mitogens, or by laminins and TGF-β (101, 102). Paradoxically, growth 
factors like insulin and TGF-β may have both mitogenic and pro-contractile 
properties in airway smooth muscle cells. The mechanism behind this 
differentiated regulation is still unknown. In this thesis, the role of TGF-β in airway 
smooth muscle phenotype regulation will be investigated in detail. 
To distinguish between both phenotypic states of airway smooth muscle cells, 
unique markers have been identified. Modulation of airway smooth muscle cells 
to a proliferative/synthetic phenotype is associated with downregulation of sm-α-
actin, calponin, sm-myosin, desmin, myosin light chain kinase and caldesmon and 
reduced expression of the Ca2+ handling and growth repressing functions of 
caveolae, implicating that cells in this state lose their response to contractile 
agonists (103-106). As indicated above, cells undergoing this modulation are 
characterised by abundant organelles involved in synthesis and secretion 
including the Golgi apparatus and mitochondria. Protein markers for the 
proliferative state include non-muscle myosin heavy chain, vimentin, CD44 
homing cellular adhesion molecule, I-caldesmon, protein kinase C α/β and β-
catenin, which are associated with decreased responsiveness to contractile 
agonists (104). Maturation of airway smooth muscle is associated with re-
expression of sm-α-actin, calponin, SM22, sm-MHC, desmin, h-caldesmon and 
increased responsiveness to contractile agonists (98, 102, 104). The amount of 
synthetic organelles is decreased in this state, whereas caveolae expression is 
increased, implicating that cells can respond to contractile agonists (106, 107). 
Transcription and translation of these specific airway smooth muscle phenotype 
markers occur under regulation of specific intracellular pathways as outlined 
below. 
 
1.2.6 Signalling mechanisms associated with phenotype switching of airway 
smooth muscle cells 
Extracellular stimuli, including peptide growth factors, extracellular matrix 
proteins and contractile agonists acting on G protein-coupled receptors can 
induce modulation or maturation of airway smooth muscle cells by activating 
specific intracellular signalling mechanisms (80, 87, 108). The RhoA/Rho kinase, 
mitogen-activated protein kinase (MAPK/ERK) and phosphoinositol 3-kinase (PI3K) 
pathways have been proposed to be key intracellular mechanisms in maturation 
and modulation of airway smooth muscle cells, by regulating transcription and 



















The RhoA/Rho kinase pathway is one of the central players in smooth muscle 
specific gene transcription by regulating the nuclear localisation of serum 
response factor (SRF). Polymerisation of sm-actin in response to RhoA/Rho kinase 
pathway activation induces the loss of monomeric globular actin (g-actin), 
allowing the release of the co-activator myocardin-related transcription factor A 
(MAL), which associates only with sm-α-actin in its monomeric form. Binding of 
two SRF molecules to a CArG box element in the promoter region of smooth 
muscle specific genes and recruitment of the co-activators myocardin and MAL to 
the SRF complex facilitates promoter activation of these genes. By contrast, when 
SRF is bound to ternary complex factors (TCFs), including phospho-Elk-1, the c-fos 
promoter is activated to facilitate transcription of proliferative genes (113). The 
MAPK pathway is responsible for the phosphorylation of Elk-1, indicating an 
important role of this pathway in determining the fate of SRF-mediated 
transcription and therefore the regulation of smooth muscle plasticity (113). In 
this way, the presence of specific transcriptional co-activators is crucial in the 
regulation of transcription of either smooth muscle specific genes or proliferative 
genes. In contrast to the MAPK/ERK pathway, the PI3K pathway is involved in the 
activation of smooth muscle specific gene transcription by disruption of the 
interaction of SRF with the inhibitory Fox04 transcription factors, allowing the co-
activator myocardin to bind to SRF (Figure 1.2) (114). Smad-dependent signalling 
can also enhance smooth muscle specific gene transcription after association with 






Figure 1.2. Mechanisms of airway smooth muscle maturation. Maturation of airway 
smooth muscle cells requires transcription and translation of contractile and contraction 
regulatory proteins. Activation of Smad-independent pathways through TGF-β signalling is 
also common. For example, RhoA can be activated followed by activation of downstream 
target proteins, such as Rho-kinase, to prompt rearrangement of the cytoskeletal 
elements associated with cell spreading, cell growth regulation, and cytokinesis. See text 
for further details. MR: muscarinic receptor; TGFR: TGF receptor; SRF: serum response 
factor; MCDN: myocardin; PKC: protein kinase C; PI3K: phosphatidyl inositide 3-kinase; 
GSK-3: glycogen synthase kinase-3, Akt: protein kinase B, mTOR: mammalian target of 
rapamycin; TCE: TGF-β control elements, 4E-BP1: eukaryotic translation initiation factor 
4E-binding protein 1. 
 
Translation of the transcripts from smooth muscle specific genes is under control 
of the PI3K/Akt and mTOR/p70S6K pathways. PI3K signalling induces activation of 
Akt1 followed by mammalian target of rapamycin (mTOR). Active mTOR 
phosphorylates eukaryotic translation initiation factor 4E-binding protein 1 (4E-
BP1) allowing the activation of the eukaryotic initiation factor eIF4. Subsequently, 
protein translation and contractile protein accumulation is initiated (111, 112). 
Activation of mTOR also allows the activation of p70S6K, responsible for 



















1.2). Another downstream target of the PI3K/Akt signalling is glycogen synthase 
kinase (GSK)-3, whose repressive effects on translational processes are reversed 
after phosphorylation by Akt (116, 117).  
 
1.2.7 TGF-β signalling and airway smooth muscle phenotype switching 
TGF-β is an important mediator of tissue remodelling in patients with asthma and 
COPD. In the lung, TGF-β can be expressed by various cell types, including 
eosinophils, macrophages, epithelial cells, fibroblasts and airway smooth muscle 
cells (52). Increased levels of TGF-β have been found in asthmatics, COPD patients 
and tobacco smokers (67, 118-121). Both the airway epithelium and airway 
smooth muscle cells of patients with COPD overexpress TGF-β compared to 
healthy smokers (120, 122). In addition, genetic studies have reported strong 
associations between polymorphisms within genes of the TGF-β superfamily and 
COPD development (25, 123). In response to epithelial damage, excessive 
production of TGF-β occurs, triggering airway remodelling (124). During 
inflammation, neutrophil elastase and mast cell tryptase promote the release of 
TGF-β1 from airway smooth muscle cells (125, 126). Plasmin regulates the release 
and the conversion of biologically active TGF-β from the extracellular matrix (127).  
The functional impact of TGF-β on airway smooth muscle cells is significant. This 
growth factor can induce airway smooth muscle modulation and maturation 
depending on its concentration, by activation of the Smad signalling followed by 
the regulation of SRF-dependent gene transcription or by inducing autocrine 
release of growth factors, including PDGF (115, 117, 128). The binding of TGF-β to 
the TGF-β receptor-type II allows recruitment and phosphorylation of the TGF-β 
type I receptor, followed by both phosphorylation and nuclear translocation of 
the “regulatory” Smads-2, -3 and -4, and activation of Smad-independent 
pathways. In turn, Smad-2, -3, and -4 can bind with the nuclear SRF to regulate 
smooth muscle specific gene transcription, and thereby promoting cell function 
including inducing a contractile phenotype (129) (Figure 1.2). As part of a negative 
feedback loop, Smad-6 and -7 antagonise TGF-β signalling by counteracting the 
induction of smooth muscle specific target genes (Figure 1.2) (115, 129). 
Maturation of smooth muscle cells is promoted by Smad-dependent pathways 
activating TGF-β control elements (TCE) on the promoters of smooth muscle 
specific target genes. In this way, TGF-β augments the expression of contractile 
proteins in airway smooth muscle cells, including sm-α-actin and calponin (130, 




RhoA/Rho kinase and PI3K/Akt pathways, thereby promoting airway smooth 
muscle cell proliferation. For example, activation of the PI3K/Akt pathway by TGF-
β can lead to airway smooth muscle proliferation by up-regulating the expression 
of cyclin D1 (132). Phosphorylation of p38 and ERK1/2 by TGF-β1 also enhances 
airway smooth muscle cell proliferation (133). Cooperative regulation between 
Smad-dependent and Smad-independent pathways has been reported (134). For 
example, crosstalk between the MAPK pathway and Smad-pathway can enhance 
cell proliferation and fibrosis (135). Moreover, RhoA can be activated via Smad-
dependent and -independent pathways to induce actin stress fibre formation 
(134). 
In fibroblasts, TGF-β triggers the deposition of extracellular matrix including 
collagen and fibronectin by promoting the expression of extracellular matrix 
genes and suppressing the activity of matrix metalloproteinases genes, which 
degrades extracellular matrix (136, 137). Similar observations were done in airway 
smooth muscle cells (127, 130). Expression of the pro-fibrotic factor CTGF is also 
induced by TGF-β; moreover, TGF-β is enhanced in airway smooth muscle cells of 
asthmatics (55). The induction of the matrix proteins requires activation of the 
Smad signalling, especially Smad-3, but also of the MAPK pathway (138). Although 
TGF-β is predominantly involved in airway remodelling, TGF-β can also regulate 
inflammatory responses by inducing the release of cytokines and chemokines, 
including IL-8, IL-6 by airway smooth muscle (64). Overall, TGF-β can regulate the 
gene/protein expression of extracellular matrix proteins, contractile proteins, 
cytokines, growth factors, and enzymes in airway smooth muscle cells, suggesting 
a major role for TGF-β in airway remodelling and inflammation (16, 64). 
 
 
1.3 Cholinergic system of the airways 
 
Classically, acetylcholine is considered a neurotransmitter of the peripheral and 
the central nervous system. Activation of the neuronal cholinergic system in the 
airways induces airway smooth muscle contraction and mucus secretion, thereby 
causing airway obstruction. The activity of the parasympathetic system in asthma 
and COPD is increased by airway inflammation. However, more than half a 
century ago already, acetylcholine was reported present in bacteria, protozoa, 
yeast, algae, fungi, and plants (139), supporting the existence of a non-neuronal 



















be ubiquitously present, including in the airways. A growing body of evidence now 
supports the notion that the non-neuronal cholinergic system also plays an 
important role in the pathogenesis and pathophysiology of asthma and COPD.  
 
1.3.1 Cholinergic system 
In neurons and in non-neuronal cells, acetylcholine is synthesised by a single-step 
reaction catalysed by the enzymes choline acetyltransferase (ChAT) or 
carnesylacetyltransferase (CarAT) using their two precursors choline and acetyl-
CoA. The uptake of choline is the rate-limiting step in acetylcholine synthesis and 
is regulated by specific choline transporters, including the high affinity choline 
transporter (CHT)1 and choline-specific transporter-like proteins (CTL1-4). In 
neurons, acetylcholine is stored in and released from synaptic vesicles by the 
vesicular acetylcholine transporter (VAChT). Although VAChT was found to be 
expressed in several epithelial cell types (secretory cells, neuroendocrine cells and 
brush cells), airway epithelial cells also have an alternative release mechanism for 
acetylcholine by active transport via organic cation transporters (OCT) (140-142). 
Rapid hydrolysis by the enzyme acetylcholinesterase (AChE) or 
butyrylcholinesterase (BChE) allows the termination of the actions of 
acetylcholine once released by neuronal and non-neuronal cells (143). In the 
airways, ChAT and CarAT are expressed in airway smooth muscle cells, fibroblasts, 
epithelial cells and inflammatory cells, such as macrophages, mast cells, 
lymphocytes and granulocytes (144). However, the release of acetylcholine by the 
majority of these cell types has not been proven yet. Remarkably, most of these 
cells also express cholinergic receptors (see for overview (144-146)). 
 
1.3.2 Muscarinic receptors subtypes in the airways 
Two types of cholinergic receptors exist, the G protein-coupled muscarinic 
receptors and the nicotinic receptors, which are ligand-gated cation channels (146, 
147). The clinically used anticholinergics for asthma and COPD are specific for 
muscarinic receptors; the role of nicotinic receptors in the airways will not be 
further discussed here (for a review see Racke et al. (148)). 
Five muscarinic receptor subtypes (M1-M5) have been identified, which are 
expressed in various tissues (149). Muscarinic M2 and M4 receptors are both Gi-
coupled receptors, inducing inhibition of adenylyl cyclase and closure of Ca2+-
dependent K+-channels. Muscarinic M1, M3 and M5 receptors are Gq-coupled 




the cytoplasmatic calcium (Ca2+) concentration through the production of inositol 
1,4,5-trisphosphate (IP3) and subsequent mobilization of Ca
2+ from the 
endoplasmatic reticulum (149). In addition, diacylglycerol (DAG) is produced, 
causing activation of protein kinase C (PKC). 
As mentioned, muscarinic receptor expression is found in many cell types, 
including neurons and a variety of non-neuronal cells (144). In the airways, 
muscarinic M1, M2 and M3 receptors are widely expressed and are involved in 
different functional responses, including the regulation of smooth muscle 
contraction, mucus secretion, cell proliferation and neurotransmitter, mediator 
























M1 Parasympathetic ganglia Facilitation of neurotransmission (150) 
 Epithelial cells facilitation of cytokine and chemotactic 
factor release (36, 151) 
  Submucosal glands Electrolyte and water secretion (152-154) 
  Mast cells Regulation of inflammatory mediator 
production, inhibition of histamine 
release (39, 139) 
 T lymphocytes Increased cytotoxicity (139, 155, 156) 
  B lymphocytes Proliferation (139, 156) 
  Neutrophils Chemotaxis (69) 
  Eosinophils Unidentified(69) 
  Macrophages/ monocytes Chemotactic factor release (e.g. LTB4) 
M2 Pre- and postganglionic 
cholinergic nerves 
Inhibition of ACh release (157-159) 
  Airway smooth muscle cells Functional antagonism of β-agonist-
induced relaxation (160-164) 
  Fibroblasts Proliferation, extracellular matrix 
production (37, 165) 
  Epithelial cells Facilitation of cytokine and chemotactic 
factor release (36, 151) 
  Sympathetic nerves Inhibition of noradrenaline release (166) 
 T lymphocytes Increased cytotoxicity (139, 155, 156) 
 B lymphocytes Proliferation (139, 156) 
 Neutrophils Chemotaxis (69) 
 Macrophages/ monocytes Chemotactic factor release (139) 
M3 Airway smooth muscle cells Contraction, proliferation, cytokine 
release, functional antagonism of β-
agonist induced relaxation (30, 34, 139, 
162, 167-171) 
  
Epithelial cells Facilitation of cytokine and chemotactic 
factor release (36, 151) 
  
Submucosal glands Mucus secretion (154)  
Electrolyte and water secretion (152, 
153) 
  Goblet cells Mucus secretion (172) 
  T lymphocytes Increased cytotoxicity (139, 155, 156) 
 B lymphocytes Proliferation (139, 156) 
 Neutrophils Chemotaxis (69) 




1.3.3 Regulation of airway smooth muscle contraction by muscarinic 
receptors 
Airway smooth muscle expresses both muscarinic M2 and M3 receptors, in a ratio 
of 4:1 (167). Although muscarinic M2 receptors are predominantly expressed, the 
muscarinic M3 receptor is responsible for contraction. In airway smooth muscle, 
activation of muscarinic M3 receptors induces the release of Ca
2+ from 
intracellular stores not only by activating PLCβ and subsequent formation of IP3, 
but also by activation of the CD38/cyclic ADP-ribose pathway via opening of 
ryanodine receptor channels in the sarcoplasmatic reticulum (174, 175). The 
release of Ca2+ activates Ca2+-calmodulin-dependent myosin light chain kinase to 
phosphorylate myosin light chain, followed by airway smooth muscle contraction 
by interaction of the myosin light chain with actin. 
Muscarinic M3 receptors also activate the Rho/RhoA pathway to facilitate airway 
smooth muscle contraction. Contraction is induced by inhibition of myosin light 
chain phosphatase (MLCP) leading to Ca2+-sensitisation, which is defined as an 
augmented contractile response at a given Ca2+ concentration (176). MLCP can be 
directly inhibited by phosphorylation by RhoA-kinase, but also by binding with the 
phosphoprotein CPI-17, which can be phosphorylated by Rho-kinase and PKC 
(177). 
 
1.3.4 Regulation of inflammation and remodelling by muscarinic receptors 
There is recent evidence that muscarinic receptors on both structural and 
inflammatory cells in the airways may be involved in airway inflammation and 
remodelling.  
Muscarinic receptor activation may contribute to structural changes in the 
airways by airway smooth muscle phenotype modulation, and differentiation and 
activation of fibroblasts. Thus, muscarinic M3 receptor stimulation may profoundly 
enhance growth factor-induced airway smooth muscle proliferation (34, 178-181). 
Cross-talk between muscarinic M3 receptors and receptor tyrosine kinases, like 
epidermal growth factor (EGF) receptors and PDGF receptors causes a synergistic 
increase in airway smooth muscle cell proliferation through PI3K/Akt- and 
mTOR/p70S6K-dependent signalling pathways (178, 180, 181). Moreover, 
muscarinic M3 receptor stimulation induces PKC-dependent GSK-3 inhibition, also 
promoting PDGF-induced airway smooth muscle proliferation (34, 179).  
As indicated above, the regulation of airway smooth muscle cell maturation is 



















of smooth-muscle specific genes (98, 102, 111, 182). Muscarinic agonists regulate 
the promoter activity of smooth muscle specific genes, including sm-22, sm-MHC 
and SRF-dependent genes, both by RhoA and PI3K signalling (110, 181, 183-184). 
RhoA-dependent promoter activity of sm-22 and sm-MHC is upregulated in 
response to inhibition of PKC (Figure 1.2) (182). Overall, this suggests an 
important role for muscarinic M3 receptor activation in the maturation of airway 
smooth muscle cells, and thus in airway remodelling. 
 
A clear role for muscarinic M2 receptors on airway smooth muscle cells in airway 
remodelling has not yet been reported. However, in fibroblasts muscarinic M2 
receptor activation induces cell proliferation through activation of the MAPK 
pathway (38). Furthermore, carbachol, a muscarinic agonist, induces the 
production of collagen by fibroblasts (37, 165). Interestingly, collagen is also 
known to induce cell proliferation (80), which might suggest a role for muscarinic 
M2 receptor-induced collagen production in the regulation of cell proliferation. 
Muscarinic receptors are also involved in the transition of fibroblasts into 
myofibroblasts, through an increase in ERK1/2 phosphorylation, RhoA activation, 
inhibition of cAMP signalling and the release of autocrine TGF-β (185).  
The role of muscarinic receptors in airway remodelling and the mechanism(s) 
involved need further clarification, particularly in concert with TGF-β as a key 
player in airway remodelling.  
Functional roles for acetylcholine in inflammation have also emerged. In bronchial 
epithelial cells, acetylcholine triggers eosinophil, monocyte and neutrophil 
chemotactic activity (186, 187). Both IL-8 and LTB4 release by epithelial cells were 
found dependent on the ERK1/2 and NF-κB pathways (36, 69, 151). In bovine 
tracheal smooth muscle, upregulation of cyclooxygenase (COX)-2, COX-1, IL-8 and 
urokinase type plasminogen activator (PLAU) gene expression was reported in 
response to the muscarinic agonist carbachol (168). Muscarinic receptor agonists 
induce modest release of IL-6 and IL-8 by airway smooth muscle cells (Figure 1.3, 
(30)). Exposure to cigarette smoke extract can significantly enhance these 
properties (30). Nonetheless, the mechanism behind this interaction is still 
unknown. Several inflammatory cells are also activated by acetylcholine, for 
example promoting lymphocyte proliferation, chemotaxis of neutrophils and 
chemotactic factor release by macrophages (Figure 1.3, table 1.1 (145)). 
Inflammatory mediators can also trigger the upregulation of muscarinic receptor 




signalling were upregulated in airway smooth muscle cells in response to TNF-α 
and IL-1β (160, 188). Collectively, these findings indicate that muscarinic receptors 
may be importantly involved in regulating inflammatory responses, suggesting an 
anti-inflammatory role of anticholinergics in obstructive airways diseases. 
 
 
Figure 1.3. Role of neuronal and non-neuronal acetylcholine release in airway 
inflammation. Stimulation of muscarinic receptors on inflammatory cells by neuronal or 
non-neuronal acetylcholine may directly activate these cells. Moreover, muscarinic 
receptor activation on epithelial and airway smooth muscle cells promotes the secretion 
of cytokines by these cells, causing infiltation and activation of inflammatory cells. See text 
for further details. LTB4: leukotriene B4; IL: interleukin; ACh: acetylcholine; MR: muscarinic 
receptor. 
 
In vivo studies support the role of muscarinic receptors in inflammation and 
remodelling. In a guinea pig model of chronic asthma, the allergen-induced airway 
smooth muscle remodelling, including increased contractile protein expression 
and airway smooth muscle thickening, but also mucous gland hypertrophy, 
increased MUC5AC-positive goblet cell numbers and eosinophilia, were inhibited 
by tiotropium bromide (33, 189, 190). Furthermore, in a murine model of asthma 
infiltration of macrophages and eosinophils and expression of IL-4, IL-5, IL-13 and 



















smooth muscle thickening were significantly inhibited by tiotropium bromide 
(191). The allergen-induced infiltration of eosinophils in the BALF was also 
inhibited by the novel muscarinic receptor antagonist, aclidinium bromide (192). 
Also in a cigarette smoke-induced mouse model of COPD, tiotropium bromide 
exerted anti-inflammatory activity, not only by inhibiting total cell number and 
neutrophils, but also by reducing the expression of cytokines, including IL-6, KC, 
TNF-α, and LTB4 in the BALF (193). A recent study using muscarinic receptor 
subtype deficient mice, showed a pro-inflammatory role for the muscarinic M3 
receptor in cigarette smoke-induced neutrophilia and cytokine release, and an 
anti-proinflammatory role for muscarinic M1 and M2 receptors (194). 
 In a guinea pig model of LPS-induced COPD, pulmonary neutrophilia and 
increased peribronchial collagen deposition were also inhibited by tiotropium 
bromide (195). Likewise, the short-acting anticholinergic ipratropium had 
inhibitory effects in a cadmium-induced rat model of pulmonary inflammation 
(196). In a diesel particle-induced rat model of acute lung injury, bilateral 
vagotomy, but also atropine reduced neutrophilia (197). Collectively, these 
studies indicate a profound role for muscarinic receptor activation in airway 
remodelling and inflammation in asthma and COPD. 
 
 
1.4 Aims of the studies 
 
Besides its role as a major regulator of airway constriction and mucus secretion, 
acetylcholine can also regulate remodelling and inflammation of the airways. The 
mechanisms involved have only partially been identified. The primary aim of this 
thesis is to investigate the functional interactions of the cholinergic system with 
inflammatory and remodelling processes in the airways. To this aim, in vitro 
studies were designed to assess the effects of muscarinic receptor stimulation 
alone or in concerted action with cigarette smoke extract or TGF-β1 on key 
features of inflammation and remodelling, using human airway smooth muscle 
cells and precision-cut lung slices. 
Airway smooth muscle cells are capable of expressing and releasing cytokines and 
growth factors, which suggests an important role of this cell type in pro-
inflammatory responses (45, 63). In particular, cigarette smoke (extract) can 
provoke inflammatory responses, including IL-8 secretion, in human airway 




receptors (30, 45, 145). The mechanism(s) by which muscarinic receptors regulate 
these pro-inflammatory responses are still unknown. In chapter 2, we 
investigated the intracellular signalling mechanisms involved in the release of IL-8 
in response to muscarinic receptor stimulation and cigarette smoke extract in 
human airway smooth muscle cells. In this study, the role of PKC and its 
downstream effectors NF-κB and ERK1/2 was investigated. 
In addition to its role in pro-inflammatory responses, muscarinic receptor 
stimulation has been shown to be involved in airway smooth muscle remodelling, 
including increased contractile protein expression, cell proliferation and 
extracellular matrix deposition (145, 198). The pro-fibrotic cytokine TGF-β has also 
been reported to be involved in these processes; however, the functional 
relationship between muscarinic receptors and TGF-β1 has thus far not been 
described. Chapter 3 and 4 address the potential interaction between muscarinic 
receptor stimulation and TGF-β1 in processes involved in airway remodelling. 
Chapter 3 discusses the effect of muscarinic receptor stimulation on TGF-β1-
induced contractile protein expression in human airway smooth muscle cells and 
elucidates the intracellular signalling mechanisms involved. In chapter 4, the 
cooperative regulation of airway smooth muscle cell proliferation by muscarinic 
receptors and TGF-β1 through autocrine regulation of extracellular matrix proteins 
is described. The roles of integrins and muscarinic receptor subtypes in this 
process were investigated by using integrin-blocking peptides and specific 
antagonists (chapter 4). 
During bronchoconstriction, mechanical forces are induced in the airways, which 
can trigger features of airway remodelling (74, 199, 200). The functional 
importance of muscarinic agonist-induced bronchoconstriction on airway 
remodelling was studied in chapter 5. This study describes mechanisms involved 
in the induction of airway remodelling by bronchoconstriction, using precision-cut 
lung slices as an in vitro model. Since a potential role for TGF-β in the induction of 
airway remodelling by bronchoconstriction was recently indicated by a clinical 
study in mild asthma patients (201), the involvement of endogenous TGF-β 
release by bronchoconstriction was studied using selective inhibitors.  
Finally, chapter 6 reviews the role of the cholinergic system in remodelling and 
inflammatory processes within the airways. 
This thesis provides new insights into the regulatory role of muscarinic receptors 
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Background: Acetylcholine, the primary parasympathetic neurotransmitter in the 
airways, plays an important role in bronchoconstriction and mucus production. 
Recently, it has been shown that acetylcholine, by acting on muscarinic receptors, 
is also involved in airway inflammation and remodelling. The mechanism(s) by 
which muscarinic receptors regulate inflammatory responses are, however, still 
unknown.  
Methods: The present study was aimed at characterizing the effect of muscarinic 
receptor stimulation on cytokine secretion by human airway smooth muscle cells 
(hASMc) and to dissect the intracellular signalling mechanisms involved. hASMc 
expressing functional muscarinic M2 and M3 receptors were stimulated with the 
muscarinic receptor agonist methacholine, alone, and in combination with 
cigarette smoke extract (CSE), TNF-α, PDGF-AB or IL-1β.  
Results: Muscarinic receptor stimulation induced modest IL-8 secretion by itself, 
yet augmented IL-8 secretion in combination with CSE, TNF-α or PDGF-AB, but not 
with IL-1β. Pretreatment with GF109203X, a protein kinase C (PKC) inhibitor, 
completely normalized the effect of methacholine on CSE-induced IL-8 secretion, 
whereas PMA, a PKC activator, mimicked the effects of methacholine, inducing IL-
8 secretion and augmenting the effects of CSE. Similar inhibition was observed 
using inhibitors of IкB-kinase-2 (SC514) and MEK1/2 (U0126), both downstream 
effectors of PKC. Accordingly, western blot analysis revealed that methacholine 
augmented the degradation of IкBα and the phosphorylation of ERK1/2 in 
combination with CSE, but not with IL-1β in hASMc. 
Conclusions: We conclude that muscarinic receptors facilitate CSE-induced IL-8 
secretion by hASMc via PKC dependent activation of IκBα and ERK1/2. This 





Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease 
characterized by airflow limitation that is not fully reversible (1). The 
pathophysiology of COPD is mainly caused by cigarette smoke. COPD is associated 
with an increase in local and systemic inflammatory cytokines including TNF-α and 







































leukotriene B4 (4) are correlated to the proportion of neutrophils present and are 
increased in induced sputum of COPD patients. Additionally, during exacerbations 
periods, IL-8 levels are increased (3). Attracted by IL-8, neutrophils play a 
significant role in the pathogenesis of COPD. Neutrophils promote tissue 
inflammation and injury by inducing the release of mediators including elastase, 
metalloproteases and reactive oxygen species (4). 
Acetylcholine, the primary parasympathetic neurotransmitter in the airways plays 
an important role in COPD, by regulating bronchoconstriction and mucus 
production (5). Parasympathetic tone may be increased in COPD (5). Therefore, 
anticholinergics -including tiotropium bromide, a long-acting bronchodilator- are 
often used as a mainstay therapy for COPD (6). Recently, however, it has been 
established that activation of the cholinergic system may also contribute to 
inflammatory responses in the lung. For example, the release of IL-8 and 
leukotriene B4 by bronchial epithelial cells (7, 8) and alveolar macrophages (9) in 
vitro appears to be induced by acetylcholine, resulting in increased neutrophil, 
monocyte, and eosinophil chemotactic activities, an effect that may be enhanced 
in COPD. Also, animal studies showed that anticholinergics are capable of 
reducing neutrophilic and eosinophilic inflammation induced by inhaled diesel-
soot (10), inhaled allergen (11), or LPS (12). Furthermore, it has been reported 
that airway vascular leakage is mediated by muscarinic receptors (13). Collectively, 
these findings suggest a role in pro-inflammatory responses for muscarinic 
receptors. Nonetheless, it is still undefined what the potential anti-inflammatory 
effects of muscarinic antagonists are in the lungs of patients with COPD (14), 
which is in part due to the unknown mechanisms behind the regulation of 
inflammatory responses by muscarinic receptors. 
Human airway smooth muscle (ASM) has been attributed an important role in 
pro-inflammatory responses in COPD (5). These cells are capable of expressing 
and releasing cytokines and growth factors, including IL-6 and IL-8 (15). 
Furthermore, it has been reported that ASM cells express cell surface molecules, 
which can directly interact with immune cells, suggesting an immunomodulatory 
role of these cells in COPD (16). Increased pro-inflammatory cytokine release is 
induced by stimulating human ASM cells (hASMc) with G-protein-coupled 
receptors, growth factors and extracellular matrix proteins (15, 16). Additionaly, 
cigarette smoke can evoke inflammatory responses in human hASMc, such as IL-8 
secretion (17). Muscarinic M2 and M3 receptors, both G-protein-coupled receptors, 




inflammatory responses by ASM (18). Indeed, we recently reported that 
muscarinic receptor stimulation augments cigarette smoke extract (CSE)-induced 
IL-8 secretion by hASMc, which was mediated by the muscarinic M3 receptor 
subtype (19). 
Although these observations illustrate the potential role for acetylcholine in 
regulating airway inflammation, the mechanism(s) by which muscarinic receptors 
regulate inflammatory responses are still unknown. In the present study, we 
investigated the regulation of cytokine secretion from hASMc by muscarinic 
receptors, alone and in concerted action with various pro-inflammatory stimuli 
involved in the pathogenesis of COPD. In addition, we investigated the 
intracellular signalling mechanisms involved, in particular the role of protein 
kinase C (PKC) and downstream pathways.  
 
 
2.2 Materials and methods 
 
2.2.1 Antibodies and reagents 
Methacholine chloride (MCh) was purchased from ICN Biomedicals (Zoetermeer, 
the Netherlands). GF109203X and U0126 were both from Tocris Cookson Inc. 
(Bristol, UK). SC514 was obtained from Calbiochem (Amsterdam, The 
Netherlands). PMA, mouse anti-ß-actin antibody, horseradish peroxidase (HRP)-
conjugated rabbit anti-mouse antibody, HRP-conjugated goat anti-rabbit, 
recombinant human TNF-α, and IL-1β were purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Human recombinant platelet-derived growth 
factor-AB (PDGF-AB) was from Bachem (Weil am Rhein, Germany). Phospho-
p44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody and p44/42 MAPK (ERK1/2) 
antibody were obtained from Cell Signalling Technology (Beverly, CA, USA). Rabbit 
anti-IкBα (clone-15) was purchased from Santa Cruz Biotechnology, INC (Santa 
Cruz CA, USA). All other chemicals were of analytical grade. 
 
2.2.2 Cell culture 
Human bronchial smooth muscle cell lines immortalized by stable expression of 
human telomerase reverse transcriptase (hTERT) were prepared as described 
previously (20). The primary cultured human bronchial smooth muscle cells used 
to generate these cell lines were prepared from macroscopically healthy 







































surgery from patients with a diagnosis of adenocarcinoma. All procedures were 
approved by the Human Research Ethics Board of the University of Manitoba. 
Cells were grown to confluence using DMEM supplemented with 10% FBS, 100 
µg/mL streptomycin, 100 U/mL penicillin and 1.5 µg/mL amphotericin B. Cultures 
were maintained in a humidified incubator at 37°C-5% CO2, and media was 
changed every 2-3 days. 
 
2.2.3 Cytokine release 
Cells were cultured in 24 well plates and grown until confluence followed by 
serum-deprivation for 1 day in DMEM supplemented with antibiotics (100 µg/mL 
streptomycin, 100 U/mL penicillin and 1.5 µg/mL amphotericin B) and ITS (5 
µg/mL insulin, 5 µg/mL transferrin, and 5 ng/mL selenium) before each 
experiment. The cells were stimulated with the muscarinic receptor agonist 
methacholine chloride (MCh, 10 μM), alone and in combination with either CSE 
(5%), TNF-α (1 ng/mL), PDGF-AB (30 ng/mL) or IL-1β (1 ng/mL) for 24 hrs to 
determine cytokine secretion in cell-free supernatant. 100 % strength CSE was 
prepared by combusting two 3R4F research cigarettes (without filter) (University 
of Kentucky, Kentucky, USA) using a peristaltic pump and passing the smoke 
through 25 mL of FBS-free medium at the rate of one cigarette per 5 min. CSE was 
freshly prepared before every experiment and was used within 15 min after 
preparation. Additionally, where appropriate, hASMc were pre-incubated with 
either the PKC inhibitor GF109203X (3 μM), the IKK-2-inhibitor SC514 (50 μM) or 
the MEK inhibitor U0126 (3 μM) for 30 min. Cells were also treated with the PKC 
activator PMA (0.1 μM). Cytokine levels were quantified using enzyme-linked 
immunosorbent assays (ELISA), according to the manufacturer’s instructions 
(Sanquin Pharmaceutical services, Amsterdam, The Netherlands). The detection 
limit was 1 pg/ml for IL-8 and 0.2 pg/ml for IL-6. We diluted samples were needed 
to remain in the range of the standard curve. 
 
2.2.4 Preparation of whole cell lysates 
HASMc were cultured in 6 well plates and grown until confluence followed by 
serum-deprivation for 1 day in DMEM supplemented with antibiotics (100 µg/mL 
streptomycin, 100 U/mL penicillin and 1.5 µg/mL amphotericin B) and ITS before 
each experiment. The cells were stimulated with the muscarinic receptor agonist 
MCh (10 μM), alone and in combination with either CSE (5 %) or IL-1β (1 ng/mL) 




cold PBS (NaCl 140 mM, KCl 2.6 mM, KH2PO4 1.4 mM, Na2HPO4.2H2O 8.1 mM, pH 
7.4), followed by lysis using ice-cold RIPA buffer (Tris 40 mM, NaCl 150 mM, Igepal 
1%, deoxycholic acid 1%, NaF 1 mM, Na3VO4 1 mM, aprotinin 10 μg/mL, leupeptin 
10 μg/mL, pepstatin A 7 μg/mL, β-glycerophosphate 1.08 mg/mL, pH 8.0). 
Sonicated lysates were assayed for protein content according to Bradford and 
stored at -20°C until further use. 
 
2.2.5 Western Blotting 
Equal amounts of protein were separated on 10 % polyacrylamide-SDS gels and 
transferred to nitrocellulose membranes. To avoid non-specific binding, 
membranes were blocked with blocking buffer (Tris-HCl 50 mM, NaCl 150 mM, 
TWEEN-20 0.1%, non-fat dried milk powder 5 %) for 1 hour at room temperature. 
The membranes were then incubated with specific primary antibodies, all diluted 
in blocking buffer, for one hour at room temperature. After washing the 
membranes three times with TBS-T 0.1% (Tris-HCl 50 mM, NaCl 150 mM, TWEEN-
20 0.1%) for 10 min, incubation with the secondary antibody conjugated to HRP 
was performed during 1 h at room temperature, followed by additional three 
washes with TBS-T 0.1%. Bands were subsequently visualized on film using 
enhanced chemiluminescence reagents and analysed by densitometry (TotallabTM, 
Nonlinear dynamics, Newcastle, UK). All bands were normalized to either β-actin 
for IкBα or to total ERK1/2 for phospho ERK1/2. 
 
2.2.6 Data analysis 
Data are presented as mean values ± SE. Statistical significance of differences 
between means was determined by a Student’s t test or by one-way ANOVA, 





2.3.1 Muscarinic receptor stimulation facilitates cytokine secretion induced by 
CSE, TNF-α and PDGF-AB 
Recently, it has been reported that stimulation of muscarinic receptors induces 
the release of IL-8 from human bronchial epithelial cells and facilitates the release 
of IL-8 from hASMc induced by CSE (8, 19). We evaluated the pro-inflammatory 







































action with CSE (5 %), PDGF-AB (30 ng/mL), TNF-α (1 ng/mL) or IL-1β (1 ng/mL) 
(Figure 2.1). Previous findings indicated that the effects of muscarinic receptor 
stimulation on ASM cytokine secretion were most profound for IL-6 and IL-8 (19), 
with maximal effects seen at a concentration of 10 μM MCh. Therefore, we used 
10 μM MCh and focused on IL-6 and IL-8 cytokines for our measurements. We 
observed a minor increase in IL-8 induced by MCh alone. CSE alone induced a 
significant increase of both IL-8 and IL-6 secretion, which was significantly and 
synergistically amplified by co-stimulation with MCh. In addition, MCh induced a 
synergistic increase in both IL-8 and IL-6 secretion in combination with TNF-α. 
Furthermore, a synergistic effect was also observed with the combination of MCh 
and PDGF-AB for IL-8 secretion. However, the effect of IL-1β, which induced a very 
high IL-8 and IL-6 production by its own, was not significantly augmented by MCh 
(Figure 2.1). IL-8 release in response to IL-1β was found concentration dependent, 
but treatment with MCh had no additional effects regardless of the concentration 
IL-1β used (data not shown). 
 
Figure 2.1. Muscarinic receptor stimulation augments cytokine secretion induced by CSE, 
PDGF-AB and TNF-α, but not by IL-1β. hASMc were stimulated with CSE (5%, n=22 and 
n=6 for IL-8 and IL-6, respectively), TNF-α (1 ng/mL, n=17 and n=5 for IL-8 and IL-6, 
respectively), IL-1β (1 ng/mL, n=17 and n=6 for IL-8 and IL-6, respectively) or PDGF-AB (30 
ng/mL, n=6 for IL-8), in the absence or presence of MCh (10 μM) for 24 hours. 
Supernatants were analyzed for the presence of IL-8 (A) or IL-6 (B). Data shown are the 
means ± SE of n independent experiments. *p< 0.05, **p< 0.01 and ***p< 0.001 
compared to basal; †p< 0.05 and ††p< 0.01 compared to the absence of MCh (Student's t-





2.3.2 PKC is involved in the synergistic effect of muscarinic receptor 
stimulation with CSE 
PKC plays an important role as a signalling intermediate in pro-inflammatory 
cytokine secretion by inducing the activation of several downstream pathways, 
including the IKK-2/IκBα/NF-κB and Raf-1/MEK/ERK1/2 pathways (21). The 
stimulation of muscarinic receptors induces the activation of PKC in ASM (22, 23). 
We hypothesized therefore, that PKC could play a central role in the synergism 
between CSE and MCh in IL-8 secretion. HASMc were pretreated with GF109203X 
(3 μM), a specific PKC inhibitor, and subsequently stimulated with MCh, CSE and 
their combination (Figure 2.2). GF109203X significantly inhibited the synergistic 
effect of MCh on CSE-induced IL-8 secretion, demonstrating a requirement for 
PKC in this synergism. Remarkably, in the absence of the muscarinic agonist, 











Figure 2.2. Involvement of PKC in the potentiation of CSE-induced IL-8 release by 
muscarinic receptor stimulation. hASMc were stimulated with CSE (5%) in the absence or 
presence of MCh (10 μM) and/or GF109203X (3 μM) for 24 hours. Supernatants were 
analyzed for the presence of IL-8. Data represent means ± SE of 7 independent 
experiments each performed in duplicate. ***p< 0.001 compared to basal; $$$p< 0.001 
compared to CSE; †p < 0.05 compared to the absence of GF109203X (One-way ANOVA 
followed by Newman-Keuls multiple comparisons test). 
 
To investigate whether PKC activation was sufficient for a synergistic IL-8 
secretion in combination with CSE, we used PMA (0.1 μM) as a PKC activator. 
Indeed, CSE-induced IL-8 secretion was highly augmented in the presence of PMA, 
which could be abolished to the level of CSE-induced IL-8 secretion when pre-







































sufficient for a synergistic interaction with CSE, which is in support of a central 
role for PKC in regulating the synergy between MCh and CSE. In contrast to MCh, 
however, PMA induced a considerable IL-8 secretion by itself, which was 
abolished when the cells were pre-treated with GF109203X.  
PKC has been shown to induce activation of the NF-кB and ERK1/2 pathways in 
different cells (21). Moreover, it has been reported that the stimulation of 
muscarinic receptors through acetylcholine mediates the release of IL-8 in human 
bronchial epithelial cells by NF-кB- and ERK1/2-dependent mechanisms (8). To 
test the involvement of the NF-кB and ERK1/2 pathways as a result of PKC 
activation, hASMc were stimulated with PMA after pre-treatment with either an 
IKK-2 inhibitor, SC514, or a MEK1/2 inhibitor, U0126. IL-8 secretion induced by 
PMA was significantly decreased in presence of these pharmacological inhibitors 
(Figure 2.3B for SC514 and Figure 2.3C for U0126, respectively). Moreover, 
western blot analysis indicated that the activation of PKC by PMA induced the 
phosphorylation of ERK1/2 and the degradation of IкBα in hASMc. Collectively, 
these data indicate that PKC is able to activate the IкBα/NF-κB and MEK/ERK1/2 





Figure 2.3. PKC activation is sufficient to facilitate CSE-induced IL-8 secretion in hASMc. 
hASMc were stimulated with PMA (0.1 μM), in the absence or presence of CSE (5%) and 
GF109203X (3 μM) (A), SC514 (50 μM) (B) or U0126 (3 μM) (C) for 24 hours. Supernatants 
were analyzed for the presence of IL-8. Data represent means ± SE of 4-6 independent 
experiments each performed in duplicate. *p < 0.05, **p< 0.01 and ***p< 0.001 
compared to basal; $$$p< 0.001 compared to PMA; †p< 0.05, ††p< 0.01 and †††p < 0.001 
compared to the absence of inhibitor (One-way ANOVA followed by Newman-Keuls 
multiple comparisons test). (D) hASMc were stimulated with PMA (0.1 μM) for 1 hour. Cell 
lysates were analyzed for IκBα breakdown and phosphorylation of ERK1/2 by western blot. 
β-actin and total ERK1/2 were used as loading controls. Western blots shown are 
representative of 4 experiments. 
 
2.3.3 Involvement of the IкBα/NF-κB pathway in the synergistic effect of 
muscarinic receptor stimulation with CSE 
HASMc were pretreated with the IKK-2 inhibitor SC514 to test the involvement of 
this pathway in the synergistic IL-8 secretion by MCh and CSE (Figure 2.4A). SC514 
completely inhibited the MCh- and CSE-induced IL-8 secretion. Furthermore, the 







































These results confirm the involvement of the IкBα/NF-κB pathway in the observed 
IL-8 secretion. Therefore, we next investigated the effects of muscarinic receptor 
stimulation on IκBα degradation, alone and in combination with CSE at different 
time points (60 and 120 min of treatment). IκBα degradation was measured by 
western blot analysis. Although MCh did not induce significant IκBα degradation 
by itself, it augmented the response induced by CSE; particularly after 120 min of 
incubation (Figure 2.4D). Overall, these results indicate that muscarinic receptor 
stimulation promotes the activation of the IкBα/NF-кB pathway induced by CSE, 
which likely contributes to the synergistic IL-8 secretion. Interestingly, and in line 
with the lack of effect of MCh on IL-1β-induced cytokine secretion, MCh did not 
augment maximal IL-1β-induced IκBα degradation at t = 60 and 120 min (Figure 
2.4E). However, IL-1β-induced IL-8 secretion in presence or absence of MCh, was 






Figure 2.4. Involvement of the IκBα/NF-κB pathway in IL-8 secretion induced by CSE, IL-
1β and MCh. hASMc were stimulated with CSE (5%) (A) or IL-1β (1 ng/mL) (B) in the 
absence or presence of MCh (10 μM) and/or SC514 (50 μM) for 24 hours. Supernatants 
were analyzed for the presence of IL-8. Data represent means ± SE of 5 independent 
experiments each performed in duplicate. **p< 0.01 and ***p< 0.001 compared to 







































compared to CSE (One-way ANOVA followed by Newman-Keuls multiple comparisons test). 
(C-E) hASMc were stimulated with CSE (5%) (C-D) or IL-1β (1 ng/mL) (C-E) in the absence or 
presence of MCh for 60 min and 120 min (representative blots shown in C) as indicated. 
IκBα degradation was determined by western blot and corrected for the expression of β-
actin, which was used as a loading control. Data represent means ± SE of 9-10 experiments. 
*p< 0.05 and ***p< 0.001 compared to basal and ††p< 0.01 compared the absence of 
MCh (Student's t-test for paired observations). 
 
2.3.4 Involvement of the MEK/ERK1/2 pathway in the synergistic effect of 
muscarinic receptor stimulation with CSE 
To test the involvement of the MEK/ERK1/2 pathway in IL-8 secretion induced by 
MCh and CSE, we pretreated the cells with the MEK1/2 inhibitor, U0126 (3 μM) 
(Figure 2.5A). In the presence of U0126, IL-8 secretion induced by co-stimulation 
of CSE with MCh was significantly decreased (Figure 2.5A). These results confirm 
the involvement of the MEK/ERK1/2 pathway in the observed IL-8 secretion. 
Therefore, we next assessed phosphorylation of ERK1/2 induced by MCh and CSE 
(Figure 2.5C-D). Although, ERK1/2 phosphorylation was not significantly increased 
when cells were stimulated with MCh alone after one hour of incubation, 15 min 
incubation is sufficient to induce significant ERK1/2 phosphorylation (23). In 
combination with CSE, MCh induced a significant increase in the phosphorylation 
of ERK1/2 at this time point (one hour). These results support the involvement of 
the ERK1/2 pathway in the synergism between CSE and MCh at the level of IL-8 
secretion. In contrast, IL-1β induced ERK1/2 phosphorylation was not increased by 
MCh and also pre-treatment with U0126 had no effect (Figure 2.5B-D). These 
results are in agreement with the results of Orsini, et al., demonstrating that IL-1β 
can induce a transient phosphorylation of ERK1/2 in human airway smooth 














Figure 2.5. Involvement of the MEK/ERK1/2 pathway in IL-8 release induced by MCh. 
hASMc were stimulated with CSE (5%) (A) or IL-1β (1 ng/mL) (B), in the absence or 
presence of MCh (10 μM) and/or U0126 (3 μM) for 24 hours. Supernatants were analyzed 
for the presence of IL-8. *p< 0.05 and **p< 0.01 compared to basal; $$$p< 0.001 compared 
to CSE alone, †††p<0.001 compared to the absence of U0126. (One-way ANOVA followed 
by Newman-Keuls multiple comparisons test). (C-D) hASMc were stimulated with CSE (5%) 
or IL-1β (1 ng/mL) in the absence or presence of MCh (10 μM) for 60 min. Cell lysates were 
analyzed for phospho-ERK1/2 by western blot and corrected for the expression of total 
ERK1/2, which was used as a loading control. Data represent means ± SE of 5 independent 
experiments each performed in duplicate. $p< 0.05 compared to CSE alone (Student's t-
test for paired observations). 
 
 
2.4 Discussion  
 
In the present study, we demonstrate that muscarinic receptors stimulate the 
secretion of the pro-inflammatory cytokine IL-8 from hASMc, and augment the 
response induced by TNF-α, CSE and PDGF-AB. Furthermore, we dissected the 
underlying mechanism of the synergistic IL-8 production. To permit the release of 
the pro-inflammatory cytokine IL-8 after activation of the muscarinic receptors 







































In parallel, the activation of PKC leads to the stimulation of MEK1/2 inducing the 
phosphorylation of ERK1/2. Both pathways regulate IL-8 secretion, which, as 
previously described, is dependent on NF-кB and AP-1 IL-8 promoter activation 
(25). 
 
Our current and previously published data (19) indicate that the activation of 
muscarinic receptors in hASMc facilitates the secretion of the pro-inflammatory 
cytokines IL-6 and IL-8. Functional muscarinic receptors are expressed on the 
majority of inflammatory cells (5). Also, the endogenous muscarinic receptor 
ligand acetylcholine and its synthesizing enzyme choline acetyltransferase (ChAT) 
are present in several extraneuronal cell types, including airway epithelial cells, 
lymphocytes, eosinophils, neutrophils, macrophages, and mast cells (5, 26). 
Furthermore, animal models showed that atropine reduces lung inflammation 
induced by diesel-soot in rats (10), and that tiotropium bromide inhibits several 
aspects of airway inflammation and remodelling in ovalbumin-sensitized guinea 
pigs (11, 27). Additionally, it has been reported that carbachol, by activation of 
muscarinic receptors, is able to increase inflammatory gene expression in ASM, 
including IL-6, IL-8 and cyclooxygenase-2 (COX-2) (28). Furthermore, acetylcholine 
(ACh) can induce leukotriene B4 (LTB4) release from sputum COPD cells (4), also 
indicating a regulatory role for ACh in inflammatory cells. Taken together, this 
indicates that acetylcholine is importantly involved in the regulation of pro-
inflammatory responses. Our current results provide new insights as we 
demonstrate that the activation of muscarinic receptors interacts with several 
cytokines and growth factors, in particular with TNF-α, PDGF-AB and CSE to 
enhance their inflammatory response in hASMc.  
 
HASMc produce a variety inflammatory mediators (15, 16, 29). This suggests an 
important role for ASM in inflammatory responses in COPD. Indeed, hASMc are a 
source of chemokines and cytokines that play a role in chronic pulmonary 
diseases like COPD and asthma, including IL-8 and IL-6. The levels of IL-8 are 
correlated with the degree of neutrophilic inflammation and are increased in 
sputum in COPD patients (3, 30). Several pro-inflammatory stimuli, including IL-17 
(31-33), gram-positive and gram-negative bacteria (34), β-tryptase (35), IL-1β (32) 
and TNF-α (17) are able to induce IL-8 secretion from human ASM. Moreover, CSE 
synergizes with TNF-α to enhance IL-8 secretion by ASM (17). We previously 




synergistic increase in IL-8 secretion by hASMc (19), which as demonstrated in this 
study, is dependent on downstream signalling to PKC and the IκBα/NF-κB and 
MEK/ERK1/2 pathways. Nicotinic receptors and muscarinic M2 receptors are not 
involved in this synergism, as gallamine had no effect on IL-8 release induced by 
either CSE or MCh (19). This indicates that acetylcholine may also play an 
important role in the inflammatory/immunomodulatory processes driven by 
human ASM. 
 
Using the PKC inhibitor GF109203X, we demonstrate that the synergism of MCh 
and CSE-induced IL-8 secretion is mediated by PKC in hASMc. In fact, activation of 
PKC was sufficient to induce synergistic IL-8 secretion in combination with CSE, 
which was confirmed by the use of the PKC activator, PMA. These observations 
correspond with an earlier study from our group demonstrating that MCh 
augments PDGF-induced cell proliferation via the activation of PKC (23) and 
appear to suggest that muscarinic M3 receptors exert their facilitatory effects on 
remodelling and inflammation to an important extent via the activation of PKC. 
Downstream, we demonstrated that PKC is able to induce the activation of 
IκBα/NF-кB and MEK/ERK1/2 pathways in hASMc and that these pathways are 
involved in the secretion of IL-8 induced by the co-stimulation of muscarinic 
receptors and CSE. Interestingly, the co-stimulation with CSE and MCh appeared 
required to reveal the importance of PKC, as stimulation with either CSE or MCh 
alone was not sufficient to demonstrate an involvement of PKC. This indicates that 
PKC stimulation by MCh is not sufficient to induce an IL-8 or IL-6 response by itself, 
but augments pro-inflammatory signalling to NF-κB and ERK1/2 induced by CSE. 
However, synergistic functional interactions with IL-1β, an important cytokine in 
COPD pathogenesis (36), were not observed, both for IL-8 secretion and for 
activation of the signalling pathways investigated, indicating that the mechanism 
of the synergistic interaction is stimulus specific. Lower concentrations of IL-1β 
were also tested and were found to be similarly unaffected by MCh (data not 
shown). 
The combination of MCh and CSE likely triggers PKC to activate IKK-2. This kinase 
allows the phosphorylation and degradation of IкBα leading to the translocation 
of NF-кB into the nucleus to regulate NF-кB gene transcription (37). Furthermore, 
PKC has been shown to be critically involved in the activation of the ERK1/2 
pathway in human aortic smooth muscle cells (38). PKC induces the 







































followed by the regulation of AP-1 dependent gene transcription. The IL-8 gene 
contains both NF-кB and AP-1 binding sites in its promoter region (25). Epithelial 
cells are also able, to induce IL-8 secretion through the activation of ERK1/2 and 
NF-кB in response to pro-inflammatory stimuli, including acetylcholine (8, 39, 40). 
Taken together, these findings and our previous findings (19) indicate that the 
synergism between muscarinic M3 receptors and CSE is mediated by PKC 
dependent activation of the downstream pathways NF-кB and ERK1/2, to induce 
the secretion of IL-8. 
 
It is unclear whether the pro-inflammatory effects of muscarinic receptor 
stimulation and CSE, as observed in our current work, are relevant to the COPD 
patient. Nonetheless, several clinical studies demonstrated that short-term 
therapy with tiotropium bromide improves airflow and hyperinflation (41, 42). 
Moreover, long-term use (up to 6 to 12 months) of this anticholinergic drug 
improved exercise tolerance, quality of life, rates of dyspnoea but also the 
exacerbation frequency in COPD patients, which are associated with periods of 
increased inflammatory cell influx (41, 43). The Understanding Potential Long-
Term Impacts on Function with Tiotropium (UPLIFT) study concluded that COPD 
patients treated with tiotropium bromide during a 4-year period improved their 
quality of life, frequency of exacerbations and lung function, but tiotropium 
bromide did not reduce the decline in FEV1 over the treatment period (44). 
Nonetheless, in a subgroup of COPD patients of the UPLIFT study, which were not 
on other controller medication, a reduction in the accelerated FEV1 decline was 
observed in the tiotropium bromide arm (post-hoc analysis of the UPLIFT study 
(44)). This was also observed in the subgroup of stage II COPD patients (45). 
Collectively, besides the well described bronchodilatory effects, these findings 
suggest additional, non-bronchodilator properties for tiotropium bromide (6). An 
anti-inflammatory role for anticholinergics is in agreement with animal and cell 
culture studies showing a role for acetylcholine in cell proliferation, extracellular 
matrix protein secretion and inflammation (5, 46, 47) and with our present 
findings showing that the inflammatory response induced by CSE, TNF-α and 
PDGF-AB can be augmented by muscarinic receptor stimulation in hASMc. It 
should be emphasized, however, that the hypothesis “tiotropium bromide may 







1. Pauwels RA, Buist AS, Calverley PM, 
Jenkins CR, Hurd SS. Global strategy for the 
diagnosis, management, and prevention of 
chronic obstructive pulmonary disease. 
NHLBI/WHO global initiative for chronic 
obstructive lung disease (GOLD) workshop 
summary. Am J Respir Crit Care Med 
2001;163:1256-1276.  
2. Edwards MR, Bartlett NW, Clarke D, 
Birrell M, Belvisi M, Johnston SL. Targeting 
the NF-kappaB pathway in asthma and 
chronic obstructive pulmonary disease. 
Pharmacol Ther 2009;121:1-13.  
3. Kim V, Rogers TJ, Criner GJ. New 
concepts in the pathobiology of chronic 
obstructive pulmonary disease. Proc Am 
Thorac Soc 2008;5:478-485.  
4. Profita M, Giorgi RD, Sala A, Bonanno A, 
Riccobono L, Mirabella F, Gjomarkaj M, 
Bonsignore G, Bousquet J, Vignola AM. 
Muscarinic receptors, leukotriene B4 
production and neutrophilic inflammation 
in COPD patients. Allergy 2005;60:1361-
1369.  
5. Gosens R, Zaagsma J, Meurs H, Halayko 
AJ. Muscarinic receptor signaling in the 
pathophysiology of asthma and COPD. 
Respir Res 2006;7:73-88.  
6. Bateman ED, Rennard S, Barnes PJ, 
Dicpinigaitis PV, Gosens R, Gross NJ, Nadel 
JA, Pfeifer M, Racke K, Rabe KF, Rubin BK, 
Welte T, Wessler I. Alternative mechanisms 
for tiotropium. Pulm Pharmacol Ther 
2009;22:533-542.  
7. Koyama S, Rennard SI, Robbins RA. 
Acetylcholine stimulates bronchial 
epithelial cells to release neutrophil and 
monocyte chemotactic activity. Am J 
Physiol 1992;262:L466-L471.  
8. Profita M, Bonanno A, Siena L, Ferraro M, 
Montalbano AM, Pompeo F, Riccobono L, 
Pieper MP, Gjomarkaj M. Acetylcholine 
mediates the release of IL-8 in human 
bronchial epithelial cells by a NFkB/ERK-
dependent mechanism. Eur J Pharmacol 
2008;582:145-153.  
9. Sato E, Koyama S, Okubo Y, Kubo K, 
Sekiguchi M. Acetylcholine stimulates 
alveolar macrophages to release 
inflammatory cell chemotactic activity. Am 
J Physiol 1998;274:L970-L979.  
10. McQueen DS, Donaldson K, Bond SM, 
McNeilly JD, Newman S, Barton NJ, Duffin 
R. Bilateral vagotomy or atropine pre-
treatment reduces experimental diesel-
soot induced lung inflammation. Toxicol 
Appl Pharmacol 2007;219:62-71.  
11. Bos IST, Gosens R, Zuidhof AB, 
Schaafsma D, Halayko AJ, Meurs H, 
Zaagsma J. Inhibition of allergen-induced 
airway remodelling by tiotropium and 
budesonide: A comparison. Eur Respir J 
2007;30:653-661.  
12. Pera T, Zuidhof AB, Gosens R, 
Maarsingh H, Zaagsma J, Meurs H. 
Tiotropium inhibits inflammation and 
remodeling in a guinea pig model of COPD. 
Am J Respir Crit Care Med 2009;179:A6328.  
13. Cui YY, Zhu L, Wang H, Advenier C, 
Chen HZ, Devillier P. Muscarinic receptors 
involved in airway vascular leakage 
induced by experimental gastro-
oesophageal reflux. Life Sci 2008;82:949-
955.  
14. Trevethick M, Clarke N, Strawbridge M, 
Yeadon M. Inhaled muscarinic antagonists 
for COPD-does an anti-inflammatory 
mechanism really play a role? Curr Opin 







































15. Chung KF. The role of airway smooth 
muscle in the pathogenesis of airway wall 
remodeling in chronic obstructive 
pulmonary disease. Proc Am Thorac Soc 
2005;2:347-354.  
16. Zuyderduyn S, Sukkar MB, Fust A, 
Dhaliwal S, Burgess JK. Treating asthma 
means treating airway smooth muscle cells. 
Eur Respir J 2008;32:265-274.  
17. Oltmanns U, Chung KF, Walters M, John 
M, Mitchell JA. Cigarette smoke induces IL-
8, but inhibits eotaxin and RANTES release 
from airway smooth muscle. Respir Res 
2005;6:74.  
18. Racke K, Matthiesen S. The airway 
cholinergic system: Physiology and 
pharmacology. Pulm Pharmacol Ther 
2004;17:181-198.  
19. Gosens R, Rieks D, Meurs H, Ninaber DK, 
Rabe KF, Nanninga J, Kolahian S, Halayko AJ, 
Hiemstra PS, Zuyderduyn S. Muscarinic M3 
receptor stimulation increases cigarette 
smoke-induced IL-8 secretion by human 
airway smooth muscle cells. Eur Respir J 
2009;34:1436-1443.  
20. Gosens R, Stelmack GL, Dueck G, 
McNeill KD, Yamasaki A, Gerthoffer WT, 
Unruh H, Gounni AS, Zaagsma J, Halayko AJ. 
Role of caveolin-1 in p42/p44 MAP kinase 
activation and proliferation of human 
airway smooth muscle. Am J Physiol Lung 
Cell Mol Physiol 2006;291:L523-L534.  
21. Park H, Park SG, Kim J, Ko YG, Kim S. 
Signaling pathways for TNF production 
induced by human aminoacyl-tRNA 
synthetase-associating factor, p43. 
Cytokine 2002;20:148-153.  
22. Bremerich DH, Warner DO, Lorenz RR, 
Shumway R, Jones KA. Role of protein 
kinase C in calcium sensitization during 
muscarinic stimulation in airway smooth 
muscle. Am J Physiol 1997;273:L775-L781.  
23. Gosens R, Dueck G, Rector E, Nunes RO, 
Gerthoffer WT, Unruh H, Zaagsma J, Meurs 
H, Halayko AJ. Cooperative regulation of 
GSK-3 by muscarinic and PDGF receptors is 
associated with airway myocyte 
proliferation. Am J Physiol Lung Cell Mol 
Physiol 2007;293:L1348-L1358.  
24. Orsini MJ, Krymskaya VP, Eszterhas AJ, 
Benovic JL, Panettieri RA,Jr., Penn RB. 
MAPK superfamily activation in human 
airway smooth muscle: Mitogenesis 
requires prolonged p42/p44 activation. Am 
J Physiol 1999;277:L479-L488.  
25. Roebuck KA, Carpenter LR, 
Lakshminarayanan V, Page SM, Moy JN, 
Thomas LL. Stimulus-specific regulation of 
chemokine expression involves differential 
activation of the redox-responsive 
transcription factors AP-1 and NF-kappaB. J 
Leukoc Biol 1999;65:291-298.  
26. Wessler I, Kirkpatrick CJ, Racke K. The 
cholinergic 'pitfall': Acetylcholine, a 
universal cell molecule in biological 
systems, including humans. Clin Exp 
Pharmacol Physiol 1999;26:198-205.  
27. Gosens R, Bos IS, Zaagsma J, Meurs H. 
Protective effects of tiotropium bromide in 
the progression of airway smooth muscle 
remodeling. Am J Respir Crit Care Med 
2005;171:1096-1102.  
28. Kanefsky J, Lenburg M, Hai CM. 
Cholinergic receptor and cyclic stretch-
mediated inflammatory gene expression in 
intact ASM. Am J Respir Cell Mol Biol 
2006;34:417-425.  
29. Clarke D, Damera G, Sukkar MB, Tliba O. 
Transcriptional regulation of cytokine 
function in airway smooth muscle cells. 
Pulm Pharmacol Ther 2009;22:436-445.  
30. Tetley TD. Inflammatory cells and 




Curr Drug Targets Inflamm Allergy 
2005;4:607-618.  
31. Vanaudenaerde BM, Wuyts WA, 
Geudens N, Dupont LJ, Schoofs K, Smeets S, 
Van Raemdonck DE, Verleden GM. 
Macrolides inhibit IL17-induced IL8 and 8-
isoprostane release from human airway 
smooth muscle cells. Am J Transplant 
2007;7:76-82.  
32. Dragon S, Rahman MS, Yang J, Unruh H, 
Halayko AJ, Gounni AS. IL-17 enhances IL-
1β-mediated CXCL-8 release from human 
airway smooth muscle cells. Am J Physiol 
Lung Cell Mol Physiol 2007;292:L1023-
L1029.  
33. Rahman MS, Yang J, Shan LY, Unruh H, 
Yang X, Halayko AJ, Gounni AS. IL-17R 
activation of human airway smooth muscle 
cells induces CXCL-8 production via a 
transcriptional-dependent mechanism. 
Clinical Immunology 2005;115:268-276.  
34. Issa R, Sorrentino R, Sukkar MB, 
Sriskandan S, Chung KF, Mitchell JA. 
Differential regulation of CCL-11/eotaxin-1 
and CXCL-8/IL-8 by gram-positive and 
gram-negative bacteria in human airway 
smooth muscle cells. Respir Res 2008;9:30.  
35. Mullan CS, Riley M, Clarke D, Tatler A, 
Sutcliffe A, Knox AJ, Pang L. Β-tryptase 
regulates IL-8 expression in airway smooth 
muscle cells by a PAR-2-independent 
mechanism. Am J Respir Cell Mol Biol 
2008;38:600-608.  
36. Chung KF. Cytokines as targets in 
chronic obstructive pulmonary disease. 
Curr Drug Targets 2006;7:675-681.  
37. Wong ET, Tergaonkar V. Roles of NF-
kappaB in health and disease: Mechanisms 
and therapeutic potential. Clin Sci (Lond) 
2009;116:451-465.  
38. Chen QW, Edvinsson L, Xu CB. Role of 
ERK/MAPK in endothelin receptor signaling 
in human aortic smooth muscle cells. BMC 
Cell Biol 2009;10:52.  
39. Holtmann H, Winzen R, Holland P, 
Eickemeier S, Hoffmann E, Wallach D, 
Malinin NL, Cooper JA, Resch K, Kracht M. 
Induction of interleukin-8 synthesis 
integrates effects on transcription and 
mRNA degradation from at least three 
different cytokine- or stress-activated 
signal transduction pathways. Mol Cell Biol 
1999;19:6742-6753.  
40. Oudin S, Pugin J. Role of MAP kinase 
activation in interleukin-8 production by 
human BEAS-2B bronchial epithelial cells 
submitted to cyclic stretch. Am J Respir Cell 
Mol Biol 2002;27:107-114.  
41. O'Donnell DE, Fluge T, Gerken F, 
Hamilton A, Webb K, Aguilaniu B, Make B, 
Magnussen H. Effects of tiotropium on lung 
hyperinflation, dyspnoea and exercise 
tolerance in COPD. Eur Respir J 
2004;23:832-840.  
42. Maltais F, Hamilton A, Marciniuk D, 
Hernandez P, Sciurba FC, Richter K, Kesten 
S, O'Donnell D. Improvements in symptom-
limited exercise performance over 8 h with 
once-daily tiotropium in patients with 
COPD. Chest 2005;128:1168-1178.  
43. Casaburi R, Mahler DA, Jones PW, 
Wanner A, San PG, ZuWallack RL, Menjoge 
SS, Serby CW, Witek T,Jr. A long-term 
evaluation of once-daily inhaled tiotropium 
in chronic obstructive pulmonary disease. 
Eur Respir J 2002;19:217-224.  
44. Tashkin DP, Celli B, Senn S, Burkhart D, 
Kesten S, Menjoge S, Decramer M. A 4-year 
trial of tiotropium in chronic obstructive 








































45. Decramer M, Celli B, Burkhart D, Kesten 
S, Mehra S, Liu D, Tashkin DP. The effect of 
tiotropium on COPD GOLD stage II during 
the four-year UPLIFT trial. Am J Respir Crit 
Care Med 2009;179:A2466.  
46. Gosens R, Zaagsma J, Grootte BM, 
Nelemans A, Meurs H. Acetylcholine: A 
novel regulator of airway smooth muscle 
remodelling? Eur J Pharmacol 
2004;500:193-201.  
47. Racke K, Juergens UR, Matthiesen S. 
Control by cholinergic mechanisms. Eur J 
Pharmacol 2006;533:57-68.  
 





stimulation augments  
TGF-β1-induced 
contractile protein expression 

















Tjitske A. Oenema 
Marieke Smit 
Lyanne Smedinga 





Am J Physiol Lung Cell Mol Physiol (2012) 303: L589-L597 




Acetylcholine (ACh) is the primary parasympathetic neurotransmitter in the 
airways. Recently, it was established that ACh, via muscarinic receptors, regulates 
airway remodelling in animal models of asthma and COPD. The mechanisms 
involved are not well understood. Here, we investigated the functional interaction 
between muscarinic receptor stimulation and transforming growth factor (TGF)-β1 
on the expression of contractile proteins in human airway smooth muscle (ASM) 
cells. ASM cells expressing functional muscarinic M2 and M3 receptors, were 
stimulated with methacholine (MCh), TGF-β1 or their combination for up to 7 days. 
Western Blot analysis revealed a strong induction of sm-α-actin and calponin by 
TGF-β1, which was increased by MCh in ASM cells. Immunocytochemistry 
confirmed these results and revealed that the presence of MCh augmented the 
formation of sm-α-actin stress fibres by TGF-β1. MCh did not augment TGF-β1-
induced gene transcription of contractile phenotype markers. Rather, 
translational processes were involved in the augmentation of TGF-β1-induced 
contractile protein expression by muscarinic receptor stimulation, including 
phosphorylation of GSK-3β and 4E-BP1which was enhanced by MCh. In conclusion, 
muscarinic receptor stimulation augments functional effects of TGF-β1 in human 
ASM cells on cellular processes that underpin airway smooth muscle remodelling 





Acetylcholine is the primary parasympathetic neurotransmitter in the airways that 
is associated with the regulation of bronchoconstriction and mucus secretion (1). 
Therefore, therapy with anticholinergics, such as tiotropium bromide, is often 
prescribed to patients with chronic obstructive pulmonary disease (COPD) and, to 
a lesser extent, with asthma. More recent evidence indicates that acetylcholine 
(either neuronal or non-neuronal) also regulates airway inflammation and airway 
remodelling, which might contribute to the therapeutic effectiveness of these 
drugs (1). Acetylcholine is synthesized by the enzyme choline acetyltransferase 
(ChAT) in different cell types including structural cells such as neurons, epithelial 
cells, airway fibroblasts and airway smooth muscle cells (2). It can act as a 













































by epithelial cells and human lung fibroblasts. The expression of ChAT is increased 
in epithelial cells and fibroblasts from COPD patients, and therefore the increased 
release of acetylcholine may promote airway inflammation and remodelling (3, 4).  
Several studies using animal models of allergic asthma demonstrated that 
tiotropium bromide inhibits increased airway smooth muscle thickness, myosin 
expression, eosinophilic airway inflammation, airway fibrosis and airway 
hyperresponsiveness induced by repeated allergen exposure (5-7). In addition, in 
animal models of COPD tiotropium reduced LPS-induced airway neutrophilia, 
collagen deposition and muscularization of microvessels (8), inhibited neutrophil 
elastase-induced goblet cell metaplasia (9), and reduced cigarette smoke-induced 
pulmonary inflammation (10). Anti-inflammatory and anti-remodelling properties 
of tiotropium have also been demonstrated in a mouse model of gastro-
oesophageal reflux disease (11). 
The multifunctional cytokine TGF-β1 plays an important role in remodelling of the 
airways in various chronic airway diseases. This pro-fibrotic cytokine is highly 
expressed in many cell types of the airways of patients with these diseases (12). 
TGF-β1 has been reported to induce proliferation and maturation of airway 
smooth muscle (ASM) cells, depending on its concentration (12, 13). In ASM cells, 
TGF-β1 promotes the expression of contractile phenotype markers, including sm-
α-actin, through both transcriptional and translational control (13). 
Transcriptional regulation requires signalling to RhoA and Smad2/3, which 
promotes the nuclear presence and transcriptional activity of serum response 
factor (SRF) at smooth muscle specific genes (13-16). In parallel, TGF-β1 signals to 
PI3K, which results in downstream phosphorylation of proteins that control 
protein translation, including p70S6K, glycogen synthase kinase 3 (GSK-3) and 4E-
binding protein1 (4E-BP1), a cellular response that requires the presence of 
caveolae (13, 17-19). Furthermore, TGF-β1 regulates cell proliferation, including 
airway epithelial cell and fibroblast proliferation, cell differentiation, including 
myofibroblast differentiation, and the synthesis of extracellular matrix proteins 
such as fibronectin and collagen (20, 21).  
Activation of the PI3K pathway by muscarinic receptor stimulation has previously 
been reported to enhance platelet-derived growth factor (PDGF)- and epidermal 
growth factor- (EGF)-induced ASM cell proliferation (22-25). Functional crosstalk 
between the cholinergic system and TGF-β1 in ASM is, however, still unknown. We 
hypothesized that muscarinic receptors contribute to ASM remodelling by 
enhancing TGF-β1 function. Therefore, in human ASM cells, we investigated the 
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effect of muscarinic receptor stimulation on TGF-β1-induced expression of the 
contractile phenotype markers calponin and sm-α-actin. In addition, we studied 
potential mechanisms of interaction, in particular at the level of transcriptional 
and translational processes, including ChAT and contractile protein mRNA 
expression and phosphorylation of GSK-3β and 4E-BP1. 
 
 
3.2 Materials and methods 
 
3.2.1 Antibodies and reagents 
Methacholine chloride (MCh) was purchased from ICN Biomedicals (Zoetermeer, 
the Netherlands). Human recombinant TGF-β1 was obtained from R&D systems 
(Abingdon, UK). Mouse anti-α smooth muscle actin (sm-α-actin) antibody, mouse 
anti-calponin antibody, horseradish peroxidase (HRP)-conjugated rabbit anti-
mouse IgG antibody, HRP-conjugated goat anti-rabbit IgG antibody, and 
interleukin-1ß (IL-1ß) were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). Phospho-GSK-3-α/β (Ser21/9) antibody and phospho-4E-BP1 
(Thr37/46) antibody were obtained from Cell signalling Technology (Beverly CA, 
USA). GAPDH antibody and total GSK-3 antibody were purchased from Santa Cruz 
Biotechnology, INC (Santa Cruz CA, USA). Cy3-conjugated secondary antibody was 
obtained from Jackson ImmunoResearch (West Grove PA, USA). The inhibitor 
LY294002 purchased from Tocris Biosciences (Bristol, UK). Tiotropium bromide 
was obtained from Boehringer Ingelheim Pharma GmbH (Biberach an der Riss, 
Germany). All other chemicals were of analytical grade.  
 
3.2.2 Cell culture 
Human bronchial smooth muscle cell lines immortalized by stable expression of 
human telomerase reverse transcriptase (hTERT) were prepared as described 
previously (26). The primary cultured human bronchial smooth muscle cells used 
to generate hTERT ASM cells were prepared from macroscopically healthy 
segments of 2nd to 4th generation main bronchus obtained after lung resection 
surgery from patients with a diagnosis of adenocarcinoma. All procedures were 
approved by the Human Research Ethics Board of the University of Manitoba. 
Cells were grown to confluence using DMEM supplemented with 10% foetal 
bovine serum, streptomycin 50 U/mL, penicillin 50 µg/mL and amphotericin B 1.5 













































media were changed every 2-3 days. The expression and function of muscarinic 
M2 and M3 receptors in these cells has previously been described (27). 
 
3.2.3 Stimulation of human ASM cells  
Cells were cultured in 6-well plates and grown until confluence. After serum 
deprivation for 24 hours in DMEM supplemented with antibiotics (100 μg/mL 
streptomycin, penicillin 100 U/mL and amphotericin B 1.5 μg/mL) and 1% ITS 
(insulin 5 μg/mL, transferrin 5 μg/mL, and selenium 5 ng/mL), the cells were 
stimulated with the muscarinic receptor agonist methacholine (MCh, 10 μM), 
TGF-β1 (2 ng/mL), or the combination of MCh (10 μM) and TGF-β1 (2 ng/mL) for 2 
hours, 1 day, 4 days or 7 days. Where mentioned, cells were pre-incubated with 
LY294002 (10 µM) or tiotropium bromide (10 nM) for 30 min. 
 
3.2.4 Western Blotting 
To obtain whole cell lysates, stimulated cells were washed once with ice-cold 
phosphate-buffered saline (PBS, composition: NaCl 140 mM, KCl 2.6 mM, KH2PO4 
1.4 mM, Na2HPO4 8.1 mM, pH 7.4), followed by lysis using ice-cold SDS-lysis buffer 
(62.5 mM Tris-HCl, 2% SDS, NaF 1 mM, Na3VO4 1 mM, aprotinin 10 μg/mL, 
leupeptin 10 μg/mL, pepstatin A 7 µg/mL at pH 8.0). Equal amounts of protein 
were separated on polyacrylamide SDS gels and transferred to nitrocellulose. To 
avoid non-specific binding, membranes were blocked with blocking buffer (Tris-
HCl 50 mM, NaCl 150 mM, TWEEN-20 0.1%, non-fat dried milk powder 5%) for 1 
hour at room temperature. Afterwards, the membranes were incubated with the 
specific primary antibody, all diluted in blocking buffer, for 1 hour at room 
temperature. After washing the membranes 3 times with Tris Buffered Saline 
Tween20 0.1% (TBS-T 0.1%: Tris-HCl 50 mM, NaCl 150 mM, TWEEN-20 0.1%) for 
10 min, incubation with the secondary antibody labelled with HRP was performed 
for 1 hour at room temperature, followed by an additional 3 washes with TBS-T 
0.1%. Bands were subsequently visualized on film using enhanced 
chemiluminescence reagents and analysed by densitometry (TotallabTM, 
Nonlinear dynamics, Newcastle, UK). All bands were normalized to either GAPDH 
for phospho-4E-BP1 or to total GSK-3 for phospho-GSK-3-α/β. 
 
3.2.5 Immunofluorescence 
Cells were cultured on Labtek IITM chamber slides and grown until confluence. 
After serum deprivation for 24 hours in DMEM supplemented with antibiotics and 
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1% ITS, the cells were stimulated with the muscarinic receptor agonist 
methacholine (MCh, 10 μM), alone and in combination with TGF-β1 (2 ng/mL) for 
1, 4 or 7 days. After washing the cells twice with cytoskeleton buffer (CB: MES 10 
mM, NaCl 150 mM, EGTA 5 mM, MgCl2 5 mM, and glucose 5 mM at pH 6.1), the 
cells were fixed with CB containing 3% paraformaldehyde (PFA) for 15 min. The 
cells were then incubated with CB buffer containing 3% PFA and 0.3% Triton-X-
100 for 5 min, followed by an additional 2 washes with CB. Cells were then 
blocked for 1 hour in cyto-TBS (Tris-base 20 mM, NaCl 154 mM, EGTA 2.0 mM, 
and MgCl2 2.0 mM at pH 7.2) with BSA 1% and normal donkey serum 2%. After 
that, cells were stained with mouse sm-α-actin antibody overnight at 4°C. After 
washing 3 times with cyto-TBS containing 0.1% Tween-20 (cyto-TBS-T) for 10 min, 
incubation with the secondary antibody Cy3-mouse (dilution 1:50 in cyto-TBS-T) 
was performed during 3 hours at room temperature. Cells were then washed 4 
times for 15 min in cyto-TBS-T and the nuclei were stained with Hoechst 33342 
(dilution 1: 1000 in cyto-TBS-T) (Invitrogen, Breda, the Netherlands) for 1 min. 
Before mounting the slides with ProLong Gold anti-fade reagent (Invitrogen, 
Breda, The Netherlands), cells were washed 4 times with ultra-pure water. After 
staining, the slides were analysed using an Olympus AX70 microscope equipped 
with digital image capture system (ColorView Soft System with Olympus U CMAD2 
lens). 
 
3.2.6 RNA isolation and real-time quantitative RT-PCR of sm-α-actin, calponin, 
ChAT and ribosomal subunit 18S 
Total cellular RNA was isolated using the Rneasy mini kit (Qiagen, Venlo, The 
Netherlands). RNA concentration was determined by Nanodrop ND1000 
(Wilmington DE, USA). By reverse transcription, cDNA was synthesized using the 
Promega cDNA synthesis kit. Real-time quantitative PCR for ChAT, sm-α-actin and 
calponin was performed using an IQ5 real time detection system (Biorad, 
Veenendaal, The Netherlands). The specific primer sets used to detect ribosomal 
subunit 18S (18S rRNA), ChAT, sm-α-actin and calponin are illustrated in Table 3.1. 
The abundance of gene expression for sm-α-actin and calponin was adjusted for 
the expression of 18S rRNA and normalized to the expression found in control 
















































Table 3.1. Primer sequences of sm-α-actin, calponin, ChAT, and 18S rRNA used for real-
time quantitative PCR 
Substance Sequences  
Sm-α-actin Forward   
Reverse   
5′-GACCCTGAAGTACCCGATAGAAC-3′ 
5′-GGGCAACACGAAGCTCATTG-3′ 
Calponin Forward   
Reverse   
5′-TGTTTGAGAACACCAACCATACACA-3′ 
5′-GTTTCCTTTCGTCTTCGCCAT-3′ 
ChAT Forward   
Reverse   
5′-TTTTGTGAGAGCCGTGACTG-3′ 
5′-CACAGGACCATAGCAGCAGA-3′ 
18S rRNA Forward   




3.2.7 Data analysis 
Data are presented as mean values ± SEM. Statistical significance was determined 
by one-way ANOVA or by two-way ANOVA, where appropriate, followed by a 
post-hoc Student-Newman-Keuls multiple comparisons test for paired 





3.3.1 Effect of muscarinic receptor stimulation on contractile protein 
expression induced by TGF-β1 
We first analysed the effects of MCh (10 µM), alone and in combination with TGF-
β1 (2 ng/mL) on contractile protein expression (calponin and sm-α-actin) by 
human ASM cells. TGF-β1 alone induced a significant increase in calponin and sm-
α-actin expression in these ASM cells after 7 days (Figure 3.1A-C). Interestingly, 
the induction of sm-α-actin occurred considerably later than the induction of 
calponin. MCh had no significant effect on contractile protein expression by itself. 
However, both TGF-β1-induced calponin and sm-α-actin expression were 
significantly increased by 7 days co-stimulation with MCh, to a similar extent (1.4-
fold; Figure 3.1A-C). The response of MCh was concentration dependent to induce 
the expression of contractile proteins (Figure 3.1D). 
 















































Figure 3.1. Muscarinic receptor stimulation augments contractile protein expression 
induced by TGF-β1. Human ASM cells were stimulated with TGF-β1 (2 ng/mL), in the 
absence or presence of methacholine (MCh; 10 μM) for 1, 4 or 7 days. Cells lysates were 
analysed for the presence of calponin (B) or sm-α-actin (C). Representative blots are 
shown in (A). Data shown are the means ± SE of 4-7 independent experiments. ***p≤ 
0.001 compared to basal; ##p≤ 0.01 compared to the absence of methacholine. A dose-
response for MCh was performed using the concentration 10-7 M, 10-6 M, 10-5 M in 
presence or absence of TGF-β1 (2 ng/mL) for 7 days. Cell lysates were analyzed for the 
presence of calponin or sm-α-actin. Data shown of 1 experiment (D). 
 
As we expected alterations in the morphology of the cells due to the increased 
contractile phenotype marker protein expression after treatment, 
immunocytochemistry was performed. Interestingly, increased sm-α-actin stress 
fibre formation was observed after 7 days of treatment with TGF-β1 (Figure 3.2). 
Co-stimulation with MCh clearly amplified this effect, whereas the muscarinic 
receptor agonist had no effect by itself (Figure 3.2). Collectively, these data 
indicate that human ASM cells acquired a contractile phenotype by TGF-β1 
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Figure 3.2. Methacholine augments TGF-β1-induced sm-α-actin stress fibre expression 
after 7 days of stimulation. Human ASM cells were grown to confluence. After 24 hours of 
serum deprivation, cells were treated with TGF-β1 (2 ng/mL) in absence or presence of 
MCh (10 μM) for 1, 4 or 7 days, as indicated. Cells were stained for α-actin (red) and the 
nuclei were stained with Hoechst 33342. The images shown are representative of 2 
experiments. Magnification 10x40. 
 
3.3.2 Autocrine ACh secretion is not involved in TGF-β1 induced contractile 
protein expression 
To investigate whether human ASM cells express ChAT in response to TGF-β1, we 
measured mRNA levels of ChAT induced by TGF-β1 and/or MCh after 1 (Figure 
3.3A) and 7 days (Figure 3.3B) of treatment. Baseline mRNA expression of ChAT in 
ASM was low (Cq = 31.06 and 10.42 for ChAT and 18S rRNA, respectively). Also, 
we observed no induction of ChAT expression in response to either TGF-β1, MCh 
or their combination. Next, we pre-incubated ASM cells with tiotropium bromide 
for 30 min, followed by stimulation with TGF-β1 for 7 days. TGF-β1 induced an 
increase in the expression of calponin and sm-α-actin; however, pre-treatment 













































proteins. These data suggest that the increase in contractile protein expression 
induced by TGF-β1 stimulation is not dependent on the autocrine production of 
acetylcholine by ASM. 
Figure 3.3. Autocrine ACh release is not involved in the induction of contractile proteins 
by TGF-β1. Human ASM cells were grown to confluence. After 24 hours of serum 
deprivation, cells were treated with TGF-β1 (2 ng/mL) in the absence or presence of MCh 
(10 µM). mRNA levels of ChAT were measured after 1 day (A) or 7 days (B) of stimulation. 
Further, cells were treated with TGF-β1 (2 ng/mL) in the absence or presence of tiotropium 
bromide (10 nM) for 7 days. Cells lysates were analysed for the presence of calponin and 
sm-α-actin (C). Data shown are the means ± SE of 3-6 experiments.  
 
3.3.3 Effect of muscarinic receptor stimulation on mRNA expression of 
contractile proteins induced by TGF-β1 
To establish whether the accumulation of contractile proteins was due to an 
increase in gene expression and/or increased translation, we investigated the 
mRNA expression of calponin and sm-α-actin after 1 and 7 days of treatment with 
TGF-β1 and MCh as described above. After 1 day of stimulation with TGF-β1 alone, 
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a significant increase in calponin (Figure 3.4A) and sm-α-actin (Figure 3.4B) mRNA 
expression was measured. Stimulation with MCh by itself had no effect on the 
expression of calponin and sm-α-actin mRNA (Figures 3.4A and 3.4B). Moreover, 
calponin expression induced by TGF-β1 was not affected by MCh treatment (Figure 
3.4A). Surprisingly, a significant decrease in sm-α-actin mRNA expression was 
observed after treatment with the combination of TGF-β1 and MCh as compared 
with TGF-β1 treatment alone (Figure 3.4B). On day 7, all treatments had no effect 
on the mRNA expression of either calponin or sm-α-actin (Figures 3.4C and 3.4D). 
Collectively, these data suggest that the increase in TGF-β1-induced contractile 
protein expression by MCh observed after 7 days of treatment was not due to 
amplification of TGF-β1-induced mRNA levels of these proteins. 
Figure 3.4. Muscarinic receptor stimulation does not augment mRNA expression of 
calponin and sm-α-actin induced by TGF-β1. Human ASM cells were stimulated with TGF-
β1 (2 ng/mL), in the absence or presence of methacholine (MCh; 10 μM) for 1 or 7 days. 
mRNA levels of calponin (A, C) or sm-α-actin (B, D) were measured. Data shown are the 
means ± SE of 6-7 independent experiments. **p≤ 0.01, ***p≤ 0.001 compared to basal; 














































3.3.4 Effect of muscarinic receptor stimulation on translational processes 
activated by TGF-β1 
Next, we aimed to investigate the role of translational processes in the functional 
interaction between muscarinic receptor activation and TGF-β1. We analysed the 
expression and the phosphorylation status of 4E-BP1 and GSK-3, proteins which 
are involved in the translation machinery of smooth muscle contractile phenotype 
marker proteins, and which have also been shown to play a critical role in TGF-β1 
induced contractile protein accumulation (13, 28). 
The PI3K pathway can induces the phosphorylation of p4E-BP1 and GSK-3β to 
permit the expression of contractile protein. To confirm the involvement of the 
PI3K signalling in contractile protein accumulation induced by TGF-β1, we inhibited 
the PI3K pathway with LY294002 (10µM). Treatment with LY294002 reduced the 
expression of calponin induced by TGF-β1 and MCh (Figure 3.5A). 
 
It has previously been demonstrated that TGF-β1 is able to induce the 
phosphorylation of 4E-BP1 which contributes to TGF-β1-induced sm-α-actin 
expression (29). Therefore, we investigated the potential involvement of 4E-BP1 
phosphorylation in the TGF-β1 response and the additive effect observed with 
MCh. To this aim, we stimulated ASM cells for 2 hours and 24 hours with TGF-β1 in 
the absence or presence of MCh and analysed the phosphorylation of 4E-BP1. No 
significant increase in 4E-BP1 phosphorylation was observed after 2 or 24 hours 
stimulation of ASM cells with TGF-β1 or MCh alone (Figure 3.5B). Interestingly, 
however, a significant effect was observed with the combination of both stimuli, 
at 24 hours after stimulation. To ensure that the PI3K pathway was involved in the 
phosphorylation of 4E-BP1 by TGF-β1 and MCh, ASM cells were pre-treated with 
LY294002, which led to a reduction in the phosphorylation of p4E-BP1 induced by 
TGF-β1 and MCh (Figure 3.5B). 
Recently, it has been demonstrated that inhibition of GSK-3β is sufficient for the 
induction of ASM hypertrophy and increase in contractile protein expression (17, 
29). GSK-3β is active in its unphosphorylated form and inhibits protein translation 
by phosphorylating eukaryotic initiation factor-2B (eIF-2B). Therefore, we 
investigated whether the phosphorylation of GSK-3 (ser9/ser21) was induced by 
TGF-β1 and MCh. ASM cells were stimulated for 2 and 24 hours with TGF-β1, MCh 
and their combination. For all treatments, only the phosphorylated β-isoform of 
GSK-3 was detected. Interestingly, after 2 hours of stimulation, TGF-β1 and MCh 
alone were ineffective, whereas their combination induced a significant increase 
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in GSK-3β phosphorylation (Figure 3.5C). No significant effects were observed 
after 24 hours of stimulation. To reensure that the PI3K pathway was also 
involved in the phosphorylation of GSK-3β by TGF-β1 and MCh, ASM cells were 
pre-treated with LY294002, which led to an inhibition of the phosphorylation of 
GSK-3β induced by TGF-β1 and MCh (Figure 3.5C). 
Figure 3.5. Muscarinic receptor stimulation augments TGF-β1-induced phosphorylation 
of GSK-3β and 4E-BP1. To investigate the potential involvement of the PI3K pathway in 
contractile protein accumulation induced by TGF-β1 and MCh, ASM cells were pre-













































µM) and/or TGF-β1 (2ng/mL) (A). Cells lysates were analysed for the presence of calponin. 
Data shown of 1 experiment. Human ASM cells were stimulated with TGF-β1 (2 ng/mL), in 
the absence or presence of methacholine (MCh; 10 μM) for 2 and 24 hours. Cells lysates 
were analysed for the presence of phosphorylated 4E-BP1 (B) or phosphorylated GSK-3β 
(C). Representative blots are shown next to the graphs. Data shown are the means ± SE of 
4-7 independent experiments. **p≤ 0.01, ***p≤ 0.001 compared to basal; #p≤ 0.05, ##p≤ 
0.01 compared to the absence of methacholine. Additionally, to confirm the that PI3K is 
involved in the phosphorylation of 4E-BP1 and GSK-3β induced by TGF-β1 and MCh, ASM 
cells were pre-incubated with LY294002 (10 µM) for 30 min, followed by 24 hrs (for 
phosphorylation of 4E-BP1 (B)) or 2 hrs (for phosphorylation of GSK-3β (C)) stimulation 
with MCh (10 µM) and/or TGF-β1 (2ng/mL). Cells lysates were analysed for the 





In the present study, we demonstrate that a cross-talk between TGF-β receptors 
and muscarinic receptors regulate the expression of contractile phenotype marker 
proteins and the formation of sm-α-actin stress fibres in human ASM cells. We 
show that this cross-talk is independent of transcriptional regulation and of the 
autocrine release of ACh, but requires translational mechanisms, such as the 
phosphorylation of GSK-3β and 4E-BP1. These studies provide a potential 
mechanistic explanation for inhibition of allergen-induced contractile protein 
expression and ASM contractility by anticholinergic treatment in animal models of 
asthma (13). Furthermore, these studies are the first to demonstrate functional 
cross-talk between G-protein coupled receptors and TGF-β in ASM. 
 
ASM remodelling in asthma is characterized by phenotype alterations leading to 
maturation of the muscle cells (19). The multifunctional cytokine TGF-β plays an 
important role in ASM remodelling in asthma (12). Patients with asthma as well as 
with COPD, diseases associated with airway remodelling, have increased 
expression of TGF-β in lung tissue (21, 30). In addition, its role in wound healing, it 
is well known that TGF-β induces the maturation of ASM cells. Goldsmith et al., 
reported that TGF-β induces a time-dependent increase in sm-α-actin expression 
in primary human bronchial smooth muscle cells (13). In agreement with this 
finding, we demonstrate that TGF-β induces the expression of the contractile 
phenotype protein markers sm-α-actin and calponin in human ASM cells. 
Interestingly, muscarinic receptor stimulation enhanced the TGF-β1-induced 
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expression of these proteins, suggesting that muscarinic receptors facilitate ASM 
remodelling processes induced by TGF-β1.  
In support of a role for muscarinic receptors in ASM remodelling, an in vivo study 
from our group showed that tiotropium bromide reduces airway remodelling in 
repeatedly ovalbumin challenged guinea pigs. The administration of tiotropium 
bromide before each allergen challenge resulted in a reduction of ASM 
hyperplasia and of the increased contractility and contractile protein expression 
(6). In vitro, muscarinic receptor stimulation augmented the mitogenic responses 
of human ASM in response to EGF and PDGF (23, 25). Here, we show that 
muscarinic receptor stimulation also enhances the expression of contractile 
proteins in response of TGF-β1 in human ASM cells, thus providing a plausible 
explanation for the observed effects of tiotropium in vivo. In line with this 
contention, in muscarinic M3 receptor transfected canine ASM cells, carbachol has 
been reported to induce increased promoter activity of the sm-MHC and SM22 
genes (31). Additionally, the exposure to carbachol in strained human ASM cells 
leads to an augmentation in the expression of myosin light-chain kinase (32). 
Furthermore, muscarinic receptor stimulation augments the IL-6 and IL-8 
secretion by human ASM cells in response to various stimuli, including cigarette 
smoke extract and PDGF (chapter 2). Collectively, these findings and our current 
work are in agreement with a strong regulatory role for muscarinic receptors in 
ASM remodelling. The cholinergic system has also been implicated in fibrosis and 
fibroblast proliferation (33, 34), suggesting that anticholinergics may have 
beneficial effects on multiple pathological tissue remodelling processes in 
obstructive airways diseases.  
Previous studies indicated that ASM expresses mRNA for ChAT, the synthesizing 
enzyme for ACh (35). Also, ChAT expression and autocrine ACh release by 
fibroblasts and epithelial cells was proposed to regulate cell proliferation and 
cytokine release by these cells (3, 36). Our studies show that although ChAT 
mRNA is expressed, the expression levels are in fact quite low. Furthermore, the 
expression of ChAT was unchanged in response to TGF-β1, and antagonism of 
muscarinic receptors using tiotropium had no effect on TGF-β1 induced contractile 
protein accumulation. This implies that an autocrine loop involving ACh release is 
not involved in the acquisition of contractile protein expression induced by TGF-β1 
and suggests that the above mentioned regulatory effects of muscarinic receptors 














































The signalling mechanisms that underpin these remodelling processes have thus 
so far not fully been established. The expression of contractile and contraction 
regulatory proteins, such as sm-α-actin, calponin, SM22 and desmin, which mark 
the maturation of ASM cells are under the control of transcriptional and 
translational processes. Smooth muscle-specific gene transcription is induced by 
the stimulation of the RhoA/Rho-kinase pathway and the Smad2/3 pathway 
leading to the nuclear translocation and transcriptional activation of the 
transcription factor serum response factor (SRF) and its co-activators myocardin 
and megakaryocytic acute leukaemia (MAL) (13-16, 37). The translation of the 
smooth muscle-specific genes is, however, dependent on the PI3K/Akt signalling 
pathway (13, 38-41). Thus, TGF-β1-induced contractile protein expression is 
paralleled by the phosphorylation of GSK-3β and 4E-BP1, both downstream 
targets of PI3K/Akt signalling (13, 42), and the phosphorylation of 4E-BP1 is 
required for TGF-β-induced contractile protein expression (41). We and others 
have reported that muscarinic receptor stimulation facilitates PDGF-induced 
proliferation of human ASM cells through the cooperative activation of the PI3K 
pathway, leading to the synergistic phosphorylation of Akt, p70S6K and GSK-3β 
(22-25). Interestingly, our current results show that the increased expression of 
contractile proteins induced by TGF-β1 and muscarinic receptor stimulation are 
also mediated by translational processes, including the phosphorylation of GSK-3β 
and 4E-BP1, but not by transcriptional processes, as mRNA expression of these 
smooth muscle specific genes was not affected. This suggests that muscarinic 
receptor stimulation exerts its action through cooperative activation of the 
PI3K/Akt/GSK-3-signaling pathway by TGF-β1, inducing the accumulation of 
contractile proteins, and not through the regulation of RhoA/Rho-kinase/SRF 
pathway. In this context, and in the context of our earlier work (23), it is therefore 
of interest that in a mouse model of asthma increased phosphorylation of GSK-3β 
has been reported, which correlated with ASM hyperplasia, hypertrophy and 
expression of contractile proteins, including as sm-α-actin (42).  
 
To our knowledge, this is the first study reporting cross-talk between a GPCR and 
TGF-β in ASM remodelling. Panettieri et al. showed that the expression of 
extracellular matrix proteins induced by TGF-β1 was not influenced by CysLT1 
receptor stimulation in human ASM cells (43), indicating that this cross-talk may 
be receptor dependent. In neural progenitor cells, Morishita et al. reported the 
ability of a GPCR and TGF-β to enhance the activity of the sm-α-actin promoter; 
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however, these activities were independent of each other (44). Collectively, our 
findings suggest that GPCRs and TGF-β are able to cooperatively induce airway 
remodelling processes, although clearly it cannot be assumed that this occurs for 
all GPCR classes. These findings are nonetheless of interest to future studies, as 
many remodelling processes, also outside the airways, involve cooperative 
regulation by GPCR ligands and growth factors (24).  
 
In the Understanding Potential Long-term Impacts on Function with Tiotropium 
(UPLIFT) study, COPD patients treated with tiotropium bromide during a 4 year 
period had a better quality of life and lung function, whereas also the frequency 
of exacerbation was reduced. The rate of decline in FEV1 (forced expiratory 
volume in 1 second) remained, however, unchanged during the trial period (45). 
In a post-hoc analysis of this study, a pre-specified subgroup of COPD patients, 
GOLD stage II patients treated only with tiotropium bromide, had a lower risk of 
exacerbations, but also a reduction in the rate of decline in post-bronchodilator 
FEV1 over the 4 year period compared to placebo (46). In addition, a subgroup of 
young patients with COPD showed a significant reduction in the decline in post-
bronchodilator FEV1) when treated with tiotropium on top of usual care (47). This 
may suggest that tiotropium has disease modifying properties in younger patients 
with COPD and in GOLD stage II patients. In support, regardless of the smoking 
status of the patient, the long-term benefits of treatment with tiotropium 
sustained (48). Moreover, exacerbations accelerate disease progression. Recently, 
tiotropium has also been proven to improve the lung function in patients with 
severe uncontrolled asthma (49). The mechanisms behind these effects are still 
unknown. However, muscarinic receptor induced airway remodelling, as 
demonstrated in the current and in other studies, could be involved. Indeed, a 
recent trial showed that repeated inhalations with the muscarinic receptor 
agonist methacholine induces airway remodelling in asthma patients, including 
the expression of TGF-β and collagen I in bronchial biopsies (50). This 
substantiates the hypothesis that cholinergic activation leads to remodelling via 
cross-talk with TGF-β in these patients. These effects were suggested by the 
authors to result from mechanical forces resulting from the bronchoconstriction 
itself. However, functional cross-talk of MCh and TGF-β on structural cells, 














































In conclusion, our results indicate that the stimulation of muscarinic receptors 
enhances the expression of contractile phenotype marker proteins induced by 
TGF-β1. These findings provide a plausible mechanistic explanation for our earlier 
observations that demonstrate protective effects of tiotropium on ASM 
remodelling in repeatedly allergen challenged guinea pigs. This implies a role for G 
protein coupled receptors in TGF-β1-induced remodelling in the pathogenesis of 
chronic airway diseases like asthma and COPD. 
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Transforming growth factor-β1 (TGF-β1) is a central mediator in tissue remodelling 
processes, including fibrosis and airway smooth muscle (ASM) hyperplasia as 
observed in asthma. The mechanisms underlying this response, however, are 
unclear as TGF-β1 has only weak mitogenic effects on ASM cells. In this study we 
hypothesized that the mitogenic effect of TGF-β1 on ASM is indirect and requires 
prolonged exposure to allow extracellular matrix (ECM) deposition. To address 
this hypothesis, we investigated the effects of acute and prolonged treatment 
with TGF-β1, alone and in combination with the muscarinic receptor agonist 
methacholine on human ASM cell proliferation. Acutely, TGF-β1 had no mitogenic 
effect; however, prolonged treatment (7 days) with TGF-β1 increased ASM cell 
proliferation and potentiated the PDGF-induced mitogenic response. Muscarinic 
receptor stimulation with methacholine synergistically enhanced the effect of 
TGF-β1. Interestingly, the integrin-blocking peptide RGDS (Arg-Gly-Asp-Ser) as well 
as integrin α5β1 function-blocking antibodies inhibited the effects of TGF-β1 and 
its combination with methacholine on cell proliferation. Accordingly, prolonged 
treatment with TGF-β1 increased fibronectin expression, which was also 
synergistically enhanced by methacholine. The synergistic effects of methacholine 
on TGF-β1-induced proliferation were reduced by the long-acting muscarinic 
receptor antagonist tiotropium and the M2 receptor subtype selective antagonist 
gallamine, but not the M3 selective antagonist DAU5884. In line with these 
findings, the irreversible Gi-protein inhibitor pertussis toxin also prevented the 
potentiation of TGF-β1-induced proliferation by methacholine. We conclude that 
prolonged exposure to TGF-β1 enhances ASM cell proliferation, which is mediated 






The pleiotropic growth factor transforming growth factor-β (TGF-β) is widely 
synthesized throughout the body and regulates a variety of cellular responses 
contributing to morphogenesis, embryonic development, inflammation and 
wound healing (1). Moreover, abnormal TGF-β regulation and expression in 








































extracellular matrix (ECM) proteins (2). Traditionally, (myo)fibroblasts are 
perceived as the major source of ECM proteins; however, smooth muscle cells 
have also been identified as a rich source of these extracellular components (3, 4). 
Exposure of airway smooth muscle (ASM) cells to TGF-β increases the expression 
of various ECM proteins, including collagens, proteoglycans and fibronectin (3, 5, 
6). In addition to their function as a scaffold, ECM proteins also modulate a variety 
of cellular functions, including migration, differentiation and proliferation. For 
example, ASM cells cultured on fibronectin or collagen type I matrices show 
enhanced mitogenic responses to growth factors such as platelet-derived growth 
factor (PDGF) (7-12). Interaction of these cells with the ECM occurs mainly 
through integrins, a group of heterodimeric transmembrane glycoproteins. 
Studies on the role of integrins in smooth muscle cell proliferation have indicated 
an important role for these ECM receptors; e.g. both angiotensin II- and PDGF-
induced proliferation of vascular smooth muscle cells requires signalling through 
α5β1 integrins (7, 13). In addition, proliferation of human ASM cells can be 
mediated by integrins as well, in particular by the α5β1 integrins (9, 14, 15). 
Various studies have addressed the mitogenic properties of TGF-β on smooth 
muscle proliferation. In vivo studies demonstrated that overexpression of TGF-β1 
in mice increases ASM mass, whereas allergen-induced increases in ASM mass in a 
murine model of asthma could be prevented by anti-TGF-β1 antibodies (16-18). In 
vitro studies, however, have shown that TGF-β1 has variable mitogenic properties 
on ASM cells (19-23).  
In addition to receptor tyrosine kinases, serine threonine kinase receptors and 
integrins, G-protein coupled receptors (GPCR), including muscarinic receptors, 
have been associated with cell proliferation (24, 25). In bovine and human ASM 
cells, muscarinic M3 receptor stimulation enhanced the mitogenic responses to 
PDGF and EGF (26, 27). ASM cell proliferation, leading to ASM thickening, is an 
important contributor to airway remodelling as observed in airway diseases (28, 
29). In vivo animal models of asthma showed that muscarinic receptor stimulation 
also contributes to allergen-induced increase in ASM mass (30-32). Moreover, 
airway fibrosis could be prevented by treatment with the muscarinic receptor 
antagonist tiotropium bromide (32, 33). Interestingly, Matthiesen et al. and Haag 
et al. found that muscarinic M2 receptor stimulation increases proliferation and 
collagen deposition by human lung fibroblasts in vitro (34, 35). Overall, these data 
suggest that muscarinic receptor stimulation plays a role in airway fibrosis and 
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ASM remodelling, which may involve both muscarinic M2 and muscarinic M3 
receptors. 
Collectively, a role for TGF-β and G-protein coupled receptors like muscarinic 
receptors in the induction of smooth muscle cell proliferation via autocrine 
production of ECM proteins and subsequent activation of integrins may be 
envisaged. In the present study, we hypothesized that exposure of human ASM 
cells to TGF-β1 enhances the deposition of ECM proteins, resulting in the 
subsequent induction of proliferation of these cells via activation of integrins. 
Furthermore, we hypothesized that these processes may be reinforced by 
muscarinic receptor stimulation. Our results for the first time demonstrate that 
prolonged exposure to TGF-β1 is followed by ASM cell proliferation, which occurs 
via deposition of ECM proteins such as collagen type I and fibronectin and 
subsequent activation of the α5β1 integrin. Combined treatment with the 
muscarinic receptor agonist methacholine synergistically enhanced fibronectin 




4.2 Materials and methods 
 
4.2.1 Materials 
Active, recombinant human TGF-β1 was purchased at R&D systems (Abingdon, UK). 
Dulbecco’s Modified Eagle’s Medium (DMEM), foetal bovine serum (FBS), 
streptomycin, penicillin and amphotericin B were from Gibco BRL Life 
Technologies (Paisley, UK). Methacholine chloride was from ICN Biomedicals 
(Zoetermeer, The Netherlands). Horseradish peroxidase (HRP)-conjugated rabbit 
anti-mouse antibodies, HRP-conjugated rabbit anti-goat antibodies, human 
platelet-derived growth factor (PDGF)-AB, fibronectin (human plasma), gallamine 
and pertussis toxin (PTX) were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). Anti-GAPDH and anti-fibronectin (C-20) antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). From Southern Biotech (ITK 
Diagnostics BV, Uithoorn), the anti-collagen I antibody was purchased. RGDS (H-
Arg-Gly-Asp-Ser-OH) and GRADSP (H-Gly-Arg-Ala-Asp-Ser-Pro-OH) were purchased 
at Calbiochem (Nottingham, UK). Monomeric collagen type I (calf skin) was 
obtained from Fluka (Buchs, Switzerland). [methyl-3H]-thymidine (0.25 µCi/mL) 








































DAU5884 were provided by Boehringer Ingelheim (Ingelheim, Germany). All other 
chemicals were of analytical grade.  
 
4.2.2 Airway smooth muscle cell culture 
Human bronchial smooth muscle cell lines, immortalized by stable expression of 
human telomerase reverse transcriptase (hTERT), were used for all experiments. 
hTERT airway smooth muscle cells were generated from primary cultured human 
bronchial smooth muscle cells as described previously (chapter 2). All procedures 
were approved by the Human Research Ethics Board of the University of 
Manitoba. Cells were grown to confluence on uncoated culture dishes using 
DMEM supplemented with 10% foetal bovine serum and antibiotics (50 U/mL 
streptomycin, 50 µg/mL penicillin and 1.5 µg/mL amphotericin B). Cultures were 
maintained in a humidified incubator at 37°C, gassed with 95% O2 and 5% CO2, 
Culture medium was replaced every 2-3 days. 
 
4.2.3 Preparation of whole cell lysates 
Cells were plated in 6-well plates and grown until confluence. After serum 
deprivation for 24 hours in DMEM supplemented with antibiotics, the cells were 
stimulated with TGF-β1 (2 ng/mL) alone or in combination with the muscarinic 
receptor agonist methacholine (10 μM) for 7 days. Culture medium was refreshed 
after 4 days of stimulation. To obtain whole cell lysates, stimulated cells were 
washed once with ice-cold phosphate-buffered saline (PBS, composition: 140 mM 
NaCl, 2.6 mM KCl, 1.4 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4), followed by lysis 
using cold SDS-lysis buffer (composition: 62.5 mM Tris-HCl, 2% SDS, 1 mM NaF, 1 
mM Na3VO4, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 10 μg/mL pepstatin A, pH 
8.0). 
 
4.2.4 Western Blotting 
Equal amounts of protein were separated on SDS polyacrylamide gels and 
transferred onto nitrocellulose. To avoid non-specific binding, membranes were 
blocked with blocking buffer (composition: 50 mM Tris-HCl, 150 mM NaCl, 0.1% 
Tween-20, 5% non-fat dried milk powder) for 1 hour at room temperature. 
Subsequently, the membranes were incubated with the primary antibodies 
diluted in blocking buffer for 1 hour at room temperature. After washing the 
membranes 3 times with 0.1% Tris Buffered Saline Tween-20 (0.1% TBS-T 
composition: 50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) for 10 min, 
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membranes were incubated with HRP-labelled secondary antibodies for 1 hour at 
room temperature, followed by an additional 3 washes with 0.1% TBS-T. By using 
enhanced chemiluminescence reagents, bands were recorded in the G:BOX 
iChemi gel documentation system equipped with GeneSnap image acquisition 
software (Syngene; Cambridge; UK). Band intensities were quantified by 
densitometry using GeneTools analysis software (Syngene; Cambridge; UK). All 
bands were normalized to GAPDH. 
 
4.2.5 Coating of culture plates with extracellular matrix proteins 
Monomeric collagen I was reconstituted in hydrochloric acid (10 mM) at 5 mg/mL. 
ECM-coated culture plates were prepared by covering 24-well culture plates with 
dilutions of collagen I (50 μg/mL, diluted in PBS) or fibronectin (10 μg/mL, diluted 
in PBS). ECM proteins were absorbed overnight and air-dried at room 
temperature. Unoccupied protein-binding sites were blocked using sterile 0.1% 
BSA in PBS for 30 min. Subsequently, plates were washed twice with plain DMEM 





Two different protocols were used to investigate DNA synthesis in ASM cells; an 
acute treatment and a prolonged treatment protocol (Figure 5.1A). 
For the acute treatment protocol, ASM cells (20 000 cells/well) were plated on 
uncoated or ECM-coated 24-well plates and allowed to attach overnight. 
Subsequently, cells were serum deprived for 72 hours in DMEM supplemented 
with antibiotics and 1% ITS (5 μg/mL insulin, 5 μg/mL transferrin and 5 ng/mL 
selenium). After serum-deprivation, cells were stimulated with TGF-β1 (2 ng/mL), 
PDGF-AB (10 ng/mL) or methacholine (10 µM) for 28 hours, the last 24 hours in 
the presence of [methyl-3H]-thymidine. 
For the prolonged treatment, ASM cells (20 000 cells/well) were plated on 
uncoated 24-well plates and allowed to attach overnight. Subsequently, cells were 
serum deprived for 24 hours in DMEM supplemented with antibiotics. After 
serum deprivation, cells were treated with TGF-β1, alone or in combination with 
methacholine (10 μM) for 7 days. Subsequently, cells were washed and stimulated 
in the absence or presence of PDGF-AB (10 ng/mL) for 28 hours, the last 24 hours 
in the presence of [methyl-3H]-thymidine. 
After stimulation, cells were washed twice with PBS at room temperature and 








































insoluble fraction was dissolved in 1 mL NaOH (1 M). Incorporated [methyl-3H]-
thymidine was quantified by liquid-scintillation counting using a Beckman LS1701 
β-counter. 
To investigate the involvement of integrins in TGF-β1-induced cell proliferation, 
cells were incubated 30 min before and during stimulation with the integrin-
blocking peptide RGDS (100 μM) or its negative control GRADSP (100 µM); or with 
integrin function-blocking monoclonal anti-α5 (10 mg/mL, clone P1D6; Chemicon) 
and anti-β1 (10 mg/mL, clone 6S6; Chemicon, Chemicon, Chandler’s Ford, UK) 
antibodies or mouse IgG control antibodies (10 mg/ml; Chemicon). Furthermore, 
to investigate the muscarinic receptor subtype involved, cells were incubated 30 
min before and during stimulation with selective muscarinic receptor antagonists 
(gallamine (10 μM), DAU5884 (100 nM), tiotropium bromide (10 nM)). Gi proteins 
were inactivated by overnight incubation with pertussis toxin (PTX, 100 ng/mL) for 
16 hours before stimulation. Newly synthesized Gi proteins were inhibited by 
incubation with PTX (50 ng/mL) during stimulation.  
 
4.2.7 RNA isolation and real-time quantitative RT-PCR 
Cells were plated in 6-well plates and grown until confluence. After serum 
deprivation for 24 hours in DMEM supplemented with antibiotics, the cells were 
stimulated with TGF-β1 (2 ng/mL), alone or in combination with methacholine (10 
μM) for 1 or 7 days. Culture medium was refreshed after 4 days of stimulation. 
Total cellular RNA was isolated using the Nucleospin RNA II kit (Machery-Nagel, 
Bioke, Leiden, The Netherlands). RNA concentration was determined by Nanodrop 
ND1000 (Thermo Scientific, Wilmington, MA). Total RNA was reverse transcribed 
using the Promega cDNA synthesis kit. Real-time quantitative PCR for fibronectin, 
collagen I α1, integrin β1 and integrin α5 was performed using an Illumina Eco 
Personal qPCR System (Westburg, Leusden, The Netherlands) using the specific 
primers listed in Table 4.1. Cycle parameters were: denaturation at 94°C for 30 
seconds, annealing at 58°C for 30 seconds and extension at 72°C for 30 seconds 
for 40 cycles. The abundance of the target gene was normalized to the 
endogenous reference 18S rRNA (designated as ΔCq). Relative differences were 
determined by using the equation 2−(ΔΔCq). 
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Table 4.1. Primer sequences of fibronectin, collagen I α1, integrin β1, integrin α5 and 18S 





4.3.1 Mitogenic properties of TGF-β1 in human ASM cells 
To elucidate the mitogenic effects of TGF-β1 on ASM cell proliferation, human 
ASM cells were treated with TGF-β1 (2 ng/mL) for 1 or 7 days (Figure 4.1A). DNA 
synthesis was determined using a [3H]-thymidine incorporation assay. After 1 day 
of treatment, TGF-β1 did not enhance DNA synthesis in these cells, in contrast to 
the mitogen PDGF (10 ng/mL) (Figure 4.1B). However, prolonged treatment (7 
days) with TGF-β1 significantly (p< 0.05) increased DNA synthesis. After 7 days, 
PDGF still induced DNA synthesis, which was significantly enhanced in cells pre-
treated with TGF-β1 (p< 0.001, Figure 4.1C). A mitochondrial reduction assay and 
cell number determination confirmed these findings, as we observed a time-
dependent increase in cell number when cells were stimulated with TGF-β1 for up 
to 7 days (Table 4.2). Collectively, these results indicate that the TGF-β1-induced 
proliferation of human ASM cells is delayed in its onset and requires prolonged 








Substance Sequences  
Fibronectin Forward   
Reverse   
5'- TCGAGGAGGAAATTCCAATG -3' 
5'- ACACACGTGCACCTCATCAT -3' 
Collagen Iα1 Forward   
Reverse   
5'- AGCCAGCAGATCGAGAACAT-3' 
5'- TCTTGTCCTTGGGGTTCTTG-3' 
Integrin α5 Forward   
Reverse   
5'- GGAACTCAGATCCAGGACA -3' 
5'- CATGTCTGGCCCAAAGAACT-3' 
Integrin β1 Forward   
Reverse   
5'- CCCTTGCACAAGTGAACAGA -3' 
5'- TCTTGTCCTTGGGGTTCTTG -3' 
18S rRNA Forward   











































Figure 4.1. Mitogenic properties of TGF-β1 in human ASM cells. Effects of TGF-β1 on DNA 
synthesis in human ASM cells. Two different protocols were used to investigate the 
effects of TGF-β1 on ASM proliferation. In the acute treatment protocol, ASM cells were 
plated and allowed to attach overnight before serum deprivation in the presence of 1% ITS 
for 3 days. Subsequently, cells were treated with serum-free medium, TGF-β1 or PDGF-AB 
for 28 hours, the last 24 hours in the presence of [methyl-3H]-thymidine. In the prolonged 
treatment protocol, ASM cells were plated and allowed to attach overnight after which 
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serum deprivation occurred for 1 day. Subsequently, cells were treated with serum-free 
medium or TGF-β1 for 7 days. Cells were then washed and incubated with serum-free 
medium or PDGF-AB for 28 hours, the last 24 hours in the presence of [methyl-3H]-
thymidine. After both protocols thymidine incorporation was determined as described in 
the Materials and Methods section. (B) Effect of acute treatment with TGF-β1 on ASM 
proliferation. Human ASM cells were treated with serum-free medium (basal), TGF-β1 (2 
ng/mL) or PDGF-AB (10 ng/mL), according to the acute DNA synthesis treatment protocol 
(Figure 4.1A). Data represent means ± s.e.m. of 7 experiments, each performed in 
triplicate. *p< 0.05 compared to basal (one-way ANOVA, post-hoc Newman-Keuls). (C) 
Effect of prolonged treatment with TGF-β1 on ASM proliferation. Human ASM cells were 
treated with serum-free medium (basal) or TGF-β1 (2 ng/mL) for 7 days after which cells 
were stimulated with serum-free medium (control) or PDGF-AB (10 ng/mL), according the 
prolonged treatment DNA synthesis protocol (Figure 4.1C). Data represent means ± s.e.m. 
of 9 experiments, each performed in triplicate. *p< 0.05, **p< 0.01, ***p< 0.001 
compared to basal control. ###p< 0.001 compared to TGF-β1 control (one-way ANOVA, 
post-hoc Newman-Keuls). 
 
4.3.2 Mitogenic properties of TGF-β1 are dependent on extracellular matrix 
protein production and integrins 
The delay in onset of the mitogenic response of TGF-β1 on human ASM cells could 
involve ECM production, therefore, we stimulated human ASM cells with TGF-β1 
and determined the expression of collagen type I and fibronectin by Western 
analysis. TGF-β1 significantly (p< 0.01) increased the expression of collagen I and 
fibronectin protein after 7 days treatment (Figure 4.2A). In line, an increase of 
collagen I α1 and fibronectin mRNA was observed, both after 1 and after 7 days of 
TGF-β1 stimulation (Figure 4.2A-B), whereas after 1 day of stimulation a significant 
increase in protein expression was observed for fibronectin, but not for collagen I 
(Figure 4.2B). ECM proteins such as fibronectin and collagen have been reported 
to increase basal ASM cell proliferation (8, 9). In addition, they may interact with 
growth factors like PDGF to enhance their mitogenic properties (9, 11). To 
investigate whether the enhanced proliferation was (partly) due to synergism 
between the produced ECM and TGF-β1 itself, human ASM cells were plated on 
uncoated, collagen I- or fibronectin-coated plates and stimulated with TGF-β1. As 
observed previously (8, 9), both collagen I and fibronectin increased ASM cell 
proliferation (p< 0.01). However, TGF-β1 had no further effects on the 
proliferation induced by these ECM proteins (Figure 4.2C), suggesting that the 
mitogenic properties of TGF-β1 might be indirect and could involve autocrine 








































ECM proteins may enhance ASM cell proliferation through binding of integrin 
receptors (9, 15). Integrins are heterodimeric transmembrane glycoproteins, 
which interact with specific sequences in ECM proteins. The α5β1 integrin has 
been shown to be importantly involved in collagen I- and fibronectin-induced 
smooth muscle cell proliferation, which can be inhibited by the integrin blocking 
peptide Arg-Gly-Asp-Ser (RGDS) (9, 13-15, 39). Using the RGDS peptide (100 μM), 
we investigated whether the TGF-β1-induced proliferation could be due to the 
production of collagen I and fibronectin and their subsequent interaction with 
integrins on the ASM cell. We observed that treatment with RGDS reduced DNA 
synthesis induced by prolonged TGF-β1 treatment (Figure 4.2D), whereas its 
negative control Gly-Arg-Ala-Asp-Ser-Pro (GRADSP, 100 μM) had no effect. 
Similarly, function-blocking anti-α5 and anti-β1 antibodies also fully blocked the 
TGF-β1-induced proliferation (Figure 4.2E), indicating a key role for the major 
fibronectin binding α5β1 integrin in these effects. To investigate whether the TGF-
β1-induced ASM cell proliferation could also involve an increase in α5β1 integrin 
expression, we assessed the mRNA expression of the integrin α5 and β1 subunits. 
No effects of TGF-β1 were observed on the mRNA expression of the α5 subunit. 
However, an increase in mRNA levels of the integrin subunit β1 was observed 
after 7 days of treatment with TGF-β1 (p< 0.001), whereas a trend towards an 
increased mRNA expression was observed after 1 day (p< 0.07, Figure 4.2F). 
Collectively, these results indicate that TGF-β1 enhances ASM proliferation 
primarily through the autocrine effects of ECM proteins such as collagen I and 
fibronectin on the α5β1 integrin, which could possibly be reinforced by enhanced 




















Figure 4.2. Involvement of extracellular matrix proteins in the mitogenic properties of 
TGF-β1. (A) Human ASM cells were treated with serum-free medium (basal) or TGF-β1 (2 








































determined by Western analysis. Representative blots of collagen I, fibronectin and 
GAPDH are shown. Data represent means ± s.e.m. of 6-8 experiments. **p< 0.01 
compared to basal (Student’s t-test). (B) Protein expression of collagen I and fibronectin 
after 1 day of stimulation and mRNA levels of collagen I α1 and fibronectin in response to 
TGF-β1 after stimulation for 1. Data represent means ± s.e.m. of 3-6 experiments. *p< 0.05 
compared to basal (Student’s t-test). (C) Human ASM cells were plated on uncoated plastic 
surfaces or on collagen type I- or fibronectin-coated matrices. Subsequently, cells were 
treated with serum-free medium (control) or TGF-β1 (2 ng/mL), according to the acute 
treatment protocol (see Figure 4.1A). Data represent means ± s.e.m. of 7 experiments, 
each performed in triplicate. *p< 0.05, **p< 0.01 compared to uncoated control (one-way 
ANOVA, post-hoc Newman-Keuls). (D) Human ASM cells were treated with serum-free 
medium (basal) or TGF-β1 (2 ng/ml) for 7 days, in the absence or presence of the integrin 
blocking peptide RGDS or its negative control GRADSP (both 100 μM), according to the 
prolonged treatment protocol (see Figure 4.1A). Data represent means ± s.e.m. of 8 
experiments, each performed in triplicate. *p< 0.05, ** p< 0.01, ***p< 0.001 compared to 
basal control. #p< 0.05 compared to TGF-β1 control (one-way ANOVA, post-hoc Newman-
Keuls). (E) Human ASM cells were treated with serum-free medium (basal) or TGF-β1 (2 
ng/ml) for 7 days, in the absence or presence of the integrin function-blocking monoclonal 
anti-α5 (10 mg/mL) and anti-β1 (10 mg/mL) antibodies or mouse IgG control antibodies 
(10 mg/mL), according to the prolonged treatment protocol. Data represent means ± 
s.e.m. of 6-7 experiments, each performed in duplicate (one-way ANOVA, post-hoc 
Newman-Keuls) *p< 0.05 compared to basal control. #p< 0.05 compared to TGF-β1 control. 
(F) mRNA levels of integrin subtypes β1 and α5 relative to basal expression of these 
subtypes after stimulation with TGF-β1 for 1 and 7 days. Data represent means ± s.e.m. of 
6 experiments (one-way ANOVA, post-hoc Newman-Keuls). ***p< 0.001 compared to 
basal.  
 
4.3.3 Muscarinic receptor stimulation enhances TGF-β1-induced ASM cell 
proliferation 
To assess the functional interaction between TGF-β1 and muscarinic receptor 
stimulation at the level of cell proliferation, ASM cells were pre-treated with TGF-
β1 (2 ng/mL), methacholine (10 µM) or their combination for 7 days. As described 
above, TGF-β1 treatment significantly (p< 0.001) increased DNA synthesis after 7 
days of treatment. Interestingly, this increase was significantly augmented by co-
treatment with the muscarinic receptor agonist methacholine (p< 0.001), whereas 
no effect of methacholine was observed in the absence of TGF-β1 (Figure 4.3A). 
Similar results were observed for cell number (Table 4.2). 
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Table 4.2. Proliferative responses of human ASM cells in the absence of TGF-β1 (2 ng/mL) 
and/or methacholine (10 µM) after 7 days of incubation. 
Data are expressed as percentage of TGF-β1-induced responses. Data represent means ± 
s.e.m. of 4-9 experiments performed I triplicate ([3H]-thymidine-incorporation) or 
duplicate (Alamar Blue conversion and cell number). **p< 0.01, ***p< 0.001 compared to 
control. ##p< 0.01, ###p< 0.001 compared to TGF-β1 control. 
 
To investigate whether muscarinic receptor stimulation could amplify the 
mitogenic properties of the TGF-β1-induced ECM proteins, ASM cells were plated 
on collagen I- or fibronectin-coated beds and treated with methacholine (10 µM) 
for 1 day. Stimulation with methacholine did not enhance the mitogenic effects of 
the ECM proteins (Figure 4.3B), indicating that the interaction between TGF-β1 
and muscarinic receptor stimulation was not due to a direct interaction between 
muscarinic receptors and collagen type I or fibronectin.  
 
Figure 4.3. Muscarinic receptor stimulation enhances mitogenic properties of TGF-β1. (A) 
Human ASM cells were treated with serum-free medium (basal), TGF-β1 (2 ng/mL), 
methacholine (MCh, 10 µM) or their combination for 7 days, according to the prolonged 
treatment protocol (see Figure 4.1A). Data represent means ± s.e.m. of 9 experiments, 
each performed in triplicate. ***p< 0.001 compared to basal control. ###p< 0.001 
 Control Methacholine 





58 ± 9 100 ± 0*** 60 ± 11 149 ± 10***,### 
Alamar Blue 
conversion 
72 ± 1 100 ± 0*** 74 ± 1 115 ± 6***,## 








































compared to TGF-β1 control (one-way ANOVA, post-hoc Newman-Keuls). (B) Human ASM 
cells were plated on uncoated plastic surfaces or on collagen I- or fibronectin-coated 
matrices and serum deprived for 3 days. Subsequently, cells were treated with serum-free 
medium or methacholine (10 µM), according to the acute treatment protocol. Data 
represent means ± s.e.m. of 7 experiments, each performed in triplicate (one-way ANOVA, 
post-hoc Newman-Keuls). *p< 0.05, **p< 0.01 compared to uncoated control. 
 
Therefore, we investigated whether muscarinic receptor stimulation enhanced 
ECM deposition induced by TGF-β1. ASM cells were treated with TGF-β1 (2 ng/mL), 
methacholine (10 µM) or their combination for 7 days. Subsequently collagen I 
and fibronectin expression were measured by Western analysis. Interestingly, 
although TGF-β1 clearly increased the expression of both collagen I and 
fibronectin, methacholine selectively increased the TGF-β1-induced protein 
expression of fibronectin, while methacholine was ineffective by itself (Figure 
4.4A). This suggests that the enhanced deposition of fibronectin might be involved 
in the functional interaction between TGF-β1 and muscarinic receptor stimulation. 
To further substantiate this hypothesis, ASM cells were treated with or without 
RGDS while stimulated with TGF-β1, methacholine or their combination for 7 days. 
RGDS blocked the enhanced mitogenic response induced by the co-stimulation 
with TGF-β1 and methacholine (Figure 4.4B), whereas no effects were found for 
GRADSP (data not shown). Furthermore, function-blocking anti-α5 and anti-β1 
antibodies significantly reduced the enhanced DNA synthesis induced by TGF-β1 
and methacholine (Figure 4.4C). In line with an increased activation of the α5β1 
integrin, no effects of methacholine were observed on the mRNA expression of α5 
and β1 integrins either, indicating that the synergistic effect of methacholine on 
TGF-β1-induced proliferation cannot be explained by increased integrin 
abundance (Figure 4.4D). Collectively, these data indicate that the synergistically 
enhanced deposition of fibronectin and α5β1 activation in response to muscarinic 
receptor and TGF-β1 stimulation importantly contributes to their functional 
interaction on ASM proliferation. 
 
 










































Figure 4.4. Involvement of extracellular matrix proteins in the enhanced mitogenic 
response induced by muscarinic receptor stimulation in the presence of TGF-β1. (A) 
Human ASM cells were treated for 7 days with serum-free medium (basal), TGF-β1 (2 
ng/mL), methacholine (MCh, 10 µM) or their combination. Protein expression of collagen I 
and fibronectin was determined by Western analysis. Representative blots of collagen I, 
fibronectin and GAPDH are shown. Data represent means ± s.e.m. of 7-8 experiments 
(one-way ANOVA, post-hoc Newman-Keuls). (B) Human ASM cells were treated with 
serum-free medium (basal), TGF-β1 (2 ng/ml), methacholine (10 µM) or their combination 
for 7 days, in the absence or presence of the integrin blocking peptide RGDS (100 μM), 
according to the prolonged treatment protocol. Data represent means ± s.e.m. of 8 
experiments, each performed in triplicate (one-way ANOVA, post-hoc Newman-Keuls). (C) 
Human ASM cells were treated with serum-free medium (basal), TGF-β1 (2 ng/ml), or TGF-
β1 (2ng/mL) + methacholine (10 µM) for 7 days, in the absence or presence of the integrin 
function-blocking monoclonal anti-α5 (10 mg/mL) and anti-β1 (10 mg/mL) antibodies or 
mouse IgG control antibodies (10 mg/mL), according to the prolonged treatment protocol. 
Data represent means ± s.e.m. of 6-7 experiments, each performed in duplicate (one-way 
ANOVA, post-hoc Newman-Keuls). (D) mRNA levels of integrins subtypes β1 and α5 after 
stimulation with TGF-β1 and methacholine for 1 and 7 days. Data represent means ± s.e.m. 
of 6 experiments (one-way ANOVA, post-hoc Newman-Keuls).*p< 0.05, **p< 0.01, 
***p< 0.001 compared to basal control. #p< 0.05, ##p< 0.01, ###p< 0.001 compared to TGF-
β1 control. 
$$$p< 0.001 compared to TGF-β1 + methacholine. 
 
4.3.4 Muscarinic M2 receptors are responsible for the cross-talk with TGF-β1 
We have previously reported that the enhancement of PDGF-induced ASM cell 
proliferation by methacholine is mediated by Gq-coupled muscarinic M3 receptors 
(26). Distinct signalling pathways are involved in the activation of receptor 
tyrosine kinases by growth factors and serine/threonine kinase receptors by TGF-
β1 (38, 39). This could implicate that their cross-talk with muscarinic receptors 
may require different muscarinic receptor subtypes. Therefore, we aimed to 
investigate the muscarinic receptor subtype involved in the cross-talk between 
the serine/threonine kinase TGF-β receptor and muscarinic receptor stimulation. 
To this aim, we stimulated ASM cells with TGF-β1 (2 ng/ml), methacholine (10 μM) 
and their combination in absence and presence of the subtype-selective 
muscarinic receptor antagonists DAU5884 and gallamine for 7 days. The clinically 
used, non-subtype-selective long-acting muscarinic receptor antagonist 
tiotropium bromide was also used. Concentrations of the selective antagonists 
were chosen based on the work of Roffel and coworkers, such that approximately 
99% of the M2 receptors and approximately 8 % of the M3 receptors were 
occupied with the muscarinic M2 receptor selective antagonist gallamine and less 
than 30% of the M2 receptors and more than 99% of the M3 receptors with the 
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muscarinic M3 receptor selective antagonist DAU5884 (40-43). DNA synthesis was 
assessed using a [3H]-thymidine incorporation assay. We observed that both the 
muscarinic receptor antagonist tiotropium bromide and the muscarinic M2 
receptor antagonist gallamine significantly (p< 0.01) reduced the DNA synthesis 
induced by co-stimulation with TGF-β1 and methacholine, to levels observed after 
stimulation with TGF-β1 alone (Figure 4.5A). No effects were observed for the 
muscarinic M3 receptor antagonist DAU5884. In addition, no effects of the 
antagonists were observed on basal or TGF-β1-induced proliferation. This indicates 
that the interaction between TGF-β1 and muscarinic receptor stimulation was 
mediated by the muscarinic M2 receptor. 
Since muscarinic M2 receptors couple to Gi proteins, the contribution of the 
muscarinic M2 receptors to TGF-β1 and methacholine-induced ASM cell 
proliferation was further assessed using the irreversible Gi protein inhibitor 
pertussis toxin (PTX). ASM cells were treated with PTX (100 ng/ml) for 16 hours, 
after which the cells were stimulated with TGF-β1 (2 ng/mL), methacholine (10 μM) 
and their combination, in absence and presence of PTX (50 ng/mL) for 7 days. In 
line with a role for the muscarinic M2 receptor, we observed that the synergistic 
effect of methacholine on the TGF-β1-induced response could be attenuated by 
PTX treatment, whereas no effects of PTX were observed on any of the other 
treatments (Figure 4.5B). Collectively, these results demonstrate that cross-talk 











































Figure 4.5. Muscarinic M2 receptors enhance mitogenic properties of methacholine in 
the presence of TGF-β1. (A) Human ASM cells were treated with serum-free medium 
(basal), TGF-β1 (2 ng/mL), methacholine (MCh, 10 µM) or their combination in absence 
and presence of the non-selective muscarinic receptor antagonist tiotropium bromide (10 
nM), the M2-selective muscarinic receptor antagonist gallamine (10 μM) or the M3-
selective muscarinic receptor antagonist DAU5884 (100 nM) for 7 days, according to the 
prolonged treatment protocol. Data represent means ± s.e.m. of 8 experiments, each 
performed in triplicate (one-way ANOVA, post-hoc Newman-Keuls). (B) Human ASM cells 
were treated with serum-free medium (basal), TGF-β1 (2 ng/mL), methacholine (10 µM) or 
their combination in presence or absence of PTX (100 ng/mL for 16 hours, followed by 50 
ng/mL during the entire treatment period) for 7 days, according to the prolonged 
treatment protocol. Data represent means ± s.e.m. of 8 experiments, each performed in 
triplicate (one-way ANOVA, post-hoc Newman-Keuls). *p< 0.05, **p< 0.01, ***p< 0.001 
compared to basal control. ##p< 0.01, ###p< 0.001 compared to TGF-β1 control. 
$$p< 0.01, 
$$$p< 0.001 compared to TGF-β1 + methacholine. 




In the current study, we demonstrate that prolonged treatment with TGF-β1 is 
required to induce ASM cell proliferation via the enhanced deposition of ECM 
proteins and the subsequent autocrine activation of the α5β1 integrin. Our data 
show that TGF-β1 enhances fibronectin and collagen I expression and that these 
ECM proteins subsequently interact with RGD-binding integrins, including the 
α5β1 integrin, to induce ASM cell proliferation. Moreover, TGF-β1-induced 
proliferation was synergistically enhanced by muscarinic receptor stimulation, 
which required increased protein expression of fibronectin, but not collagen type I. 
Furthermore, we demonstrate that muscarinic M2 receptors, but not muscarinic 
M3 receptors, contribute to this enhancement of TGF-β1-induced ASM cell 
proliferation. 
 
The cytokine TGF-β is a ubiquitously expressed and multifunctional cytokine that 
regulates various processes in the human body, including morphogenesis, 
inflammation, cell growth, wound healing and fibrosis (1). Studies investigating 
the effects of TGF-β on smooth muscle indicate that TGF-β is importantly involved 
in differentiation and maturation. In ASM cells, TGF-β increases the expression of 
smooth muscle α-actin, calponin and smooth muscle myosin (chapter 3, 44, 45). 
Moreover, maturating ASM cells release higher concentrations of TGF-β, which in 
turn enhance ASM maturation in an autocrine fashion (46). In addition to its role 
in the maturation of smooth muscle cells, TGF-β also enhances fibrogenic 
responses. In vitro studies have demonstrated that TGF-β1 enhances deposition of 
collagen type I, fibronectin and versican by smooth muscle cells as well (3, 4, 47). 
TGF-β also contributes to smooth muscle hyperplasia and/or hypertrophy; in vivo 
administration of an anti-TGF-β antibody reduces allergen-induced increases in 
ASM mass in a mouse model of asthma, which was associated with a decreased 
ECM deposition in the airway wall (47). Conversely, overexpression of TGF-β in 
mice increased smooth muscle mass and ECM deposition in the lung (17, 48). 
Previous in vitro studies have indicated that TGF-β could stimulate proliferation of 
ASM cells directly (19-23). In the current study, we also demonstrated that TGF-β1 
increased ASM proliferation, which required prolonged treatment and was 
associated with an enhanced production of ECM proteins fibronectin and collagen 
I. This increase in proliferation after prolonged exposure experiments could not be 








































before [3H]-thymidine incorporation was assessed. In line with previous studies 
showing that fibronectin and collagen I enhance both basal and growth factor-
induced smooth muscle proliferation, we found that ASM proliferation was 
increased when cells were grown on fibronectin or collagen type I. Proliferation of 
ASM cells on these matrices requires multiple β1-integrins, including the α5β1 
integrins (9, 15). These α5β1 integrins are also found to be important in the 
proliferation of vascular smooth muscle cells in response to angiotensin II and 
PDGF (7, 13). Proliferation in response to these stimuli could be inhibited by the 
use of integrin-blocking peptides containing the RGD motif, but also by anti-α5 
and anti-β1 function-blocking antibodies (9, 13, 37). In the current study, we 
found that the RGD-binding integrin α5β1 is also importantly involved in the 
induction of ASM proliferation following prolonged TGF-β1 treatment. These 
findings may not only be important in vitro, but also in vivo as RGD-binding 
integrins plays a key role in ASM remodelling in a guinea pig model of allergic 
asthma (9). In line with previous findings (37), we also found an increase in mRNA 
expression of integrin subtype β1 following TGF-β1 stimulation. However, mRNA 
expression of the integrin subtype α5 remained unchanged. Taken together, our 
findings indicate an important role for TGF-β1 and autocrine ECM signalling in 
smooth muscle remodelling, leading to smooth muscle proliferation. 
 
Muscarinic receptors, belonging to the family of G protein-coupled receptors, are 
associated with contraction of smooth muscle cells in the airways. In addition, 
proliferation of ASM cells in response to peptide growth factors PDGF and EGF is 
enhanced by muscarinic receptor stimulation, with an important role for the 
muscarinic M3 receptor (26, 27). The functional interactions between the TGF-β 
receptor serine/threonine kinase and GPCRs, however, are still not well 
characterized. Currently, we demonstrate that muscarinic receptor stimulation 
enhanced the mitogenic properties of TGF-β1 and augmented the deposition of 
the ECM protein fibronectin, but not collagen I. As reported previously (26, 52), 
muscarinic receptor stimulation had no mitogenic properties by itself. Similarly, 
when grown on ECM beds of collagen I and fibronectin, methacholine did not 
enhance ASM cell proliferation. Using pharmacological antagonists at selective 
concentrations, we demonstrate that the interaction between TGF-β1 and 
methacholine was dependent on the muscarinic Gi-coupled M2 receptor. This was 
confirmed using the irreversible Gi protein inhibitor pertussis toxin. Also in human 
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lung fibroblasts, activation of the muscarinic M2 receptors induces cell 
proliferation and collagen deposition (34, 35, 51). 
The intracellular signalling pathways involved in the increased ECM deposition in 
response to muscarinic M2 receptor and TGF-β receptor stimulation are still 
largely unknown. However, we have recently demonstrated that combined 
muscarinic receptor and TGF-β1 stimulation enhanced the phosphorylation of 4E-
BP1 and GSK-3β resulting in the increased expression of contractile proteins, 
including sm-α-actin and calponin in human ASM cells (chapter 3). Furthermore, 
as fibronectin expression after TGF-β1 stimulation has been shown to be under 
the regulation of the GSK3β target β-catenin (3), these observations suggest an 
important role for the GSK-3 signalling axis in the increased fibronectin expression 
after TGF-β1 and methacholine stimulation.  
Taken together, these findings suggest that in addition to muscarinic M3 receptors, 
also muscarinic M2 receptors may importantly contribute to remodelling 
processes, leading to airway fibrosis and ASM remodelling. 
ASM remodelling is considered to be a major factor contributing to lung function 
decline and airway hyperresponsiveness in asthma and chronic obstructive 
pulmonary disease (COPD) (52, 53). Airway hyperresponsiveness is characterized 
by increased responsiveness of the airways to pharmacological, chemical and 
physical stimuli such as methacholine, smoke and cold air (54-56). Acute, variable 
airway hyperresponsiveness is considered to be dependent on airway 
inflammation, whereas chronic persistent airway hyperresponsiveness is 
considered to reflect airway remodelling. The mechanisms underlying ASM 
remodelling in airway diseases are still incompletely understood, however, 
inflammation appears to play an important role. In addition, recent studies 
indicate that also bronchoconstriction may promote airway remodelling, as 
bronchoconstriction in response to methacholine challenge increases the 
expression of TGF-β and the deposition of subepithelial collagen in patients with 
asthma, without increasing inflammation (57). Not only ASM changes, but also 
ECM changes may contribute to airway responsiveness, as a significant correlation 
has been found between airway responsiveness and the deposition of collagen 
and elastin in the airway wall (58, 59). These findings indicate that remodelling 
characteristics, including the deposition of ECM by ASM cells, may contribute to 
airway hyperresponsiveness. Interestingly, our findings demonstrated that TGF-β1 
and methacholine induce proliferation of ASM cells via the deposition of the ECM 








































hyperresponsiveness and ASM remodelling in asthma (9). In line with these 
findings, increased ASM mass induced by repeated allergen challenges in guinea 
pig model of asthma is inhibited by the use of the muscarinic receptor antagonist 
tiotropium bromide, well-known for its bronchodilator effects (31). In a murine 
model of asthma, tiotropium bromide not only inhibited smooth muscle 
thickening but also the expression of TGF-β1 in the bronchoalveolar lavage (BAL) 
fluid (32). This relationship between the cholinergic system and TGF-β1 may in 
part be explained by the fact that cellular contraction is required for the release 
and activation of TGF-β from its inactive complex with latency-associated peptide 
by the αvβ5 integrin on the ASM cell membrane (60). In addition, our current data 
indicate that in addition to M3 mediated effects, also M2 mediated effects may 
contribute to ASM remodelling.  
In summary, our study has demonstrated that TGF-β1 enhances ASM proliferation 
by enhancing ECM deposition and the subsequent activation of RGD-binding 
integrins, in particular the α5β1 integrin. Muscarinic receptor agonists enhance 
TGF-β1-induced ASM cell proliferation by the specific induction of fibronectin 
protein expression via the muscarinic M2 receptor. Collectively, our data suggest 
that not only muscarinic M3 receptors, but also muscarinic M2 receptors play an 
important role in processes associated with airway remodelling. 
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Airway remodelling, including smooth muscle remodelling, is a primary cause of 
airflow limitation in asthma. Recent evidence links bronchoconstriction to airway 
remodelling in asthma. The mechanisms involved are poorly understood. A 
possible player is the multifunctional cytokine TGF-β, which plays an important 
role in airway remodelling. Guinea pig lung slices were used as an in vitro model 
to investigate mechanisms involved in bronchoconstriction-induced airway 
remodelling. To address this aim, mechanical effects of bronchoconstricting 
stimuli on contractile protein expression and TGF-β release were investigated. 
Lung slices were viable for at least 48 h. Both methacholine and TGF-β1 
augmented the expression of contractile proteins (sm-α-actin, sm-myosin, 
calponin) after 48 h. Confocal fluorescence microscopy showed that increased sm-
myosin expression was enhanced in the peripheral airways and the central 
airways. Mechanistic studies demonstrated that methacholine-induced 
bronchoconstriction mediated the release of biologically active TGF-β, which 
caused the increased contractile protein expression, as inhibition of actin 
polymerization (latrunculin A) or TGF-β receptor kinase (SB431542) prevented the 
methacholine effects, whereas other bronchoconstricting agents (histamine and 
KCl) mimicked the effects of methacholine. Collectively, bronchoconstriction 
promotes the release of TGF-β, which induces airway smooth muscle remodelling. 
This study shows that lung slices are a useful in vitro model to study mechanisms 





Airway remodelling is an important pathological characteristic of chronic asthma 
(1). Airway remodelling encompasses all structural alterations of the airways, 
including remodelling of the airway smooth muscle layer which is one of the most 
striking pathological features of chronic asthma (2). Remodelling of the airway 
smooth muscle layer has been suggested to be a major cause of airflow 
obstruction in asthma (3, 4). The mechanisms underlying this pathology are, 
however, still unclear. 
During bronchoconstriction, airways are subjected to mechanical forces, which 
promote gene expression and growth factor release in resident cells (5). As such, 




































mechanical forces could promote tissue remodelling. For example, compression of 
airway epithelial cells leads to features of remodelling, including upregulation of 
gene expression of TGF-β and protein expression of fibronectin (5-8). Grainge et al. 
demonstrated that bronchoconstriction induced by repeated methacholine 
challenges can induce features of airway remodelling in mild asthma patients (9), 
including an increase in epithelial TGF-β expression and an increase in 
subepithelial collagen deposition compared to saline-challenged controls. 
Moreover, we have previously demonstrated that treatment of sensitized guinea 
pigs with the anticholinergic bronchodilator drug tiotropium inhibits airway 
remodelling induced by repeated allergen challenge (10, 11). These findings have 
provided new insights into the causality of the relationship between persistent 
airflow obstruction and airway remodelling in asthma.  
 
The multifunctional cytokine TGF-β plays an important role in airway remodelling 
(12). In the airways of asthmatics, this pro-fibrotic cytokine is highly expressed, 
particularly in epithelial cells and in eosinophils (12). In airway smooth muscle 
cells, TGF-β1 can induce proliferation (12, 13, 14) as well as increased expression 
of contractile protein markers, such as sm-α-actin and calponin through both 
transcriptional and translational control (chapter 3, 13). Activation of 
serine/threonine kinase receptors by TGF-β1 will provoke phosphorylation of 
Smad 2/3 (15), and promotes the nuclear localization of serum response factor, 
which cooperatively regulate the transcriptional activity for smooth muscle 
specific genes (16-18). Furthermore, TGF-β1 can regulate cell proliferation of 
airway epithelial cells and fibroblasts, but also cell differentiation and the 
synthesis of extracellular matrix proteins in these cells (19). Although evidence 
exist that TGF-β is upregulated after mechanical compression of airway epithelial 
cells and is involved in tissue remodelling, a direct link between 
bronchoconstriction and TGF-β-induced airway remodelling has not been 
demonstrated yet. 
 
Precision-cut lung slices have been proven a valuable in vitro tool in 
pharmacological research and drug development (20). Lung slices have various 
advantages compared to airway smooth muscle cell cultures, as all lung cell types 
are present and cell-cell contacts and cell-matrix interactions are preserved, 
which are important regulators in bronchoconstriction and airway remodelling 




muscle cells in culture, associated with a loss of sm-myosin expression and 
contractile receptors, is avoided (22, 23). Moreover, a large number of lung slices 
can be prepared from the lungs of a single animal, which allows the direct 
comparison of experimental treatments with a control from the same animal (23). 
The use of precision-cut lung slices from guinea pigs has additional advantages. 
For example, Ressmeyer et al., showed that airway responsiveness to 
methacholine was almost identical for precision-cut lung slices from humans and 
guinea pigs (23). Moreover, in contrast to other small experimental animals, there 
are great anatomical and functional similarities between guinea pig and human 
airways including the presence of small airways (4).  
 
Therefore, in the present study, precision-cut lung slices were used as an in vitro 
model to study mechanisms of bronchoconstriction-induced airway remodelling. 
Precision-cut lung slices from guinea pigs were stimulated with contractile 
agonists such as methacholine, histamine and potassium chloride, but also with 
the pleiotropic cytokine TGF-β1. Contractile protein expression was studied in 
response to these stimuli as a marker of airway remodelling. Using specific 
inhibitors, the mechanisms inducing an increase in contractile protein expression 
by bronchoconstriction were studied and were found to be dependent on 
mechanically-induced release of endogenous TGF-β. 
 
 
5.2 Materials and methods 
 
5.2.1 Animals 
Outbred, male, specified pathogen-free Dunkin Hartley guinea pigs (Harlan, 
Heathfield, UK) (740 ± 85g) were used. All protocols described in this study were 
approved by the University of Groningen Committee for Animal Experimentation, 
Groningen, The Netherlands. The animals were housed under a 12 hour light/dark 
cycle in a temperature- and humidity-controlled room with food and tap water ad 
libitum. 
 
5.2.2 Precision-cut lung slices 
Precision-cut lung slices were prepared as described in (23). In short, after 
euthanization by injection with pentobarbital (Euthasol 20%, Produlab Pharma, 
Raamsdonksveer, the Netherlands) the trachea was cannulated, and the animal 




































was ex-sanguinated via the aorta abdominalis. Lungs were filled through the 
cannula with a low melting-point agarose solution (1,5% final concentration 
(Gerbu Biotechnik GmbH, Wieblingen, Germany) in CaCl2 (0.9mM), MgSO4 (0.4 
mM), KCl (2.7 mM), NaCl (58.2 mM), NaH2PO4 (0.6 mM), glucose (8.4 mM), 
NaHCO3 (13 mM), Hepes (12.6 mM), sodium pyruvate (0.5 mM), glutamine (1 
mM), MEM-amino acids mixture (1:50), and MEM-vitamins mixture (1:100), 
pH=7.2). Subsequently, lungs were placed on ice for at least 30 min, in order to 
solidify the agarose for slicing. Tissue cores were prepared from the lobes using a 
rotating sharpened metal tube (diameter 15 mm), followed by slicing the tissue in 
medium composed of CaCl2 (1.8mM), MgSO4 (0.8 mM), KCl (5.4 mM), NaCl (116.4 
mM), NaH2PO4 (1.2 mM), glucose (16.7 mM), NaHCO3 (26.1 mM), Hepes (25.2 
mM), pH = 7.2, using a tissue slicer (Compresstome™ VF-300 microtome, 
Precisionary Instruments, San Jose CA, USA). Lung slices were cut at a thickness of 
500 µm. 
 
5.2.3 Culture medium 
Before stimulation, lung slices were incubated individually in 24 well-plates in 
minimal essential medium composed of CaCl2 (1.8mM), MgSO4 (0.8 mM), KCl (5.4 
mM), NaCl (116.4 mM), NaH2PO4 (1.2 mM), glucose (16.7 mM), NaHCO3 (26.1 
mM), Hepes (25.2 mM), sodium pyruvate (1mM), glutamine (2 mM), MEM-amino 
acids mixture (1:50), and MEM-vitamins mixture (1:100), pH=7.2, at 37°C in a 
humid atmosphere. In order to remove the agarose and cell debris from the tissue, 
medium was refreshed after 30 min, followed by 2 washes every hour. During the 
experiments, the lung slices were incubated in Dulbecco’s Modification of Eagle’s 
Medium (DMEM) supplemented with sodium pyruvate (1 mM), non-essential 
amino acid mixture (1:100), gentamycin (45 µg/mL), penicillin (100 U/mL), 
streptomycin (100 µg/mL) and amphotericin B (1.5 µg/mL) at 37°C-5% CO2. 
 
5.2.4 Lactate dehydrogenase release 
To assess the viability of the lung slices, the amount of lactate dehydrogenase 
(LDH) released from the slices into the incubation medium relative to the total 
slice content was measured. Slices were incubated in 6 well-plates (2 slices/well) 
in 4 mL incubation medium for 1, 2, 3 or 4 days. Maximal LDH release was 
determined by lysing 2 slices with 1% Triton X-100 for 30 min at 37°C at the 
beginning of the experiment. Supernatants were stored -80 °C. LDH release in the 




(Groningen, The Netherlands) using the Roche/Hitachi Modular system (Roche, 
Mannheim, Germany). 
 
5.2.5 Mitochondrial activity assay 
Mitochondrial activity, as an additional measure of tissue viability, was assessed 
by conversion of Alamar blue into its reduced form, as described previously (24). 
Lung slices were incubated with Hanks’ balanced salt solution, containing 10% 
Alamar blue solution (BioSource, Camarillo, CA), for at least 30 min at 37°C-5% 
CO2.  
 
5.2.6 Treatment of lung slices 
Lung slices were cultured in 6-well plates, using 2 slices per well. The slices were 
stimulated with methacholine (10 μM), TGF-β1 (0.1, 0.2, 1 and 2 ng/mL), KCl (60 
mM) or histamine (1 µM) for 1 or 2 days continuously, as indicated. Where 
mentioned, lung slices were pre-incubated with the inhibitor of actin 
polymerization latrunculin A (0.3 µM) or the selective inhibitor of the TGF-β type I 
receptor activin receptor-like kinase ALK5, SB431542 (0.3 µM) for 30 min. 
 
5.2.7 Stimulation of MRC-5 fibroblasts by conditioned media of stimulated 
lung slices 
MRC-5 lung fibroblasts were cultured in Ham’s F12 medium supplemented with 
10% foetal bovine serum (FBS), L-glutamine (2 mM), streptomycin (100 µg/L) and 
penicillin (100 U/mL). For each experiment, cells were grown to confluence and 
subsequently culture medium was substituted with Ham’s F12 medium 
supplemented with 0.5% FBS, L-glutamine and antibiotics for a period of 24 hours. 
Thereafter, cells were stimulated for 1 h with TGF-β1 (2 ng/mL), methacholine (10 
µM) or with conditioned media obtained from incubated lung slices. Conditioned 
media used were taken from control slices and from slices treated with TGF-β1 (2 
ng/mL) or MCh (10 µM), both in the presence and absence of the inhibitors 
latrunculin A (0.3 µM) or SB431542 (0.3 µM), for 48 h. 
 
5.2.8 Immunofluorescence 
Lung slices were stimulated in 6 well-plates, using 2 slices per well. Slices were 
stimulated with methacholine (10 μM) or TGF-β1 (2 ng/mL) for 2 days 
continuously. After washing twice with cytoskeleton buffer (CB: MES (10 mM), 
NaCl (150 mM), EGTA (5 mM), MgCl2 (5 mM), and glucose (5 mM) at pH=6.1), the 




































lung slices were fixed with CB containing 3% paraformaldehyde (PFA) for 15 min. 
The slices were subsequently incubated with CB buffer containing 3% PFA and 
0.3% Triton-X-100 for 5 min, followed by an additional 2 washes with CB buffer. 
Lung slices were then blocked for 1 h in cyto-TBS (Tris-base (20 mM), NaCl (154 
mM), EGTA (2.0 mM) and MgCl2 (2.0 mM), pH=7.2), supplemented with BSA (1%) 
and normal donkey serum (2%). After that, lung slices were stained with mouse 
sm-myosin antibody overnight at 4°C. After washing 3 times with cyto-TBS 
containing 0.1% Tween-20 (cyto-TBS-T) for 10 min, incubation with the secondary 
antibody (Cy3-mouse, 1:50 in cyto-TBS-T) was performed during 3 h at room 
temperature. Lung slices were then washed 4 times for 15 min in cyto-TBS-T, 
followed by 4 washes with ultra-pure water. The slides were mounted with 
ProLong Gold anti-fade reagent (Invitrogen, Breda, The Netherlands). After 
staining, the slides were analysed using a Leica TCSSP2 confocal microscope. All 
conditions within one experiment were analysed in the same session using 
identical microscopic settings. Excitation wavelength was 543 nm. 
 
5.2.9 Western Blotting 
Lung slices or MRC-5 cells were washed once with ice-cold phosphate-buffered 
saline (PBS, composition: NaCl (140 mM), KCl (2.6 mM), KH2PO4 (1.4 mM), 
Na2HPO4 (8.1 mM), pH 7.4), followed by lysis using ice-cold SDS-lysis buffer (Tris-
HCl (62.5 mM), SDS (2 %), NaF (1 mM), Na3VO4 (1 mM), aprotinin (10 μg/mL), 
leupeptin (10 μg/mL), pepstatin A (7 µg/mL) at pH 8.0). Equal amounts of protein, 
determined by Pierce protein determination according to the manufacturer’s 
instructions, were separated on SDS polyacrylamide gels and transferred onto 
nitrocellulose, followed by standard immunoblotting techniques. All bands were 
normalized either to β-actin or to total Smad 2/3 expression. 
 
5.2.10 Antibodies and reagents 
Methacholine chloride was purchased from ICN Biomedicals (Zoetermeer, the 
Netherlands). Human recombinant TGF-β1 was obtained from R&D systems 
(Abingdon, UK). Mouse anti-α smooth muscle actin (sm-α-actin) antibody, mouse 
anti-calponin antibody, mouse anti-β-actin (β-actin) antibody, horseradish 
peroxidase (HRP)-conjugated rabbit anti-mouse IgG antibody, histamine were 
purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Mouse anti-myosin 
smooth muscle myosin (sm-myosin) was purchased from Neomarkers 




was obtained from Jackson ImmunoResearch (West Grove PA, USA). The 
inhibitors latrunculin A and SB431542 were purchased from Tocris Biosciences 
(Bristol, UK). All other chemicals were of analytical grade. 
 
5.2.11 Data analysis 
Data are presented as mean values ± SEM. Statistical significance was determined 
by paired Student’s t-test with two-tailed distribution or one-way ANOVA for 
paired observations, followed by a Newman-Keuls multiple comparisons test 





5.3.1 Lung slice viability 
To determine the viability of cultured precision-cut lung slices, LDH release and 
mitochondrial activity were assessed after 1, 2, 3 and 4 days of incubation. We 
observed a significant increase in LDH release over time; however, LDH release 
was still below 15% of maximal content on day 2 (Figure 5.1A) as observed 
previously in Ressmeyer et al. (23). The time course of LDH release was closely 
paralleled by that of the mitochondrial activity assay, which demonstrated a 
significant reduction in activity starting on day 3 (Figure 5.1B). Based on these 
data, we used lung slices that were cultured for up to 2 days. 





































Figure 5.1. Lung slice viability. (A) LDH release from lung slices after 1, 2, 3 and 4 days of 
culture. Maximal LDH content of the slices was established by lysis with 1% Triton X-100. 
Data shown are the means ± SE of 3-7 independent experiments. (B) Mitochondrial 
activity in lung slices after 1, 2, 3 and 4 days of culture. Data shown are the means ± SE of 
5 independent experiments. *: p<0.05 and ***: p<0.001 compared to basal (one-way 
ANOVA, posthoc Newman-Keuls). 
 
5.3.2 Contractile protein expression in response to TGF-β1 
TGF-β1 is a potent cytokine that induces cellular biological processes leading to 
airway remodelling (12). Therefore, in order to investigate the usefulness of lung 
slices as an in vitro model to study airway remodelling, we studied the effect of 
TGF-β1 treatment on contractile protein expression in lung slices. Lung slices were 
incubated in a dose- and time-dependent manner for 1 or 2 days in the presence 
or absence of TGF-β1 (0.1, 0.2, 2 ng/mL) and analysed for the expression of sm-
myosin, sm-α-actin and calponin. We observed that TGF-β1 induced a time- and a 
concentration-dependent increase in the expression of sm-myosin, sm-α-actin 
and calponin (Figure 5.2A-B). The maximal response measured for sm-myosin was 
obtained by incubating the slices with 2 ng/mL TGF-β1 for 2 days continuously 













Figure 5.2. Concentration and time-dependent effects of TGF-β1 on contractile protein 
expression. Lung slices were treated in a time- and concentration-manner with TGF-β1 (0, 
0.1, 0.2, 2 ng/mL) for 1 or 2 days, as indicated. Lung slice lysates were analysed for sm-
myosin, sm-α-actin, or calponin, using β-actin as a loading control. (A) Representative 
blots of TGF-β1-induced contractile protein expression. (B) Densitometric analysis of sm-
myosin expression. Data shown are means ± SE of 3 independent experiments. *: p<0.05, 
**: p<0.01, and ***: p<0.001 compared to basal (one-way ANOVA, posthoc Newman-Keuls). 
 
5.3.3 Contractile protein expression in response to methacholine-induced 
bronchoconstriction 
We next determined whether bronchoconstriction also induced the expression of 
contractile proteins. Stimulation of lung slices with 10 µM methacholine for 2 days 
resulted in an increased expression of sm-myosin and calponin (1,69 ± 0.23- and 
2.89 ± 0.59- fold induction, respectively). However, methacholine did not induce 
an increase in the expression of sm-α-actin (Figure 5.3A-D). 





































Figure 5.3. Methacholine stimulation induces contractile protein expression in lung 
slices. Lung slices were treated with TGF-β1 (2 ng/mL), methacholine (MCh; 10 µM) or 
medium (basal) for 2 days. Lung slice lysates were then analysed for the presence of sm-
myosin (B), sm-α-actin (C), or calponin (D) using β-actin as a loading control. 
Representative blots are shown in (A). Data shown in graphs are the means ± SE of 3-4 
independent experiments. ***: p<0.001 compared to basal (one-way ANOVA, posthoc 
Newman-Keuls). 
 
In view of these data, we further investigated the localization of increased 
contractile protein expression induced by TGF-β1 and methacholine in the airways. 
Therefore, lung slices incubated with either TGF-β1 (2 ng/mL) or methacholine (10 
µM) were stained immuno-cytochemically for sm-myosin and visualized using 
confocal fluorescence microscopy. Staining intensity within the smooth muscle 
bundle was quantified (Figure 5.4A-C). To distinguish peripheral airways from 
central airways, the diameter of the airways was measured. Airways with a 
diameter under 100 µm were considered as peripheral airways and with a 
diameter above 400 µm as central airways. Increased expression of sm-myosin, 
but not of sm-α-actin (data not shown) in response to methacholine and TGF-β1 as 
visualized by confocal fluorescence microscopy was found in peripheral airways 
with a diameter smaller than 100 µM (1.8 ± 0.3 and 1.6 ± 0.1 fold-induction for 
methacholine and TGF-β1, respectively, Figure 5.4A-B), and in the central airways, 







Figure 5.4. Localization of sm-myosin expression after TGF-β1 and methacholine 
treatment. Lung slices were treated with TGF-β1 (2 ng/mL), methacholine (MCh; 10 µM) or 
medium (basal) for 2 days. Lung slices were then fixed, stained for sm-myosin and 
analysed by confocal immunofluorescence microscopy. The images shown in (A) are taken 
from the peripheral airways (diameter smaller than 100 µm). Staining intensity within the 
muscle bundle was quantified and data shown from the peripheral airways (B) and central 
airways (diameter larger than 400 µm; C) are the means ± SE of 3 independent 
experiments. *: p<0.05 compared to basal (one-way ANOVA, posthoc Newman-Keuls). 
 
 




































5.3.4 Mechanisms of bronchoconstriction-induced airway remodelling  
Bronchoconstriction induced by methacholine causes an increase in the release of 
epithelial TGF-β in asthma patients (11). Also, co-culture of airway smooth muscle 
cells and epithelial cells causes the release of biologically active TGF-β in response 
to contractile agonists such as lysophosphatidic acid and methacholine (26). 
Therefore, the increase in contractile protein expression we observed in response 
to bronchoconstriction may be due to the release of TGF-β by lung slices. To 
establish whether biologically active TGF-β is involved in the increased contractile 
protein expression in response to methacholine, biologically active TGF-β was 
determined in conditioned media from stimulated precision-cut lung slices, using 
Smad-3 phosphorylation in human MRC-5 fibroblasts as a bio-assay. Human MRC-
5 fibroblasts were incubated for 1 hour with the conditioned media obtained from 
methacholine-stimulated lung slices, followed by analysis of phosphorylated 
Smad-3, which is specifically activated by TGF-β. The phosphorylation of Smad-3 
was significantly increased by conditioned media from methacholine-stimulated 
lung slices compared to basal controls (Figure 5.5A). As controls, the direct 
phosphorylation of Smad-3 in response to TGF-β1 and methacholine in human 
MRC-5 fibroblasts were investigated. TGF-β1, but not methacholine, induced 
direct phosphorylation of Smad-3 in the MRC-5 cells (Figure 5.5A), confirming that 
the effect of methacholine was due to the release of biologically active TGF-β 
from the lung slices. 
To investigate whether bronchoconstriction is involved in methacholine-induced 
contractile protein expression and release of TGF-β, we inhibited actin 
polymerization with latrunculin A. Latrunculin A prevented the increase in sm-
myosin expression in response to methacholine and TGF-β1 (Figure 5.5B). In 
addition, the release of bioactive TGF-β by methacholine was inhibited by 
latrunculin A, whereas latrunculin A had no direct effect on TGF-β1-induced Smad-
3 phosphorylation (Figure 5.5C). Moreover, inhibition of TGF-β type I receptor 
kinase with SB431542 prevented the increase in expression of sm-myosin induced 
by either TGF-β1 or methacholine (Figure 5.5B). Collectively, these findings 
indicate that bronchoconstriction induced by methacholine leads to the release of 
TGF-β, which enhances the expression of contractile proteins. 
To establish whether the increase in contractile protein expression was only seen 
with the contractile agonist methacholine, we stimulated lung slices also with the 
contractile agonists histamine (His, 1 µM) and potassium chloride (KCl, 60 mM) in 




expression of sm-myosin was enhanced in response to the contractile agonists 
methacholine, histamine and KCl, and these responses were similarly inhibited by 
latrunculin A and SB431542 (Figure 5.5D). This suggests that bronchoconstriction 
leads to the release of TGF-β inducing the expression of the contractile protein 
sm-myosin irrespective of the contractile agonist used. 
 




































Figure 5.5. Bronchoconstriction induces the release of biologically active TGF-β leading 
to contractile protein expression. Human MRC-5 fibroblasts were stimulated for 1 hour 
with TGF-β1 (2 ng/mL), methacholine (MCh; 10 µM) or medium (basal), or with 
conditioned media obtained from lung slice cultures treated for 2 days with and without 
10 µM methacholine. MRC-5 cell lysates were analysed for phosphorylated (ser 423/425) 




response to conditioned media are shown in (A). Data shown are the means ± SE of 4 
independent experiments. *: p<0.05, compared to basal (paired Student’s t-test with two-
tailed distribution). (B) Lung slices were pre-treated with latrunculin A (0.3 µM), SB431542 
(0.3 µM), or medium (basal) for 30 min, followed by 2 days of treatment with 
methacholine (MCh; 10 µM), TGF-β1 (2ng/mL), or medium (basal). Lung slice lysates were 
analysed for the presence of sm-myosin, using ß-actin as a loading control. Blots shown 
are representative of 3 experiments. (C) Human MRC-5 fibroblasts were stimulated for 1 
hour with conditioned media obtained from lung slice cultures after treatment with 
methacholine (MCh; 10 µM), TGF-β (2ng/mL) or medium (basal), in the absence and 
presence of latrunculin A (0.3 µM) or SB431542 (0.3 µM). MRC-5 cell lysates were 
analysed for phosphorylated (ser 423/425) and total Smad-3. Blots shown are 
representative of 3 experiments. (D) Lung slices were pre-incubated with latrunculin A (0.3 
µM), SB431542 (0.3 µM), or medium (basal) for 30 min, followed by 2 days stimulation 
with methacholine (MCh; 10 µM), TGF-β1 (2ng/mL), histamine (His, 1 µM), KCl (K
+, 60 mM) 
or medium (basal). Lung slice lysates were analysed for sm-myosin, using β-actin as a 





After validation of lung slices as an in vitro model for TGF-β induced airway 
smooth muscle remodelling, we studied the mechanisms involved in the induction 
of airway remodelling in response to bronchoconstriction. We show that 
bronchoconstriction induced by contractile agonists including methacholine, 
histamine and KCl, stimulates the release of TGF-β from lung tissue, which leads 
to an enhanced expression of contractile phenotype markers by the airway 
smooth muscle, similar to what is observed in patients with asthma (27, 28). 
Airway remodelling is a multicellular process, in which structural cell-cell 
interactions and cell-matrix interactions play a major regulatory role (29). 
Therefore, lung slices appear to be a useful in vitro model to study multicellular 
remodelling processes as most cell-cell contacts, and the cell-matrix interactions 
are preserved in this model. This has already been established for other organ 
systems, such as liver slices, in which ethanol or CCl4 induced liver fibrosis can be 
adequately mimicked (30-32). Another advantage of lung slices in culture is that 
the loss of sm-myosin expression that is typical for cultured airway smooth muscle 
cells is not observed. The choice for guinea pig lung slices in the present study is 
based on the observations that airway responsiveness to methacholine in guinea 
pig lung slices is very similar to that in human tissue (4). Furthermore, guinea pigs 




































have great anatomical and functional similarities compared to human airways 
including the presence of small airways in contrast to other animals (24).  
The use of lung slices also has some limitations. The major disadvantages of lung 
slices as an in vitro model include the lack of circulation and oedema formation 
(33), which interferes with the ability to clear soluble factors, including TGF-β. 
Also, relevant to the present study, tachyphylaxis to sustained 
bronchoconstriction could occur during 2 days of culture with bronchoconstricting 
agonists. However, as bronchoconstriction remained visible after 2 days of culture, 
and as other contractile agonists, including histamine and potassium chloride 
produced very similar results, we believe that even though tachyphylaxis may 
have occurred to some extent, its impact on the overall conclusion is small. 
Furthermore, the period during which lung slices can be maintained in culture is 
limited. Nonetheless, after 2 days of culture, we still measured low levels of LDH 
release and no decline in mitochondrial activity, indicating good viability. Very 
importantly, we observed an increase in contractile protein expression in 
response to TGF-β1 as a marker of airway remodelling, which underscores the 
usefulness of this culture system. Overall, this model offers a great perspective for 
future experiments, particularly in studying research questions in which intact 
cell-cell and cell-matrix interactions are essential. 
 
The pleiotropic cytokine TGF-β is an important growth factor involved in airway 
remodelling processes in asthma (12). Increased expression of TGF-β is found in 
lung tissue and bronchoalveolar lavage fluid of patients with asthma (33). TGF-β 
promotes important aspects of airway remodelling, including maturation of 
airway smooth muscle cells characterized by increased expression of contractile 
phenotype marker proteins (34). Indeed, we previously showed that TGF-β 
induces increased expression of the contractile phenotype markers sm-α-actin 
and calponin in human airway smooth muscle cells in a time-dependent manner, 
which was synergistically enhanced by muscarinic receptor stimulation (chapter 3, 
13). Patients with chronic asthma show an increase in sm-α-actin and myosin light 
chain kinase staining in the airways (26, 27). In agreement with these data, we 
show that lung slices in culture exhibit a time- and concentration-dependent 
increase of contractile phenotype markers including sm-myosin, in response to 
TGF-β. This implies that TGF-β responses in lung slices are similar to those 





Our studies provide important insights into the mechanisms behind the induction 
of contractile protein expression in response to bronchoconstricting agents. Our 
previous studies using cultured airway smooth muscle cells showed that 
muscarinic receptor stimulation had no effect on cell proliferation, cytokine 
production or contractile protein expression by its own but required functional 
interactions with growth factors (e.g. PDGF-AB, TGF-β), cytokines (e.g. TNF-α) or 
cigarette smoke extract to induce these cellular responses (35-37, chapter 2 and 
3). Cooperative regulation of contractile protein expression by TGF-β and 
methacholine was found to be associated with enhanced GSK-3 and 4EBP-1 
phosphorylation (chapter 3). The present study shows that in lung slices, in which 
cell-cell interactions and contractility are preserved, bronchoconstriction induced 
by methacholine is sufficient to promote the expression of contractile proteins, 
including sm-myosin and calponin, which is explained by the release of biologically 
active TGF-β which may functionally interact with methacholine to induce 
contractile expression. Other bronchoconstricting agents, including histamine and 
KCl were also sufficient to induce these effects. Notably, bronchoconstriction 
induced by methacholine did not enhance the expression of the contractile 
protein sm-α-actin. We previously demonstrated that sm-α-actin positive area in 
guinea pig airways is larger compared to sm-myosin positive area suggesting that 
actin positive, myosin negative cells exist within the smooth muscle bundle (10). 
Moreover, allergen-challenged guinea pigs show much greater induction of sm-
myosin expression in comparison to sm-α-actin (10). Although we cannot directly 
compare the effect of allergen with methacholine, the similarity with our current 
data is remarkable and suggests that sm-α-actin is less susceptible to regulation 
than sm-myosin in guinea pig airways. The TGF-β response by itself was also 
affected by the actin polymerization inhibitor latrunculin A, suggesting a basal 
tone of the airways, leading to the release of TGF-β or a requirement of actin 
polymerization for the induction of smooth muscle specific gene expression, also 
in response to TGF-β (38-40). Taken together, this suggests that 
bronchoconstriction induces the release of biologically active TGF-β, leading to 
contractile protein expression. 
 
In response to bronchoconstriction induced by methacholine or house dust mite, 
epithelial-TGF-β levels are increased in patients with asthma (9). In the airways 
biopsies of human lung, immunostaining revealed that TGF-β was mainly localized 
to the bronchial epithelial compartment, and to a lesser extent in smooth muscle 




































cells (41). Mechanical stimulation of bronchial epithelial cells induced the release 
of TGF-β, playing an important role in subepithelial processes observed in asthma 
(8). In response to static transmembrane pressures, rat epithelial cells also 
promote the gene expression of TGF-β, endothelin-1 and early growth response-1 
(42). Additionally, mechanical stimulation induces an increase in fibronectin 
production in epithelial cells (5). This may suggest that the primary sources of 
TGF-β in the airways are the epithelial cells, which release this growth factor in 
response to mechanical stimulation during bronchoconstriction. Nonetheless, the 
airway smooth muscle may also play an important role as Tatler et al. 
demonstrated that airway smooth muscle cells can activate TGF-β through αVβ5 
integrins in response to bronchoconstrictors in vitro (25). Moreover, blocking the 
αVβ5 integrins caused a reduction in the increased ASM layer in vivo with an 
ovalbumin-challenged mice model (25). Furthermore, in response to the 
contractile agonists lysophosphatidic acid and methacholine, airway smooth 
muscle cells from asthma patients released TGF-β to a greater extent than airway 
smooth muscle cells from healthy controls (25). Therefore, epithelial release of 
TGF-β and subsequent activation of the latent form into the biologically active 
form by αVβ5 integrins on airway smooth muscle is a plausible mechanism for the 
effects of bronchoconstriction observed in our study. 
 
Our findings have important implications for the management of chronic asthma. 
As bronchoconstriction can promote airway remodelling, the beneficial effects of 
bronchodilator drugs may exceed their acute effects on lung function. In vitro and 
in vivo studies are supporting this hypothesis. In a murine model of asthma, levels 
of TGF-β were reduced in bronchoalveolar lavage fluid (BALF) by the 
anticholinergic drug tiotropium. Additionally, tiotropium inhibited the thickening 
of airway smooth muscle and airway fibrosis in this model (43). Tiotropium 
treatment also inhibited the increase in contractile protein expression and 
thickening of the airway smooth muscle layer, in response to allergen-challenge in 
guinea pigs (10, 11). In fact, anticholinergics have multiple anti-inflammatory and 
anti-remodelling properties in animal studies (for review, see chapter 6), however, 
the underlying mechanism are still not understood. β-agonists, which are widely 
prescribed as bronchodilator drugs to asthmatics, can also reduce, though only 
partially, TGF-β-induced contractile protein expression in human bronchial 




In conclusion, using lung slices as an in vitro model, our findings demonstrate that 
bronchoconstriction can induce the release of TGF-β which promotes contractile 
protein expression. Therefore, our data suggest that bronchodilators may have 
beneficial effects on airway remodelling which should be followed up in future 
studies. Also our data suggest that the use of precision cut lung slices is a suitable 
model to study airway remodelling processes in response to bronchoconstriction. 
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Acetylcholine is the primary parasympathetic neurotransmitter in the airways and 
an autocrine/paracrine secreted hormone from non-neuronal origins including 
inflammatory cells and airway structural cells. In addition to the well-known 
functions of acetylcholine in regulating bronchoconstriction and mucus secretion, 
it is increasingly evident that acetylcholine regulates inflammatory cell chemotaxis 
and activation, and also participates in signalling events leading to chronic airway 
wall remodelling that is associated with chronic obstructive airways diseases 
including asthma and COPD. As muscarinic receptors appear responsible for most 
of the pro-inflammatory and remodelling effects of acetylcholine, these findings 
have significant implications for anticholinergic therapy in asthma and COPD, 
which is selective for muscarinic receptors. Here, the regulatory role of 
acetylcholine in inflammation and remodelling in asthma and COPD will be 
discussed including the perspectives that these findings offer for anticholinergic 





Acetylcholine is the primary parasympathetic neurotransmitter in the airways and 
a paracrine/autocrine hormone released from non-neuronal origins. The role of 
acetylcholine in the regulation of bronchomotor tone and mucus secretion from 
airway submucosal glands is well established (1). More recent findings suggest 
that acetylcholine, acting on muscarinic receptors, regulates additional functions 
in the airways, including inflammation and remodelling in obstructive airways 
diseases such as asthma and COPD (2-4). Based on these findings, we have 
previously questioned the traditional view on the role of acetylcholine, and 
suggested new possibilities for therapeutic targeting of muscarinic receptors in 
asthma and COPD (2). In this review, we will discuss the role of muscarinic 
receptors in obstructive airways disease further and update the discussion in view 
of these recent research papers and trials. In view of the selectivity of currently 
used anticholinergics for muscarinic receptors, we will not elaborate on the role 
of nicotinic receptors in this review. Nicotinic receptors are, however, expressed 
in the airways and mediate anti-inflammatory effects of acetylcholine. For 
excellent reviews on the anti-inflammatory role of nicotinic receptors, we would 




































6.2 Acetylcholine and muscarinic receptors in the  
          airways 
 
6.2.1 Biosynthesis, metabolism and mode of action of acetylcholine 
Acetylcholine is synthesized from choline and acetyl-CoA mainly by the enzyme 
choline acetyltransferase (ChAT) (6). Airway neurons and non-neuronal cells such 
as airway epithelial cells express ChAT and release acetylcholine (8). Further, 
macrophages, mast cells, lymphocytes, granolucytes, fibroblasts and smooth 
muscle cells all have been suggested to express ChAT (6), although the release of 
acetylcholine from these cells has not yet been demonstrated directly. 
Acetylcholine can bind to and activate a family of G protein coupled muscarinic 
receptors, but also a family of nicotinic receptors, which are ligand gated cation 
channels (9). Most inflammatory and airway structural cells express muscarinic 
and/or nicotinic receptors (2). The individual receptor subtypes and subunits 
expressed by these cells have been reviewed extensively by Wessler and 
Kirkpatrick (6).  
The mechanisms that regulate the metabolism of non-neuronal acetylcholine by 
airway epithelial cells are still not fully established, although recent studies have 
yielded important new insights. The uptake of choline is the rate-limiting step in 
the synthesis of acetylcholine. Choline uptake in airway epithelial cells is regulated 
by the high affinity choline transporter (CHT1) and by choline-specific transporter-
like proteins (CTL) (10, 11). Organic cation transporter (OCT) subtypes 1 and 2 play 
a dominant role in the release of acetylcholine by airway epithelial cells (10, 11). 
Furthermore, the expression of the vesicular acetylcholine transporter (VAChT) by 
some epithelial cell types, including secretory cells, neuroendocrine cells and 
brush cells has been reported, suggesting that storage and release of 
acetylcholine via vesicles may mediate acetylcholine release by non-neuronal cell 
type (10, 11). The expression of muscarinic receptors, nicotinic receptors, 
synthesizing enzymes such as ChAT and the release of acetylcholine from non-
neuronal cells is solid evidence for the existence of a non-neuronal cholinergic 





6.2.2 Muscarinic receptor expression and function in the airways 
Muscarinic receptors are the target for anticholinergic therapy in obstructive 
airways diseases as asthma and COPD and are the focus of this review. Muscarinic 
receptors are expressed by structural cells in the airways, predominantly airway 
smooth muscle, airway epithelium and airway fibroblasts. The parasympathetic 
neural network penetrates deep into the airway wall, and regulates 
bronchoconstriction, the release of mucus from submucosal glands, and to a 
lesser degree from goblet cells in the airway epithelium (2). The functional role of 
non-neuronal acetylcholine released from the airway epithelium is less well 
described, although recent studies suggest a role in airway smooth muscle 
contraction (12). It should be noted however that this finding is still controversial 
(13, 14). Additionally, acetylcholine, either neuronal or non-neuronal, may 
modulate airway inflammation and remodelling, as will be discussed further on. 
The distribution of muscarinic receptor subtypes throughout the bronchial tree is 
mainly restricted to muscarinic M1, M2 and M3 receptors (2). Muscarinic M1 
receptors are expressed by epithelial cells, where they play a modulatory role in 
electrolyte and water secretion, and in the ganglia, where they facilitate 
parasympathetic neurotransmission. Muscarinic M2 receptors are expressed by 
neurons, where they function as autoreceptors, inhibiting the release of 
acetylcholine from both preganglionic nerves and from parasympathetic nerve 
terminals. Muscarinic M2 autoreceptors are dysfunctional in allergic asthma due 
to eosinophil-derived release of major basic protein which acts as an allosteric 
antagonist of the M2 receptor (15), augmenting acetylcholine release. 
Furthermore, M2 receptors are widely expressed by airway mesenchymal cells 
such as fibroblasts and smooth muscle cells (2). Recent studies suggest that they 
may modulate cellular responses associated with airway remodelling (16). Also, a 
role in inhibition of Gs mediated airway smooth muscle relaxation has been 
proposed (1). Muscarinic M3 receptors are probably the best characterized 
subtype and are the dominant receptor subtype in the regulation of mucus 
secretion from submucosal glands and airway smooth muscle contraction (2). As a 
result, muscarinic M3 receptors are the primary target for anticholinergics, and M3 
subtype-selectivity has been advocated for by several research groups (17-22).  
 
6.2.3 Muscarinic receptors as therapeutic targets for asthma and COPD 
Anticholinergic therapy in COPD, and to a lesser extent asthma, is mainly aimed at 
inhibition of bronchoconstriction by inhibition of muscarinic receptors. Although 
































the term anticholinergic is most commonly used, all available anticholinergics 
used for the treatment of asthma and COPD are in fact specific antimuscarinics as 
they lack binding affinity at the nicotinic receptor. Clinically available 
anticholinergics are the short-acting ipratropium and the long-acting tiotropium. 
In addition to its longer duration of action, tiotropium has a considerably slower 
rate of dissociation from the M1 and the M3 receptor than from the M2 receptor, 
making the drug ‘kinetically selective’ for M1 and M3 receptors (21). It is 
conceivable that this functional selectivity of tiotropium is beneficial, as smooth 
muscle contraction is primarily mediated by muscarinic M3 receptors, whereas 
muscarinic M2 receptor blockade facilitates acetylcholine release from 
parasympathetic nerves (2). However, direct evidence for a beneficial clinical 
effect of this functional M3 selectivity of tiotropium is still lacking and the major 
difference between these drugs appears to be the duration of action. 
The Understanding the Potential Long-term Impacts of on Function with 
Tiotropium (UPLIFT) trial has demonstrated that treatment with tiotropium 
provides a significant and sustained improvement in lung function and quality of 
life in COPD patients, and reduces exacerbations and hospitalizations (23). 
Currently available anticholinergics are the short-acting ipratropium and the long-
acting tiotropium. These can be used either as monotherapy or in combination 
with β2-agonists and provide significant improvement in FEV1 in both asthma and 
COPD patients (24-27). The combination therapy with β2-agonists is more 
effective than anticholinergic treatment alone; nonetheless, monotherapy is 
already markedly effective (104). The explanation for this relatively large effect of 
monotherapy may lie within the role that mediators of inflammation (e.g. 
thromboxane A2, histamine) have in activating the airway cholinergic system. 
Airway inflammation has several ways to increase the output of neuronally 
released acetylcholine, as it results in exposure and activation of afferent C-fibres 
that facilitate ganglionic and central parasympathetic neurotransmission. Further, 
the release of acetylcholine can be facilitated directly via excitatory receptors for 
inflammatory mediators (e.g. prostaglandins, tachykinins) present on 
parasympathetic nerve terminals, and indirectly via inhibition of the M2 
autoreceptor through the release of eosinophil derived major basic protein that 
acts as an allosteric M2 receptor antagonist (1, 2). As a result, the 
bronchoconstrictor response (and perhaps additional responses) induced by pro-
inflammatory mediators such as thromboxane A2 is for a large part mediated by 




histamine after the early asthmatic response can be inhibited by ipratropium in a 
guinea pig model of asthma (29). This advocates for the use of anticholinergic 
therapy not only in COPD – where parasympathetic tone is the primary reversible 
component of airway obstruction (30) – but also in asthma. Indeed, recent clinical 
trials indicate significant improvements in lung function in asthma patients on top 
of usual care, and show that tiotropium therapy is non-inferior to β2-agonist 
therapy when combined with corticosteroids in severe asthma patients (25, 26, 
31). The additional observations that next to FEV1 also exacerbation rate and lung 
function decline in subgroups of COPD patients are improved by treatment with 
tiotropium (20, 32) has prompted speculations on the possible beneficial effects 
of anticholinergics on airway inflammation and remodelling (33).  
 
 
6.3 Airway inflammation 
 
Asthma and COPD are both characterized by chronic airway inflammation, albeit 
that the patterns of inflammation are markedly different. Different subtypes of T 
cells are involved in asthma and COPD: in asthma there is an increase in TH2 (CD4
+) 
cells, whereas in COPD CD8+ T cells predominate. Furthermore, the inflammation 
that occurs in asthma can be described as eosinophilic, whereas that occurring in 
COPD is mainly neutrophilic. However, when disease severity increases these 
differences become less pronounced (34).  
 
6.3.1 Inflammation and the non-neuronal cholinergic system 
Increasing evidence suggests that acetylcholine contributes to airway 
inflammation. In 2004, Wessler et al. found that in patients with atopic dermatitis, 
a condition characterized by TH2 type inflammation and often associated with 
bronchial asthma, expression of ChAT is increased in skin biopsies, with a 
consequent increase in acetylcholine (35). Further, Profita et al. (2011) 
demonstrated that cigarette smoke extract upregulated the non-neuronal 
cholinergic system in bronchial epithelial cells, by showing that expression of 
muscarinic M2 and M3 receptors and ChAT mRNA and protein were increased, 
whereas muscarinic M1 receptor levels were not affected. Consequently, 
acetylcholine levels in cell extracts were significantly higher after stimulation with 
cigarette smoke extract. This increase could be reduced by tiotropium (36). In 
contrast, lungs of ovalbumin challenged rats and mice show a significant decrease 
































in ChAT and other components of the cholinergic system, including the 
functionally relevant choline transporter CHT1 (37). Future studies are clearly 
warranted within this area to better understand the complex mechanism of 
regulation of the cholinergic system by inflammation and the significance of this 
process in asthma and COPD. 
 
6.3.2 Inflammatory cells 
Acetylcholine has been shown to affect inflammatory cells involved in asthma and 
COPD directly, by inducing proliferation or cytokine release from these cells. 
Carbachol can induce the proliferation of macrophages from mice in vitro (38). 
Also T-cell proliferation can be observed ex vivo after treatment of rats with the 
muscarinic agonist oxotremorine, whereas atropine suppresses the proliferation 
of T-cells (39). These anti-inflammatory properties of atropine were also 
demonstrated in rats in vivo, were it suppressed the turpentine-induced 
infiltration of leukocytes (39). Moreover, bovine alveolar macrophages exhibit 
neutrophil, eosinophil and monocyte chemotactic activity in response to 
acetylcholine, which is likely explained by cholinergic induction of leukotriene B4 
(LTB4) release (40). Recently, this was confirmed for primary human macrophages 
(41). Moreover, it was shown that acetylcholine-induced release of chemotactic 
activity from monocytes, macrophages and epithelial cells could be inhibited by 
tiotropium (41). It has also been shown that acetylcholine can induce the release 
of LTB4 from sputum cells of COPD patients (42). These results are consistent with 
a study demonstrating that tiotropium and also acetylcholinesterase, the 
degrading enzyme of acetylcholine, inhibited alveolar macrophage mediated 
migration of neutrophils from COPD patients (43). Using the M3-selective 
antagonist 4-DAMP it was shown that this effect is mediated via the muscarinic 
M3 receptor (43). Further, although R,R-glycopyrrolate, a muscarinic receptor 
antagonist, did not inhibit LPS-induced TNF-α release by itself, it synergistically 
inhibited the rolipram and budesonide induced decrease in TNF-α release from 
human primary monocytes (44). All these findings support a broad role for 
acetylcholine acting on muscarinic receptors in the regulation of airway 





Figure 6.1. The regulatory role of acetylcholine in inflammatory cell chemotaxis and 
activation. Acetylcholine can be neuronally released or secreted as an autocrine or 
paracrine hormone from inflammatory cells and airway structural cells, most notably 
airway epithelial cells. In susceptible individuals, the release of acetylcholine may be 
enhanced in response to environmental factors such as cigarette smoke or allergens. As a 
consequence, pro-inflammatory cytokines including IL-6, IL-8 and LTB4 are produced, 
which attract and activate inflammatory cells, most notably neutrophils. Muscarinic M3 
receptors expressed on airway smooth muscle and muscarinic M1-3 receptors expressed 
by airway epithelial cells mediate the release of these factors via activation of ERK1/2 and 
NF-kB signaling pathways. 
 
6.3.3 Epithelial cells 
The expression of non-neuronal acetylcholine is relatively high in bronchial 
epithelial cells (8). Acetylcholine is known to induce eosinophil, monocyte and 
neutrophil chemotactic activity in bronchial epithelial cells (45, 46). The increase 
in epithelial neutrophil chemotactic activity by acetylcholine could be inhibited by 
tiotropium, indicating the involvement of muscarinic receptors in this response 
(47). The acetylcholine-induced neutrophil chemotactic activity from epithelial 
cells is partially dependent on IL-8 release, since it is inhibited by an anti-IL-8 
monoclonal antibody (47). In line with this contention, the increase in IL-8 release 
in response to acetylcholine could be partially inhibited by tiotropium. In addition, 
acetylcholine induced LTB4 release from bronchial epithelial cells in a tiotropium 
sensitive manner (36). Both IL-8 and LTB4 release from bronchial epithelial cells is 
mediated via ERK1/2 and NF-κB signalling pathways and dependent on multiple 
































muscarinic receptor subtypes (M1/M2/M3) (36, 47). Taken together, these studies 
implicate an important role for epithelial acetylcholine in airway inflammation, via 
the activation of muscarinic receptors (Figure 6.1). 
Another potential mechanism by which tiotropium could inhibit inflammation 
induced by epithelial cells is by attenuating respiratory syncytial virus (RSV) 
replication in these cells (48). RSV is one of the major causes of acute lower 
respiratory tract infection and has been detected in patients with exacerbations of 
asthma and COPD (49). In an in vitro study, Iesato et al. demonstrated that the 
attenuation of virus replication by tiotropium was partially due to inhibition of 
RhoA activity. Moreover, tiotropium inhibited epithelial IL-6 and IL-8 production 
induced by RSV infection (48). In vivo studies are needed to investigate the 
importance of inhibition of infection-induced airway inflammation by tiotropium. 
 
6.3.4 Airway smooth muscle cells 
The airway smooth muscle is increasingly recognized for its role in modulating 
inflammation by secreting cytokines and chemokines (50), and it has been shown 
that muscarinic receptors on airway smooth muscle cells are involved in these 
responses. Stimulation of bovine airway smooth muscle strips with the muscarinic 
agonist carbachol induces pro-inflammatory gene expression, including IL-6, IL-8 
and cyclo-oxygenase-2 (51). Furthermore, carbachol augmented the cyclic stretch-
induced expression of these genes (51). Stimulation of airway smooth muscle cells 
with carbachol also induces the protein release of IL-6 and IL-8 via muscarinic M3 
receptors (52). Furthermore, methacholine strongly augmented cigarette smoke 
extract (CSE) induced IL-8 release (52). In line with findings in epithelial cells, IL-8 
release induced by stimulation with methacholine and CSE in airway smooth 
muscle is ERK1/2 and NF-κB dependent (chapter 2).  
 
6.3.5 In vivo studies 
The regulatory role of muscarinic receptor signalling in inflammatory processes 
involved in asthma and COPD has been confirmed by in vivo studies, using animal 
models of these diseases.  
Wollin and Pieper (2010) were the first to report anti-inflammatory properties of 
tiotropium in an animal model of cigarette smoke induced COPD. Total cell 
number and neutrophils in the bronchoalveolar lavage fluid (BALF) were 
concentration-dependently decreased after treatment with tiotropium. 




including IL-6, KC, TNF-α and LTB4 (53). Similar inhibitory effects of tiotropium on 
airway neutrophilia were observed in a guinea pig model of LPS-induced COPD 
(54). Moreover, neutrophilia was inhibited by ipratropium in a cadmium-induced 
rat model of pulmonary inflammation (55), by tiotropium in a HCl-induced rat 
model of gastro-oesophageal reflux (7) and by bilateral vagotomy or treatment 
with atropine in a diesel particle-induced rat model of pulmonary inflammation 
(56). Of interest, the latter study found that atropine was more effective in 
inhibiting pulmonary inflammation than bilateral vagotomy, suggesting a role for 
non-neuronal acetylcholine in this response (56). 
These findings may also be relevant for asthma. Our group has shown that 
tiotropium also partially inhibits eosinophilia in a guinea pig model of asthma (57), 
which has been confirmed by Buels et al. (58). In line with these findings, 
infiltration of macrophages and eosinophils in the BALF was significantly inhibited 
by tiotropium treatment in a murine model of asthma. Furthermore, expression 
levels in BALF of IL-4, IL-5 and IL-13 were decreased by tiotropium treatment (59). 
In addition, aclidinium, a novel muscarinic receptor antagonist which is kinetically 
selective for the muscarinic M3 receptor, inhibited infiltration of eosinophils in 
BALF in a mouse model of Aspergillus fumigatus-induced asthma (60). A recent 
study also suggested that M3 receptors regulate these inflammatory responses, 
although the selectivity profile of the antagonist bencycloquidium that was used 
in this study precludes firm conclusions on the involvement of other receptor 
subtypes (61). Since both tiotropium and aclidinium are kinetically selective for 
the muscarinic M3 receptor, this suggests predominant involvement of this 
receptor subtype in the observed anti-inflammatory effects in asthma and COPD 
models described above. This is supported by our own data on M3 
-/- mice, in 
which neutrophilia and cytokine release in BALF were inhibited compared to wild-
type mice after exposure to cigarette smoke (62). 
Clearly, all these in vivo studies indicate a profound role for acetylcholine in 
inflammation in asthma and COPD, which is in accordance with results of in vitro 
studies that report pro-inflammatory effects of muscarinic receptors (Figure 6.1). 
The implication of these findings is that treatment with anticholinergics may have 
beneficial effects that exceed their bronchodilatory properties, a contention 
confirmed in several models of pulmonary inflammation. However, the exact 
mechanism responsible for the regulatory role of acetylcholine in inflammation is 
far from understood.  
 
































6.4 Airway remodelling  
 
Airway inflammation in chronic airway diseases such as asthma and COPD is often 
associated with cellular and structural alterations in the airways, referred to as 
airway remodelling (63). Airway remodelling is considered a major component of 
irreversible airflow limitation in these diseases (64), is progressive, and correlates 
with disease severity (65, 66). Airway remodelling in asthma and COPD is 
characterized by mucus gland hypertrophy, goblet cell hyperplasia and pulmonary 
vascular remodelling (63). In addition, in asthma the basement membrane is 
thickened, there is subepithelial fibrosis, and there is considerable thickening of 
the airway smooth muscle bundle (64). In contrast, in COPD the fibrosis is mostly 
peribronchial, and although increased airway smooth muscle mass may occur, this 
appears restricted to severe stages of COPD (65). Airway structural alterations 
may accelerate decline of lung function (67). 
 
6.4.1 Epithelial cells / mucus production 
The airway epithelial layer is in continuous interaction with the external 
environment. To protect itself from exogenous stimuli, mucus is secreted under 
the control of the cholinergic system by muscarinic receptors (68). Mucus 
secretion can be increased by electrical field stimulation of the vagal nerve in 
bronchial preparations, predominantly via muscarinic M3 receptors on the 
submucosal glands (68). In addition, electrolyte and water secretion are regulated 
by muscarinic M1 and M3 receptors (69, 70). Neuronal muscarinic M2 
autoreceptors appears to regulate the extent of the secretory response, by 
limiting neuronally released acetylcholine (70). In response to acetylcholine, 
glandular goblet cells also produce mucus (68).  
Mucus hypersecretion is an important pathological feature of chronic airway 
diseases contributing to airway obstruction (68). MUC5A/C expression in airway 
epithelial cells and airway submucosal glands is directly correlated to airway 
obstruction in smokers (71) and in smokers, COPD patients and asthma patients; 
the expression of the MUC5A/C gene is augmented (32). Also, the expression of 
MUC5B and the insoluble MUC2 are increased, particularly in COPD. The ratio of 
mucus cells to serous cells in the submucosal glands is also increased in COPD 
patients (72). In vitro studies demonstrated that aclidinium suppressed carbachol-
induced MUC5A/C overexpression in human bronchial tissue. Additionally, the 




extract and carbachol could be attenuated by the use of aclidinium or atropine 
(73). Moreover, epidermal growth factor (EGF) stimulation enhanced the ACh-
induced response on mucus cell activation in airway submucosal glands (74). In 
vivo studies confirm the role of acetylcholine in mucus hypersecretion and 
demonstrate that tiotropium reduces allergen-induced mucus gland hypertrophy 
and MUC5A/C-positive goblet cell number in guinea pigs (57). Further, it has been 
reported that tiotropium inhibits neutrophil elastase-induced goblet cell 
metaplasia in mice (75) and that treatment with tiotropium inhibited the 
increased MUC5A/C expression and mucus gland hypertrophy in a guinea pig 
model of COPD (54). This demonstrates the important role of acetylcholine in the 
regulation of mucus secretion, both in vitro and in animal models of asthma and 
COPD in vivo (Figure 6.2). 
Acetylcholine may also regulate the proliferative and pro-fibrotic responses of 
airway epithelial cells. Bronchoconstriction induced by repeated challenges with 
methacholine induced epithelial cell proliferation and an increase in the 
expression of the profibrotic cytokine TGF-β by these cells in mild asthmatic 
subjects (76). In line with these findings, airway constriction induced by 
methacholine significantly increased the phosphorylation of the EGF receptor in 
airway epithelial cells (77). Moreover, in rat tracheal epithelial cells, acetylcholine 
induces proliferation mediated by muscarinic M1 receptors (78) and autocrine 
release of acetylcholine is sufficient to induce monkey airway epithelial cell 
proliferation (8). Thus, the cholinergic system is able to regulate epithelial cell 
proliferation, either through the induction of mechanical strain or in an 
autocrine/paracrine manner, which is required for the repair of the airway 
epithelial layer.  
































Figure 6.2. The regulatory role of acetylcholine in airway wall remodelling. Acetylcholine 
is neuronally released and secreted as an autocrine or paracrine hormone from airway 
structural cells and inflammatory cells. In the inflamed airway, inflammatory cells and 
airway epithelial cells also secrete growth factors that in concerted action with 
acetylcholine activate cell proliferation and matrix production by airway mesenchymal 
cells, including airway fibroblasts and airway smooth muscle cells. Furthermore, 
acetylcholine activates smooth muscle contraction leading to airway wall compression, 
which activates inflammatory cells and promotes remodelling responses by airway 
epithelial cells. Acetylcholine also directly promotes mucus production by and cell 





6.4.2 Mesenchymal cells 
Airway mesenchymal cells (e.g. fibroblasts, airway smooth muscle cells) 
contribute to airway remodelling by means of proliferation, contractile protein 
expression and the release of components such as mediators, extracellular matrix 
proteins and matrix metalloproteinases (MMPs) (79, 80). In vitro studies showed 
that the stimulation of muscarinic receptors on lung fibroblasts induces cell 
proliferation and the synthesis of collagen (16, 81) through the activation of the 
mitogen-activated protein kinase pathway (81, 82). This effect was mediated by 
the activation of muscarinic M2 receptors (16). Interestingly, acetylcholine-
induced cell proliferation is enhanced in human lung fibroblasts from COPD 
patients compared with healthy non-smokers and healthy smokers without COPD 
(83). The higher activation of cell proliferation in fibroblasts from COPD patients 
was due to enhanced ERK1/2 and NF-κB phosphorylation. Notably, the 
synthesizing enzyme ChAT was also increased in lung fibroblasts from healthy 
smokers and COPD patients (83). 
MMPs play a key role in airway remodelling, inflammation and emphysema (84). 
In COPD patients, increased expression levels of MMP-1, MMP-2 and MMP-9 have 
been reported (85, 86). The activity of the MMPs can be inhibited by tissue 
inhibitor of matrix metalloproteinases (TIMPs) (84). Recently, it was demonstrated 
that tiotropium inhibited TGF-β-induced protein expression of both MMP-1 and 
MMP-2 in human lung fibroblasts, but had no effect on the TGF-β-induced TIMP-1 
and TIMP-2 expression (87, 88). Therefore, these data suggest that treatment 
with tiotropium improves the balance between MMPs and TIMPs, inhibiting pro-
fibrotic responses. As MMPs also play important roles in the infiltration of 
inflammatory cells, this effect could also contribute to the anti-inflammatory 
properties of anticholinergics. 
Airway smooth muscle thickening is a characteristic pathological feature of 
asthma, and to a lesser extent of COPD. The induction of airway smooth muscle 
cell proliferation by growth factors, including PDGF and EGF, can be enhanced by 
the stimulation of muscarinic receptors (89-92). Specifically, Gβγ subunits derived 
from Gq protein coupled receptors cooperate with receptor tyrosine kinases (e.g. 
the PDGF/EGF receptor) to induce synergistic activation of PI3K/Akt/p70S6K 
signalling leading to cell proliferation (89, 91, 92). Moreover, the activation of 
conventional PKC isoenzymes, likely via muscarinic M3 receptor mediated Gαq 
stimulation, leads to GSK-3 inactivation, which potentiates both translational and 
transcriptional processes (90). These pathways are also involved in the acquisition 
































of contractile protein expression by TGF-β via transcriptional and translational 
processes (93-95) and can be activated by muscarinic receptor stimulation (96). 
Indeed, the expression of myosin light-chain kinase was augmented by carbachol 
in human airway smooth muscle cells exposed to cyclical mechanical strain (97). 
Additionally, we recently described that muscarinic receptor stimulation 
enhanced the TGF-β1-induced contractile protein expression in human airway 
smooth muscle cells (chapter 3). Collectively, these findings suggest an important 
role of muscarinic receptor stimulation in the proliferation and maturation of 
mesenchymal cells (Figure 6.2). 
 
6.4.3 In vivo studies 
Inhibitory effects of anticholinergics on airway mesenchymal cell remodelling 
have indeed been reported in animal models of asthma and COPD. Treatment 
with tiotropium significantly inhibited airway smooth muscle remodelling in a 
guinea-pig model of chronic asthma using repeated challenges with ovalbumin 
(98). This was associated with the inhibition of increased contractile protein 
expression and of airway smooth muscle thickening. In a murine model of asthma, 
it was shown that tiotropium could also significantly inhibit smooth muscle 
thickening and the expression of TGF-β1 in BALF (59). Similar effects have been 
described for the muscarinic M3 receptor selective antagonist bencycloquidium 
bromide (61). Furthermore, bencycloquidium bromide reduced mucus production, 
globet cell metaplasia and collagen deposition and inhibited the upregulation of 
MMP-9, but not of TIMP-1 mRNA (61). Treatment with tiotropium also inhibited 
the increased peribronchial collagen deposition in a guinea pig model of COPD 
(54). Similarly, in a chronic gastro-oesophageal reflux model, tiotropium 
treatment prevented the increase in airway fibrosis (7). Taken together, these in 
vivo studies confirm in vitro studies showing that anticholinergics have anti-
remodelling properties in asthma and COPD (Figure 6.2). 
 
 
6.5 Clinical implications 
 
The above mentioned in vitro and in vivo studies indicate significant pro-
inflammatory and remodelling effects for acetylcholine via muscarinic receptors, 
suggesting that anticholinergics may have anti-inflammatory and anti-remodelling 




in clinical studies, however. In the UPLIFT study, COPD patients treated with 
tiotropium during a 4 year period showed an improved quality of life and lung 
function, and a reduction in the frequency of exacerbations. Although tiotropium 
did not reduce FEV1 decline in the overall study population (23), in pre-specified 
post-hoc studies, GOLD stage II and young COPD patients with rapid lung function 
decline had a significant improvement in the accelerated post-bronchodilator FEV1 
decline (20, 99). No notable reduction in exacerbation frequency was reported for 
ipratropium (100, 101). This suggests a beneficial role for tiotropium as a long-
acting anticholinergic or a possible role for muscarinic M3 receptor subtype 
selectivity, as tiotropium is kinetically selective for muscarinic M3 receptors 
compared with ipratropium. Moreover, it also indicates anti-inflammatory effects 
of tiotropium, since patients who have more exacerbations demonstrate 
increased levels of inflammatory markers at stable state (102). However, Powrie 
et al. (2007) were not able to demonstrate a reduction in sputum IL-6 or IL-8 
levels in patients treated with tiotropium during one year, even though the 
number of exacerbations was significantly decreased (103). A possible explanation 
for this discrepancy proposed by the authors is that the reduction in amount of 
sputum after tiotropium treatment might result in an increase in cytokine 
concentrations. Measurement of cytokine concentrations in sputum might 
therefore not be the optimal method. Also, Perng et al. (2009) did not find a 
decrease in sputum IL-8 levels after tiotropium treatment (104). However, the 
treatment group in their study was small and patients only received tiotropium 
for 12 weeks. Further studies are therefore needed to elucidate the mechanisms 
by which tiotropium reduces exacerbations and FEV1 decline in subgroups of 
COPD patients and whether this is based on the anti-inflammatory effects of 
tiotropium discussed in this paper or by other effects, including a reduction in 
dyspnea or mucus hypersecretion. Likewise, further studies on the beneficial 
effects of anticholinergics in asthma patients are warranted. In patients with 
severe, uncontrolled asthma it has recently been shown that treatment with 
tiotropium improves lung function (25). Furthermore, a recent clinical trial 
showed that repeated inhalations with the muscarinic receptor agonist 
methacholine induces airway remodelling in asthma patients, including the 
expression of TGF-β and collagen I in bronchial biopsies (76). Therefore, although 
a rationale for beneficial effects of anticholinergics beyond the well-described 
bronchodilator properties in asthma and COPD certainly exists, it is evident that 
this still needs to be confirmed in clinical studies.  
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Acetylcholine, the primary parasympathetic neurotransmitter in the airways, plays 
an important role in the regulation of bronchoconstriction and mucus production 
(1). Anticholinergics, by acting on muscarinic receptors inhibit the increased 
cholinergic tone in asthma and chronic obstructive pulmonary disease (COPD) 
patients. Both diseases are also characterised by inflammation and structural 
changes of the airways, defined as airway remodelling. Remodelling of the airway 
smooth muscle layer has been reported to contribute to the pathophysiology of 
both asthma and COPD. 
Recent evidence suggests that the cholinergic system contributes to inflammation 
and remodelling of the airways, particularly at the level of airway smooth muscle. 
However, the mechanisms involved in these processes have only partially been 
solved. This thesis aims to explore the potential role of the cholinergic system in 
airway smooth muscle responses involved in airway inflammation and 
remodelling, as well as intracellular mechanisms underlying these processes. 
Novel muscarinic receptor-mediated mechanisms involved in the pro-
inflammatory and remodelling responses of the airway smooth muscle are 
described in chapters 2, 3, 4 and 5. Chapter 6 gives an overview of recent 




7.1 Role of muscarinic receptors in airway  
          inflammation 
 
The role of muscarinic receptors in the regulation of airway inflammation has 
been increasingly recognised during the last decade. Thus, various subtypes of 
muscarinic receptors are expressed on a variety of inflammatory cells (1, 2). 
Moreover, ChAT expression has been detected in immune cells, including 
eosinophils, neutrophils, lymphocytes, macrophages, and mast cells (3). Structural 
cells, including airway smooth muscle cells and epithelial cells, also express 
elements of the cholinergic system (2). Non-immune cells have been reported to 
regulate airway inflammation by secreting cytokines and chemokines (4). The 
airway smooth muscle plays an important role herein, by secreting a wide variety 
of immunomodulatory mediators, including IL-8, RANTES, IL-1β and TGF-β, in 
response to various pro-inflammatory stimuli (5). Recent work from our 
department has demonstrated that airway smooth muscle cells release pro-




















inflammatory cytokines, including IL-8 and IL-6, in response to cigarette smoke 
extract (6). Muscarinic M3 receptor activation synergistically enhanced this 
cytokine release and could also induce the production of IL-8 by itself, albeit to a 
minor extent ((6) and chapter 2). Similarly, others have shown that gene 
expression of pro-inflammatory cytokines, including IL-6 and IL-8, is up-regulated 
by carbachol in airway smooth muscle cells (7). These findings were supported by 
in vivo studies, as in a mouse model of COPD tiotropium bromide significantly 
reduced the cigarette smoke-induced increase of several cytokines, including IL-6, 
in the BALF (8). Moreover, in a guinea pig model of LPS-induced COPD, 
neutrophilia was reduced by tiotropium bromide (9). However, the precise 
mechanisms by which muscarinic M3 receptors enhance the release of pro-
inflammatory cytokines such as IL-6 and IL-8 remained unclear. In chapter 2, we 
demonstrate that the activation of muscarinic receptors on human airway smooth 
muscle cells induces the secretion of pro-inflammatory cytokines IL-8 and IL-6, 
particularly in combination with TNF-α, PDGF-AB and cigarette smoke extract. The 
mechanism behind the synergism between cigarette smoke extract- and 
methacholine-induced IL-8 secretion involves signalling by PKC, NF-κB and ERK1/2. 
This mechanism could be of importance for COPD patients using anticholinergics. 
 
 
7.2 Role of muscarinic receptors in airway  
          remodelling 
 
An important mediator of airway remodelling is TGF-β, a multifunctional cytokine, 
which, among others, is involved in inflammation-induced tissue repair by 
inducing mesenchymal cell growth and extracellular matrix production. In chronic 
inflammatory conditions, as in obstructive airway diseases, this may lead to 
fibrosis. The expression of TGF-β is upregulated in the airways of asthma and 
COPD patients. Indeed, various in vivo studies have demonstrated that 
overexpression of TGF-β1 in mice increases airway smooth muscle mass and 
fibrosis (10, 11). In addition, allergen-induced increased airway smooth muscle 
mass was prevented by anti-TGF-β1 antibodies (12). Nonetheless, in vitro studies 
on the mitogenic effect of TGF-β1 on airway smooth muscle cells are not yet 
conclusive. It appears that TGF-β can regulate both proliferation and maturation 
of airway smooth muscle cells, depending on its concentration (13). In this thesis 




with muscarinic receptor stimulation, on various processes involved in airway 
smooth muscle remodelling. 
To determine the impact of TGF-β1 and muscarinic receptors on human airway 
smooth muscle phenotype, we studied the effects of TGF-β1, methacholine and 
their combination on contractile protein expression and cell proliferation 
(chapters 3 and 4). In chapter 3, we demonstrated that TGF-β1 on its own 
increases the expression of contractile phenotype markers, including sm-α-actin, 
calponin and sm-myosin, in airway smooth muscle cells (chapter 3, (20-22)). 
Despite the fact that muscarinic receptor stimulation on its own did not induce 
the expression of contractile proteins, it synergistically enhanced the TGF-β1-
induced contractile protein expression in airway smooth muscle cells. 
Furthermore, chapter 3 describes a mechanism by which the cooperative 
regulation of contractile protein expression by TGF-β1 and muscarinic receptor 
stimulation is mediated, namely through enhancing the translational activity by 
phosphorylation of glycogen synthase kinase (GSK)-3 and eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1) and not by upregulation of gene 
expression in human airway smooth muscle cells (Figure 7.1). To our knowledge, 
this is the first study reporting crosstalk between a G protein-coupled receptor 
and TGF-β in airway smooth muscle; however, it remains unclear whether this 
crosstalk is applicable to other G protein-coupled receptors. This is worthwhile to 
further elucidate as many remodelling processes, also outside the airways, involve 
cooperative regulation by G protein-coupled receptor ligands and growth factors 
(14).  





















Figure 7.1. Functional interactions of muscarinic receptors and TGF-β in airway smooth 
muscle remodelling. The release of TGF-β by damaged epithelial cells, inflammatory cells 
and extracellular matrix proteins triggers airway smooth muscle phenotype switching by 
inducing airway smooth muscle cell proliferation and contractile protein expression. 
Muscarinic receptor activation on the airway smooth muscle cell enhances these 
processes. In particular, muscarinic receptors interact with TGF-β activation to allow 
phosphorylation of 4E-BP1 and GSK-3, leading to increased smooth muscle-specific gene 
translation in airway smooth muscle cells, followed by reorganisation of actin and myosin 
filaments to induce contraction. The interaction of muscarinic M2 receptors with TGF-β 
promotes the deposition of extracellular matrix proteins, which triggers airway smooth 
muscle cell proliferation through integrins. The cooperative interactions of TGF-β and 
muscarinic receptors promoting airway smooth muscle remodelling may lead to airway 
hyperresponsiveness. TGFR: transforming growth factor receptor, TGF-β: transforming 
growth factor-β, ACh: acetylcholine, M2R: muscarinic M2 receptor, M3R: muscarinic M3 
receptor, mTOR: mammalian target of rapamycin; PI3K: phosphatidyl inositide 3-kinase, 
GSK-3: glycogen synthase kinase 3; 4E-BP1: eukaryotic translation initiation factor 4E-




Interestingly, in addition to its role in airway smooth muscle maturation, we also 
demonstrated that prolonged exposure (7 days) to TGF-β1 induced airway smooth 
muscle cell proliferation, which was similarly significantly augmented by 
muscarinic receptor stimulation (chapter 4). Overall, this indicates a pivotal role 
for TGF-β1 in airway smooth muscle phenotype switching, which is under 
important cholinergic control. Airway smooth muscle cells and extracellular matrix 
proteins communicate with each other through heterodimeric glycoproteins 
integrins (15). Integrins have been shown to be involved in airway smooth muscle 
cell proliferation; however, the potential interaction of muscarinic receptors with 
these processes has not been explored yet. Chapter 4 demonstrates that TGF-β1-
induced airway smooth muscle cell proliferation is dependent on the production 
of the extracellular matrix proteins fibronectin and collagen I and their 
subsequent interaction with RGD-binding integrin α5β1 (Figure 7.1). Prolonged 
treatment with TGF-β1 was required for the production of extracellular matrix 
proteins, which is necessary to induce airway smooth muscle cell proliferation. 
Also, muscarinic receptor activation enhanced TGF-β1-induced cell proliferation 
and fibronectin deposition. Remarkably, this process was mediated through 
activation of muscarinic M2 receptors and not M3 receptors, as previously 
reported for the interaction between PDGF and muscarinic receptors in inducing 
airway smooth muscle cell proliferation (16, 17). This implies that in addition to 
muscarinic M3 receptor-mediated effects, also muscarinic M2 receptor mediated 
effects may contribute to airway smooth muscle remodelling. Furthermore, a role 
for GSK-3 signalling can be suggested, as fibronectin expression after TGF-β1 
stimulation has been shown to be under the regulation of the GSK-3β target β-
catenin (18), whereas chapter 3 demonstrates that crosstalk between muscarinic 
receptors and TGF-β1 enhanced the phosphorylation of 4E-BP1 and GSK-3β 
resulting in increased expression of contractile proteins in the human airway 
smooth muscle cells. Overall, an important role for GSK-3 signalling in the 
crosstalk between muscarinic receptor and TGF-β1 signalling in airway smooth 
muscle remodelling processes is suggested. 
Recently, evidence for a role of methacholine-induced bronchoconstriction in 
airway remodelling was found in patients with asthma (19). Indeed, increased 
levels of collagen deposition, TGF-β expression and proliferating epithelial cells 
were measured in asthma patients, who were subjected to repeated 
methacholine challenges (19). In vitro, cyclical mechanical strain of airway smooth 
muscle enhanced the expression of contractile proteins in response to muscarinic 




















agonists (20). Moreover, contractile agonists, including methacholine, activated 
the release of TGF-β from airway smooth muscle cells through reorganization of 
the cytoskeleton and inside-out activation of αvβ5 integrins (25). This process was 
enhanced in asthmatic cells (21). In this thesis, we hypothesised that 
bronchoconstriction contributes to airway remodelling by inducing the release of 
TGF-β (Figure 7.1). This hypothesis was investigated in precision-cut lung slices. As 
demonstrated in airway smooth muscle cells ((22) and chapter 3) we observed 
that exogenous TGF-β also induced increased expression of contractile proteins in 
precision-cut lung slices in a time-and concentration-dependent manner (chapter 
5). Moreover, we demonstrated that muscarinic receptor activation induced the 
release of endogenous biologically active TGF-β in these slices, resulting in an 
increase of contractile protein expression, including sm-myosin and sm-α-actin. 
This remodelling process was shown to be due to bronchoconstriction induced by 
the muscarinic agonist, as inhibition of actin polymerization (latrunculin A) 
prevented these effects. This was apparently in contrast to chapter 3, where we 
demonstrated that muscarinic receptor stimulation by itself did not induce 
increase contractile protein expression in cultured airway smooth muscle cells. 
Moreover, in precision cut lung slices, bronchoconstriction induced by other 
contractile agonists, including histamine and potassium chloride, increased the 
expression of contractile protein phenotype markers as well. The above 
mentioned findings are in agreement with the study of Grainge et al. (19), 
demonstrating that repeated inhalations with methacholine induce the release of 
TGF-β and airway remodelling in bronchial biopsies of patients with mild asthma 
(19). Based on our findings and those of Grainge et al., we propose that 
bronchoconstriction in asthma and COPD induces airway remodelling through the 
release of biologically active TGF-β. Our results in the precision-cut lung slices 
further extend the importance of the cooperative regulation of airway 
remodelling by muscarinic receptors and TGF-β. Overall, this would imply a 
beneficial effect of bronchodilators, including anticholinergics, on airway 
remodelling, which should be followed up in future studies. Furthermore, the use 
of precision-cut lung slices has proven to be a suitable model to study processes 
involved in airway remodelling induced by bronchoconstriction. 
 
In conclusion, the findings presented in chapters 2-5 point out the important 
functional role of muscarinic receptors in pro-inflammatory and remodelling 




bronchodilator role for anticholinergics to protect against these processes. A role 
for GSK-3/4E-BP1 signalling in airway smooth muscle remodelling processes 
induced by muscarinic receptor and TGF-β is proposed. 
 
 
7.3 Clinical implications 
 
The UPLIFT study (Understanding Potential Long-Term Impacts on Function with 
Tiotropium), a recent 4 year double-blind, randomised, placebo-controlled clinical 
trial investigating the effect of tiotropium on the progressive decline in FEV1 in 
COPD patients, showed that tiotropium improved lung function, the risk of 
respiratory failure and quality of life, and reduced exacerbations and 
hospitalisations, but did not reduce the rate of decline of FEV1 (23). However, in 
post-hoc studies, young COPD patients presenting a rapid lung function decline 
and GOLD stage II patients had a reduced rate of decline of FEV1 when treated 
with tiotropium (24, 25), suggesting a potential disease-modifying effect of 
anticholinergics such as tiotropium in specific subpopulations of COPD patients. 
Recently, Kerstjens et al. demonstrated the potential of tiotropium in patients 
with severe and uncontrolled asthma, by showing a significantly improved lung 
function and reduced exacerbation frequency in these patients (26, 27). These 
effects might be explained by beneficial effects on airway inflammation and 
remodelling; however, further clinical studies are needed to substantiate this 
hypothesis. In support, repeated inhalations of methacholine induced airway 
remodelling in patients with mild asthma, by increasing the expression of TGF-β 
and collagen I (19). 
 
 
7.4 Future perspectives 
 
In this thesis, we show for the first time that muscarinic M2 receptors are involved 
in airway smooth muscle phenotype switching, by promoting cell proliferation 
through the deposition of extracellular matrix proteins. In addition, muscarinic M2 
receptors mediate both proliferation and collagen synthesis in fibroblasts (28,29). 
These findings raise the question as to whether the kinetic selectivity towards the 
M3 receptor of particularly the clinically used long-acting anticholinergics is 




















beneficial. Therefore, it will be important to study the distinct roles of M1, M2, and 
M3 receptors in airway remodelling and inflammation. 
Several approaches can be used to determine the involvement of the muscarinic 
receptor subtype(s) in inflammatory and remodelling processes. First, in vitro 
studies using selective antagonists in cultured cells are useful to identify the 
specific role of muscarinic receptor subtypes in specific cellular functions. 
However, many cell types are present in the airways and their response is highly 
dependent on intercellular communication and interaction with the environment. 
In this regard a more informative approach would be in vivo studies in animal 
models of asthma and COPD, using different experimental subtype-selective 
muscarinic receptor antagonists or muscarinic receptor subtype specific knockout 
mice. Alternatively, precision cut lung slices as described in chapter 5 can be used, 
which may also be applied to the muscarinic receptor subtype knockout mice. 
Cellular infiltration from the bloodstream is lacking in these slices; however, 
responses of infiltrated cells can be studied when the animals are first subjected 
to challenges. Using this model, fewer animals would be required, as several 
conditions can be investigated in one animal. By understanding the effects of 
specific muscarinic receptor subtypes on airway remodelling, inflammation and 
mucus production, including the intracellular mechanisms involved, an 
improvement in the treatment of asthma and COPD may be acquired. 
Further, findings described in this thesis demonstrate the ability of muscarinic 
receptors in airway smooth muscle to synergize with TGF-β-induced responses. 
Although TGF-β has anti-inflammatory properties, TGF-β is highly expressed in the 
airways of asthma and COPD patients and show as well pro-inflammatory and pro-
remodelling effects (30, 31), therapy against TGF-β could therefore be envisaged. 
To investigate the cooperative effects of TGF-β and muscarinic receptor activation 
in the airways, in vivo models could be used. For example, the effect of an 
anticholinergic in transgenic mice overexpressing TGF-β could be studied. 
Alternatively, muscarinic receptor subtype specific knockout mice (M1/M2/M3) 
could be treated with TGF-β and anti-TGF-β to acquire more information on the 
cooperative interaction of muscarinic receptors and TGF-β on airway remodelling 
and inflammation. The development of potent specific inhibitors of TGF-β 
signalling, possibly in combination with selective anticholinergics might be a 
promising drug therapy for asthma and COPD patients to halt and reverse both 
airway remodelling, inflammation and mucus production. However, decreased 




destruction in emphysema (31). SD-208, a TGF-β inhibitor has been developed; 
however, there may be long term concerns about the inhibition of TGF-β, like 
maintaining sufficient levels of regulatory T lymphocytes (32). Overall, this 




7.5 Main conclusions 
 
In conclusion, the studies described in this thesis revealed that: 
 Muscarinic receptor stimulation augments the pro-inflammatory response 
of airway smooth muscle in response to cigarette smoke extract, TNF-α 
and PDGF, as measured by IL-8 and IL-6 release (chapter 2). 
 The augmentation of IL-8 release is mediated by activation of PKC, 
followed by activation of the NF-κB- and ERK1/2-dependent pathways. 
This response is mediated by muscarinic M3 receptors (chapter 2). 
 TGF-β mediates phenotype switching, i.e. proliferation and maturation, of 
airway smooth muscle cells (chapters 3, 4 and 5). 
 Muscarinic receptor stimulation enhances TGF-β-induced contractile 
protein expression in airway smooth muscle cells (chapters 3 and 5). 
 The enhanced contractile protein expression by muscarinic receptor 
stimulation is mediated by activation of the PI3K pathway, as indicated by 
the phosphorylation of 4E-BP1 and GSK-3 (chapter 3). 
 Prolonged exposure to TGF-β is required to induce airway smooth muscle 
cell proliferation by this cytokine. This involves enhanced deposition of 
extracellular matrix proteins, which subsequently induce proliferation via 
interaction with RGD-binding (α5β1) integrins (chapter 4). 
 Muscarinic M2 receptors, but not muscarinic M3 receptors, enhance TGF-
β-induced airway smooth muscle cell proliferation by deposition of 
fibronectin, but not of collagen I (chapter 4). 
 Precision cut lung slices are a suitable model to study airway remodelling 
processes in vitro (chapter 5). 




















 Bronchoconstriction induces the release of endogenous biologically active 
TGF-β, which contributes to airway remodelling by promoting contractile 
protein expression (chapter 5). 
Beyond their role in the contraction of airway smooth muscle cells, muscarinic 
receptors are also important in inflammatory and remodelling responses by these 
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 Nederlandse samenvatting 
 
 
Chronische aandoeningen van de luchtwegen, zoals astma en chronisch 
obstructief longlijden (COPD) vormen een groot wereldwijd gezondheidsprobleem. 
De wereldwijde incidentie van zowel astma als COPD stijgt en naar verwachting 
zal COPD in 2020 epidemische proporties aannemen. Zowel astma als COPD 
worden gekenmerkt door beperking van de luchtstroom en chronische 
aanhoudende luchtwegontsteking. Acetylcholine is de primaire parasympathische 
neurotransmitter in de luchtwegen en speelt een belangrijke rol in 
luchtwegconstrictie en mucusproductie door activering van muscarinereceptoren 
in de luchtwegen. Astma- en COPD-patiënten kunnen behandeld worden met 
anticholinergica (deze blokkeren de werking van acetylcholine op de 
muscarinereceptoren) om de verhoogde cholinerge tonus (ten gevolge van 
overmatige afgifte van acetylcholine) te blokkeren. Naast een verhoogde 
cholinerge tonus spelen ontsteking en structurele veranderingen van de 
luchtwegen (luchtweg-remodelling) een belangrijke rol bij astma en COPD. 
Remodelling van de zg. gladde spierlaag rond de luchtwegen bijvoorbeeld draagt 
sterk bij aan de pathofysiologie van deze ziektes. Hierbij kunnen luchtweg-gladde 
spiercellen fenotypische veranderingen ondergaan, waarbij een omkeerbare 
overgang van een contractiel naar een proliferatief fenotype mogelijk is. 
Recentelijk is aangetoond dat acetylcholine ook kan bijdragen aan ontsteking en 
luchtweg-remodelling, in het bijzonder van de luchtweg-gladde spierlaag. Het is 
echter nog onbekend welke mechanismen hieraan ten grondslag liggen.  
In dit proefschrift wordt de potentiële rol van acetylcholine bij ontsteking en 
luchtweg-remodelling in de luchtweg-gladde spierlaag onderzocht. In hoofdstuk 2, 
3, 4 en 5 worden nieuwe mechanismen besproken die betrokken zijn bij deze 
processen. Hoofdstuk 6 geeft een overzicht van de recente ontwikkelingen op het 







Rol van muscarinereceptoren bij ontsteking van de 
luchtwegen 
 
De bijdrage van muscarinereceptoren aan luchtwegontsteking wordt steeds 
duidelijker. Niet alleen is duidelijk geworden dat verschillende subtypes van 
muscarinereceptoren tot expressie worden gebracht in ontstekingscellen, maar 
ook is gevonden dat ChAT (het enzym dat acetylcholine synthetiseert) in 
ontstekingscellen, zoals eosinofielen, neutrofielen, lymfocyten, macrofagen en 
mestcellen, tot expressie wordt gebracht. In structurele cellen, zoals luchtweg-
gladde spiercellen en epitheelcellen komen ook verschillende onderdelen van dit 
cholinerge systeem tot expressie. Ook is aangetoond dat deze laatstgenoemde 
celtypes kunnen bijdragen aan luchtwegontsteking d.m.v. de aanmaak en afgifte 
van specifieke cytokinen en chemokinen. Luchtweg-gladde spiercellen 
bijvoorbeeld reguleren de productie en afgifte van immunomodulerende 
mediatoren, zoals interleukine (IL)-8, IL-1β en transforming growth factor (TGF)-β, 
na activatie door pro-inflammatoire stimuli. Dit proefschrift toont aan dat 
luchtweg-gladde spiercellen ook pro-inflammatoire cytokinen, zoals IL-6 en IL-8, 
vrijzetten na activatie met sigarettenrook. Activatie van muscarine M3 receptoren 
versterkt deze respons, en kan ook zelf in geringe mate de IL-8 productie 
induceren (hoofdstuk 2). Deze in vitro bevindingen worden ondersteund door 
verschillende in vivo studies die aangeven dat het anticholinergicum tiotropium 
bromide de expressie van verschillende cytokinen, waaronder IL-6, significant 
remt in de bronchoalveolaire lavagevloeistof van muizen die blootgesteld zijn aan 
sigarettenrook. Tevens verminderde tiotropium bromide de neutrofiele 
luchtwegontsteking na herhaalde lipopolysaccharide-blootstelling in een 
caviamodel voor COPD. De precieze mechanismen waarmee muscarine M3 
receptoren het vrijzetten van cytokinen zoals IL-6 en IL-8 bevorderen waren 
echter nog onbekend. De resultaten in hoofdstuk 2 tonen aan dat de activatie van 
muscarinereceptoren op humane luchtweg-gladde spiercellen de afgifte van de 
cytokinen IL-8 en IL-6 bevordert, in het bijzonder in combinatie met TNF-α, 
platelet derived growth factor (PDGF)-AB en sigarettenrookextract. Het 
mechanisme achter deze synergistische effecten berust op signaaltransductie via 
de eiwitten PKC, NF-κB en ERK1/2. Dit mechanisme kan van belang zijn voor 
patiënten met COPD die anticholinergica gebruiken, omdat onsteking een 




Rol van muscarinereceptoren bij luchtweg-remodelling 
 
Een belangrijke groeifactor voor luchtweg-remodelling is TGF-β. Deze factor is 
betrokken bij meerdere processen, waaronder het herstel van weefselschade die 
door ontsteking is ontstaan. Bij weefselschade zal de groeifactor TGF-β celgroei 
(proliferatie) induceren, waaronder die van gladde spiercellen, maar ook de 
aanmaak van extracellulaire matrixeiwitten bevorderen. Bij chronische 
ontstekingsziektes, zoals COPD en astma, leiden deze mechanismen tot fibrose 
(overmatig bindweefsel). De expressie van TGF-β is verhoogd in de luchtwegen 
van astma- en COPD-patiënten. In vivo studies hebben aangetoond dat 
overexpressie van TGF-β1, een isovorm van TGF-β, in muizen leidt tot verdikking 
van de luchtweg-gladde spierlaag en tot fibrose. Het toedienen van anti-TGF-β1 
antilichamen (antilichamen die de werking van TGF-β1 blokkeren) voorkomt de 
verdikking van de luchtweg-gladde spierlaag na blootstelling van muizen aan 
allergenen. Desondanks zijn de resultaten met betrekking tot de mitogene 
eigenschappen van TGF-β1 in luchtweg-gladde spiercellen in vitro niet eenduidig. 
Het blijkt dat TGF-β1 in vitro zowel proliferatie (celgroei) als maturatie (verhoogde 
expressie van contractiele eiwitten) van de luchtweg-gladde spiercel kan 
induceren, afhankelijk van de concentratie. In dit proefschrift (hoofdstuk 3, 4, en 
5) hebben we de invloed van TGF-β1 op luchtweg-remodelling en de interactie 
met muscarinereceptoractivatie verder bestudeerd. 
Om de invloed van TGF-β1 en muscarinereceptoractivatie op het humane 
luchtweg-gladde spiercel fenotype te bepalen, hebben we de effecten van TGF-β1, 
methacholine en hun combinatie op de expressie van contractiele eiwitten 
(hoofdstuk 3) en celproliferatie (hoofdstuk 4) onderzocht. De resultaten 
beschreven in hoofdstuk 3 tonen aan dat TGF-β1 de expressie van contractiele 
eiwitten zoals sm-α-actin, calponin en sm-myosin kan induceren in luchtweg-
gladde spiercellen. Hoewel muscarinereceptoractivatie op zichzelf de expressie 
van contractiele eiwitten niet bevorderde, versterkte het significant de effecten 
van TGF-β1 hierop. Muscarinereceptoractivatie draagt derhalve bij aan de 
maturatie van de luchtweg-gladde spiercellen. Het synergistisch effect van TGF-β1 
en muscarinereceptoractivatie wordt veroorzaakt door een verhoging van de 
fosforylering van glycogen synthase kinase (GSK)-3 en eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1), en beinvloedt hiermee wel de 
eiwit-, maar niet de genexpressie van de contractiele eiwitten. Dit is de eerste 




muscarinereceptor) en TGF-β in luchtweg-gladde spiercellen heeft aangetoond. 
Verdere studies zijn nodig om te onderzoeken of deze crosstalk voorkomt bij 
andere klassen G-eiwit gekoppelde receptoren. Het is zeker de moeite waard om 
dit verder te onderzoeken, omdat veel remodellingsprocessen, ook buiten de 
luchtwegen, gekenmerkt worden door de betrokkenheid van zowel G-eiwit 
gekoppelde receptorliganden als van groeifactoren, zoals TGF-β. 
Hoofdstuk 4 laat zien dat langdurige blootstelling van luchtweg-gladde spiercellen 
aan TGF-β1 ook proliferatie kan induceren. Deze respons wordt eveneens 
significant versterkt door muscarinereceptoractivatie. Het mechanisme waarop de 
inductie van luchtweg-gladde spiercelproliferatie door TGF-β1 en 
muscarinereceptoractivatie wordt bevorderd, is nader onderzocht in dit 
hoofdstuk. Luchtweg-gladde spiercellen en extracellulaire matrix (ECM) eiwitten 
(eiwitten die toegenomen zijn bij fibrose) communiceren met elkaar d.m.v. 
integrinen, receptoren voor ECM eiwitten op de gladde spiercel. Eerder is 
aangetoond dat sommige integrinen betrokken zijn bij luchtweg-gladde 
spiercelproliferatie, maar de mogelijke interactie met muscarinereceptoren was 
nog niet eerder bestudeerd. Hoofdstuk 4 toont aan dat de door TGF-β 
geïnduceerde luchtweg-gladde spiercelproliferatie afhankelijk is van de productie 
van ECM eiwitten, zoals fibronectine en collageen I, en van hun interactie met 
α5β1 integrinen. Deze integrinen binden aan een specifieke aminozuursequentie 
(RGD) op de genoemde ECM eiwitten. Langdurige blootstelling aan TGF-β1 is 
noodzakelijk om voldoende ECM eiwit te produceren voor de inductie van 
luchtweg-gladde spiercelproliferatie. Daarnaast verhoogt muscarinereceptor-
activatie de door TGF-β1 geïnduceerde celproliferatie en fibronectine productie, 
maar niet de productie van collageen I. Dit proces wordt gemedieerd door 
muscarine M2 receptoren en niet door M3 receptoren, zoals eerder was 
aangetoond voor de interactie met de groeifactor PDGF bij de inductie van 
luchtweg-gladde spiercelproliferatie. Hoofdstuk 4 is de eerste studie die aantoont 
dat muscarine M2 receptoren ook betrokken zijn bij remodellingsprocessen van 
luchtweg-gladde spiercellen.  
Bij astmapatiënten is recent aangetoond dat bronchoconstrictie ook een rol kan 
spelen in luchtwegremodelling. In luchtwegbiopten van patiënten met astma die 
herhaald blootgesteld werden aan methacholine, werd een verhoogde 
collageendepositie, TGF-β-expressie en epitheelcelproliferatie aangetoond. 
Contractiele agonisten zoals methacholine kunnen reorganisatie van het 
cytoskelet en activatie van αvβ5 integrinen veroorzaken, wat kan leiden tot afgifte 
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van TGF-β door de luchtweg-gladde spiercellen. Dit proces bleek versterkt in 
luchtweg-gladde spiercellen van astmapatiënten. In dit proefschrift hebben we de 
hypothese onderzocht dat bronchoconstrictie bijdraagt aan luchtweg-remodelling 
door de TGF-β vrijzetting te bevorderen (hoofdstuk 5). Deze hypothese hebben 
we onderzocht door gebruik te maken van zogenaamde precision-cut lung slices 
(met precisie gesneden dunne longplakjes). Met behulp van deze methode 
hebben we aangetoond dat methacholine op een tijds- en concentratie-
afhankelijke manier de expressie van contractiele eiwitten bevordert. Daarnaast 
tonen de resultaten van hoofdstuk 5 aan dat muscarinereceptoractivatie de 
vrijzetting van endogeen, biologisch actief, TGF-β induceert in deze slices en dat 
dit de oorzaak is van de toename in contractiele eiwitexpressie. Dit effect werd 
geremd door het gebruik van latrunculin A (“verlamt” de spier door remming van 
de actinepolymerisatie nodig voor contractie) en een TGF-β receptorblokker. In 
hoofdstuk 5 werd tevens een verhoogde expressie van contractiele eiwitten in 
precision-cut lung slices gevonden met andere contractiele stimuli, zoals 
histamine en kaliumchloride. Gebaseerd op onze bevindingen en de eerder 
genoemde klinische studie, concluderen wij dat bronchoconstrictie leidt tot 
luchtwegremodelling via de vrijzetting van TGF-β. Onze bevindingen in de 
precision-cut lung slices ondersteunen derhalve het belang van de coöperatieve 
regulatie van luchtwegremodelling door muscarinereceptoractivatie en TGF-β. 
Daarnaast wijst het op potentieel gunstige effecten van bronchusverwijders, zoals 
anticholinergica, op de luchtwegremodelling. Dit zal verder moeten worden 
onderzocht. Het gebruik van precision-cut lung slices is een zeer bruikbare 
methode gebleken om bronchoconstrictie-geïnduceerde luchtweg remodelling in 
vitro te bestuderen. 
Samenvattend wijzen de bevindingen in hoofdstuk 2-5 op het belang van 
muscarinereceptoren bij ontstekings- en remodellingsprocessen in luchtweg-
gladde spiercellen en de mogelijk gunstige effecten van anticholinergica op deze 
processen. Dit proefschrift beschrijft ook een nieuwe rol voor GSK-3/4E-BP1 
signalering in remodellingsprocessen in de luchtweg-gladde spier, gemedieerd 








In dit proefschrift wordt voor de eerste keer bewezen dat muscarine M2 
receptoren betrokken zijn bij fenotype veranderingen van luchtweg-gladde 
spiercellen, met name door het bevorderen van celproliferatie via de afzetting van 
ECM eiwitten. In fibroblasten zijn soortgelijke bevindingen gedaan, waar 
muscarine M2 receptoren een rol hebben bij zowel proliferatie als 
collageensynthese. Deze bevindingen trekken het veronderstelde gunstige effect 
van selectieve muscarine M3 receptorantagonisten in twijfel. Daarom is het 
belangrijk om de specifieke rol van muscarine M1, M2 en M3 receptoren in 
luchtwegremodelling en -ontsteking verder in kaart te brengen. 
Er zijn verschillende benaderingen om de rol van de muscarinereceptorsubtype(s) 
bij ontstekings- en remodellingsprocessen te bepalen. In vitro studies met 
selectieve antagonisten in gekweekte cellen kunnen bruikbaar zijn om de 
specifieke rol van muscarinereceptorsubtypes bij specifieke celfuncties te 
identificeren. Er zijn echter veel verschillende celtypes aanwezig in de luchtwegen 
en hun respons is sterk afhankelijk van intercellulaire communicatie en interactie 
met de omgeving. In dit verband zullen in vivo studies met diermodellen voor 
astma en COPD een meer informatieve benadering vormen, waarin verschillende 
experimentele subtype-selectieve muscarinereceptorantagonisten of 
muscarinereceptorsubtype-specifieke knockout-muizen onderzocht kunnen 
worden. Een ander alternatief is het gebruik van precision-cut lung slices zoals 
beschreven in hoofdstuk 5, wat ook kan worden toegepast op de 
muscarinereceptorsubtype knockout-muizen. Alhoewel de circulatie van 
bloedcellen ontbreekt in deze slices, kan de respons van geïnfiltreerde cellen wel 
onderzocht worden wanneer de dieren eerst blootgesteld worden aan 
bijvoorbeeld allergeen. Met dit model zouden minder dieren nodig zijn, omdat 
verschillende omstandigheden van één dier onderzocht kunnen worden. Het 
begrijpen van de rol van specifieke muscarinereceptorsubtypen op 
luchtwegremodelling, -ontsteking en slijmproductie, en de betrokken 
intracellulaire signaaltransductiemechanismen, kan leiden tot een verbetering in 
de behandeling van astma en COPD. 
De bevindingen beschreven in dit proefschrift tonen het vermogen aan van 
muscarinereceptoren om de effecten van TGF-β op de luchtweg-gladde spieren te 
bevorderen. Hoewel TGF-β ontstekingsremmende eigenschappen heeft, komt 
TGF-β sterk tot expressie in de luchtwegen van astma- en COPD-patiënten en 
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heeft het ook ontstekingsbevorderende en remodellingsbevorderende effecten. 
Therapie gericht tegen TGF-β zou daarom overwogen moeten worden. Om de 
coöperatieve effecten van TGF-β en muscarinereceptoractivering in de 
luchtwegen te onderzoeken, kunnen in vivo modellen gebruikt worden. Zo zou 
bijvoorbeeld het effect van een anticholinergicum op transgene muizen die TGF-β 
tot overexpressie brengen bestudeerd kunnen worden. Een alternatief is om 
muscarinereceptorsubtype-specifieke knockout-muizen (M1/M2/M3) te 
behandelen met TGF-β en anti-TGF-β. Dit zou meer informatie op kunnen leveren 
over de coöperatieve interactie van muscarinereceptoren en TGF-β bij 
luchtwegremodelling en ontstekingsprocessen. De ontwikkeling van specifieke 
inhibitoren van TGF-β signalering, eventueel in combinatie met een selectieve 
anticholinergica, zou een veelbelovende therapie voor astma- en COPD-patiënten 
kunnen opleveren om de luchtwegremodelling, -ontsteking en slijmproductie te 
verminderen. Hierbij moet echter opgemerkt worden dat juist verminderde TGF-β 
signalering betrokken is bij de parenchymale weefselafbraak bij emfyseem. 
Bovendien is met de TGF-β-remmer SD-208 aangetoond dat langdurige remming 
van TGF-β kan leiden tot afname van regulatoire T-lymfocyten. Daarom is verdere 
opheldering van de rol van TGF-β bij chronische luchtwegaandoeningen, zoals 





De belangrijkste conclusies van dit proefschrift zijn: 
 Activatie van muscarinereceptoren versterkt de door sigarettenrook, TNF-
α en PDGF geïnduceerde vrijzetting van IL-6 en IL-8 door luchtweg-gladde 
spiercellen (hoofdstuk 2). 
 De bovengenoemde toename in IL-8 afgifte wordt gemedieerd door PKC-
activatie, gevolgd door de activatie van NF-κB en ERK1/2-afhankelijke 
signaaltransductieroutes. De cholinerge respons wordt gemedieerd door 
muscarine M3 receptoren (hoofdstuk 2). 
 TGF-β kan zowel proliferatie als maturatie van luchtweg-gladde 
spiercellen induceren (hoofdstuk 3, 4 en 5). 
 Activatie van muscarinereceptoren verhoogt de door TGF-β geïnduceerde 





 De door muscarinereceptoractivatie verhoogde contractiele 
eiwitexpressie wordt gemedieerd door fosforylatie van 4E-BP1 en GSK-3 
(hoofdstuk 3). 
 Langdurige blootstelling aan TGF-β is noodzakelijk om proliferatie te 
induceren in luchtweg-gladde spiercellen. Hiebij speelt een verhoogde 
depositie van ECM eiwitten door TGF-ß een cruciale rol. De proliferatie 
wordt veroorzaakt door interactie tussen de ECM eiwitten en de 
luchtweg-gladde spiercel via de RGD-bindende (α5β1) integrinen 
(hoofdstuk 4). 
 Muscarine M2 receptoren versterken de door TGF-β geïnduceerde 
luchtweg-gladde spiercelproliferatie door bevordering van de depositie 
van fibronectine, maar niet van collageen I (hoofstuk 4). 
 Precision-cut lung slices zijn een uitstekend model om 
luchtwegremodelling in vitro te bestuderen (hoofdstuk 5). 
 Bronchoconstrictie induceert de afgifte van endogeen en biologisch actief 
TGF-β. Dit draagt bij aan luchtwegremodelling, waaronder de expressie 
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PBS  Phosphate-buffered saline 
PDGF  Platelet-derived growth factor 
PI3-kinase  Phosphatidyl inositol 3-kinase 
PKC  Protein kinase C 
PMA  phorbol 12-myristate 13-acetate 
RANTES  Regulated upon Activation, Normal T-cell Expressed and Secreted 
RGD   Arginine-Glycine-Aspartic acid 
RGDS  Arginine-Glycine-Aspartic acid-Serine 
RhoA  Ras homolog gene family, member A 
RSV  Respiratory syncytial virus 
RT  Room temperature 
SDS/PAGE Sodium dodecyl sulfate/polycrylamide gel electrophoresis 
SM22  Transgelin 
sm-α-actin  Smooth muscle α-actin 
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sm-MHC  Smooth-muscle-specific myosin heavy chain 
SRF  Serum response factor 
TBST  Tris-buffered saline with tween 
TGF-β   Transforming growth factor-β 
TH cells  T helper cells 
TIMP  Tissue Inhibitor of MMPs 
TNF-α  Tumor necrosis factor-α 
UPLIFT Understanding the Potential Long-term Impacts on Function  
with Tiotropium 
VAChT  Vesicular acetylcholine transporter 
VEGF   Vascular endothelial growth factor 
 
